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Abstract 
 
 
The sigma-1 receptor, although originally classified as an opioid receptor is now thought 
of as distinct receptor class, sharing no homology with any other known mammalian 
protein. The receptor has been implicated with a number of diseases including cancer and 
depression. Modulation of the receptors activity with agonists has potential antidepressant 
activity whereas antagonists lead to death of cancer cells.  
 
Using radioligand binding assays, utilizing the cancer cell line MDA-MB-468, which 
highly expresses the sigma-1 receptor, a series of novel specific, high affinity, sigma-1 
receptor ligands have been characterised. These ligands differed from any previous sigma-
1 receptor ligand in that they are very simple ammonium salts, containing a single nitrogen 
atom and either straight or branched carbon chains. The binding studies revealed that the 
straight-chain ammonium salts gave nH values of 1 whereas the branched-chain 
ammonium salts had statistically significant lower nH values. 
 
The ammonium salts were tested for sigma-1 receptor activity in vitro using ratiometric 
Fura-2 calcium assays and the MTS cell proliferation assay. Branched-chain ammonium 
salts appeared to have sigma-1 receptor antagonist like effects on cytoplasmic calcium and 
cell proliferation, whereas the straight-chain ammonium salts behaved as sigma-1 receptor 
agonists. Three ammonium salts stood out as potential effective sigma-1 receptor drugs, 
the straight-chain ammonium salt dipentylammonium, and two branched-chain ammonium 
salts, bis(2-ethylhexyl)ammonium and triisopentylammonium. The ammonium salts were 
then tested in vivo, dipentylammonium showed significant antidepressant properties when 
tested in behavioural models for depression and bis(2-ethylhexyl)ammonium and 
triisopentylammonium were able to significantly inhibit the growth of tumours implanted 
in mice. 
 
Finally I looked at the coupling of the sigma-1 receptor with G-proteins and show that 
sigma-1 receptor antagonists dose dependently reduce G-protein activity and inhibition of 
G-proteins enhanced the sigma-1 antagonists’ effects of calcium signalling.  
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1 Introduction 
 
1.1 The importance of receptors and receptor theory 
 
Cells need to respond to a vast number of extracellular signals, whether the signal is telling 
the cell to produce a product, pass on a signal, divide, differentiate or die, the cell needs to 
be able to detect and distinguish between different signals. The cell does this by making 
use of receptors, which may be embedded in the membrane or free in the cytoplasm of the 
cell. There are vast arrays of receptors, which have evolved to sense the thousands of 
different signals, which a cell may need to respond to. However, the majority of receptors 
fall in to one of five classes: G-protein-linked; ion channel-linked; containing intrinsic 
enzymatic activity; tyrosine kinase-linked and intracellular. In order for a receptor to be 
effective at sensing the signals that are meant for a particular cell in which it is expressed, 
the receptor must have specificity for a particular ligand (or range of ligands), be able to 
detect these ligands and be able to transmit the message that the signalling molecule is 
conveying to the cell.  
 
Receptors, therefore, usually have affinity for their ligand within the range that it is likely 
to encounter the signalling molecule or molecules, and contain a specifically shaped 
binding site such that only the specific ligand or ligands for that receptor will bind 
effectively at the concentrations that the cell is likely to encounter the ligand. Activation of 
a receptor by a ligand results in a conformational change (Couette et al., 1996, Henchman 
et al., 2005) that allows the signal to be conveyed in the cell. For example in G-protein 
coupled receptors this consists of activating a G-protein, which activates a downstream 
signalling cascade and in ion channel-linked receptors, ligand binding can open the 
channel allowing ions to flow through the membrane (Jelacic et al., 1999). 
 
A simple receptor model known as the 2 state model suggests a receptor may exist as an 
equilibrium between 2 states: active or inactive (Black and Leff, 1983, Del Castillo and 
Katz, 1957) and a ligand known as an agonist has high affinity for and stabilises the active 
conformation of the receptor shifting the equilibrium to the active state resulting in a 
physiological response. A ligand known as an inverse agonist has high affinity for and 
stabilises the inactive state, therefore shifting the equilibrium to the inactive state and 
removing any constitutive activity, resulting in a negative physiological response (Figure 
1.1). 
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Figure 1.1 Example of a dose response to different types of ligands. The full agonist is 
able to produce a maximal response, whereas the partial agonist does not, even when 
occupying the maximum number of receptors. The inverse agonist induces a negative 
response by reducing any constitutive activity of the receptor. 
 
A receptor agonist may only need to occupy a small fraction of the available receptors in 
order to produce a maximal response, whereas a ligand known as a partial agonist may 
need to occupy a greater proportion of receptors in order to elicit a response, and may not 
be able to elicit a maximal response despite occupying all the available receptors. The 
relationship between receptor occupancy and receptor activation is known as efficacy. 
Efficacy can be thought of as a ligand’s preference for the active receptor over the inactive 
receptor, i.e. if the ligand has a higher affinity for the active receptor than the inactive 
receptor this will result in positive efficacy and therefore, if the ligand has higher affinity 
for the inactive state of the receptor this results in negative efficacy. A ligand that shows 
no preference in affinity for the active or inactive receptor has zero efficacy and is known 
as an antagonist. An antagonist does not activate or inactivate a receptor rather it blocks 
the binding site preventing the binding of other ligands. For a review on the classification 
of receptor ligands see Kenakin, 1984. 
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1.2  History of the σ-1 receptor 
 
The search for understanding of the sigma-1 receptor (σ-1R) has been a long, mysterious 
and as yet incomplete journey. The receptor has mostly been studied within the central 
nervous system (CNS). However, more recent work over the past decades has shown the 
receptor to be abundant in neuronal, and non-neuronal tissues (Vilner et al., 1995b) leading 
to the study of the σ-1 receptor in cancer biology (Spruce et al., 2004).  
 
The sigma opioid receptor was proposed as a novel fourth opioid receptor in 1976 to 
account for the effects of N-allylnormetazocine (SKF-10,047) which could not be 
accounted for by the µ (morphine) receptor, κ (ketocyclazocine) receptor or δ receptor 
(Martin et al., 1976). Rather than causing analgesia, as with morphine, benzomorphans 
such as SKF-10,047 and pentazocine cause psychotomimesis. Martin proposed that SKF-
10,047 was acting as a sigma opioid receptor agonist, in order to cause the psychological 
and behavioural effects which were observed (Martin et al., 1976).  
 
SKF-10,047 was defined as an agonist as it raised pulse and respiration rates, as well as 
body temperature and caused dilation of pupils in Beagles. Interestingly, µ receptor 
agonists lowered pulse and respiration rates, as well as body temperature and produced 
classic pin-point pupils. Antagonists were defined as agents which were able to prevent 
these responses (Martin et al., 1976). Later biochemical studies suggest that biochemically 
agonists do not cause activation of the receptor but can block the effects of antagonists, 
which do (Hayashi et al., 2000, Katnik et al., 2006, Monnet et al., 2003, Spruce et al., 
2004, Tchedre et al., 2008). More recently, data obtained using mice in which the σ-1R 
has been knocked out further cloud the picture (Cendan et al., 2005, De La Puente et al., 
2009, Entrena et al., 2009, Langa et al., 2003, Sabino et al., 2009). Expression of σ-1R 
acts as a prosurvival signal (Spruce et al., 2004, Wang et al., 2005) and treatment with 
antagonists causes apoptosis (see below) – perhaps suggesting that antagonists could be 
acting as inverse agonists at the receptor. Without further understanding the σ-1R, it is 
premature to redefine the concept of agonist and antagonist at this time. For the purpose of 
clarity, I will continue to describe agonists as those mimicking the effects of SKF-10,047 
although accepting that with hindsight one could argue that SKF-10,047 is really an 
antagonist. In 1982 Su identified a nanomolar affinity SKF-10,047 binding protein using 
[3H] SKF-10,047. This SKF-10,047 binding protein appeared to be different from the 
sigma opioid receptor identified by Martin in 1976 (Su, 1982), as the opioid antagonist 
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naloxone showed no affinity under the conditions tested. Further study of this protein 
showed stereoselectivity for the dextrorotary benzomorphans such as (+) SKF-10,047 and 
(+) pentazocine, rather than the laevorotatory enantiomers. This stereoselectivity is the 
opposite to that found in the other opioid subtypes in either binding or behavioural studies, 
further suggesting that the SKF-10,047 binding protein was not an opioid receptor. Su 
proposed that the receptor was a novel system distinct from the opioid subclasses and may 
not represent a single homogeneous receptor population. The receptor was later termed 
“sigma receptor” distinguishing it from the opioid receptors (Su, 1982).  Su also noted that 
none of the endogenous opioid ligands potently inhibited sigma receptor binding and 
speculated on a potential endogenous sigma ligand. However an endogenous ligand for the 
sigma receptor has yet to be conclusively identified. 
 
The sigma receptor then became confused with the 1-(1-phenylcyclohexyl)piperidine 
(PCP) site of the N-methyl-D-aspartic acid (NMDA) receptor, since SKF-10,047 binds the 
PCP site well, and PCP also happens to bind the sigma receptor with a notable affinity 
(Vaupel, 1983). Further binding studies using the more specific ligands for both the sigma 
receptor and the NMDA receptor revealed them to be distinct from each other (Quirion et 
al., 1987, Tam, 1985). This distinction was furthered when using autoradiographic 
techniques identified the locations of the PCP and the SKF-10,047 sites and found them to 
be distributed differently (Gundlach et al., 1986, Largent et al., 1986). Since then the 
radioligand of choice for sigma receptor studies has been [3H] (+) pentazocine in place of 
[3H] (+) SKF-10,047. 
 
Further studies of the sigma receptor using (+) pentazocine found a second sigma-like 
binding site, which has a similar binding profile to that of the receptor previously described 
by Su (Su, 1982). However the affinities for the (+) benzomorphans were lower, and 
moreover in some instances there appeared to be a greater selectivity for the (-) isoforms 
(Bowen et al., 1990, Hellewell and Bowen, 1990). This led to the classification of the two 
subclasses of the sigma receptor, the sigma-1 receptor (σ-1R) and the sigma 2 receptor (σ-
2R). Following the identification of the 2 subtypes there was an attempt to clear up the 
confusion in the literature caused by studies using non specific sigma ligands (Quirion et 
al., 1992). A proposal was laid out specifying the binding properties of the σ-1R  and σ-
2R, concluding amongst other things that the preferred radioligands should be [3H] (+) 
pentazocine for the σ-1R and [3H] (+) 1,3-di-o-tolylguanidine (DTG) in the presence of σ-
1R blockers for the σ-2R (Quirion et al., 1992).  
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1.3 σ-1 receptor ligands  
 
The σ-1R was identified for its affinity for dextrorotary benzomorphans such as (+) 
pentazocine or (+) SKF-10,047 (Martin et al., 1976). However since its discovery the σ-1R 
has become known for its ability to bind a wide range of ligands including antipsychotics 
such as haloperidol (Su, 1982), antidepressants such as imipramine and fluoxetine 
(Bermack and Debonnel, 2005), and neurosteroids including progesterone (Su et al., 1988, 
Waterhouse et al., 2007). A vast number of synthetic compounds have been synthesised, 
with high σ-1R affinities including 1-(4-iodophenyl)-3-(2-adamantyl)guanidine (IPAG) 
and DTG. For a list of σ-1R ligands, structures and affinities see table 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 6 
Table 1.1 
σ-1 Ligand Affinity 
(µM) 
Function Structure 
Benzomorphans 
(+) SKF-10,047 0.060b Agonist 
 
(-) SKF-10,047 5.2b Agonist  
 
 
 
 
(+) Pentazocine 0.003b Agonist  
 
(-) Pentazocine 0.083b Agonist  
 
(+) 3-PPP 0.03b Agonist 
 
Antipsychotics  
Chlorpromazine 0.685i Antagonist 
 
Haloperidol 0.0037b Antagonist 
 
Rimcazole  0.9c Antagonist 
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Table 1.1 continued 
 
Antidepressants 
Citalopram 
 
0.292a Agonist 
 
Fluoxetine 0.240 a Agonist 
 
Fluvoxamine  0.036 a Agonist 
 
Igmesine 0.039g Agonist 
 
Imipramine 0.343a Agonist 
 
Neurosteroids 
Dehydroepiandrosterone 1.000h Agonist 
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Table 1.1 continued 
 
Other Synthetic Compounds 
Progesterone 0.061b Antagonist 
 
4-PPBP 0.0008e Antagonist 
 
BD 1008 0.0022b Antagonist 
 
BD1047 0.036j Antagonist 
     
DTG 0.028b Agonist 
 
IPAG 0.0028d Antagonist 
 
NE 100 0.0046b Antagonist 
 
SA4503 
 
0.017f Agonist 
 
Table 1.1  
Sigma-1 receptor ligands, their affinities (µM), σ-1 agonist/antagonist and structure.   
aNarita et al., 1996  eGlennon et al., 1991  iItzhak et al., 1990 
bWhittemore et al., 1997 fMatsuno et al., 1997  jMatsumoto et al., 1995  
cGilmore et al., 2004  gRoman et al., 1990  
dWilson et al., 1991  hSu et al., 1988 
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The endogenous ligand for the σ-1R has yet to be identified. Neurosteroids, in particular 
progesterone, are the main candidates for the endogenous ligand (Ramamoorthy et al., 
1995, Su et al., 1988). However their affinities for the σ-1R (Figure 1.2 and Table 1.2) 
appear to be too low for them to be endogenous ligands. The physiological levels of 
progesterone during pregnancy can reach up to 400nM, however only 2% of this is free to 
pass the blood brain barrier (Pardridge, 1988, Schwarz et al., 1989), resulting in only 
approximately 8nM free progesterone that is able to interact with σ-1Rs in the CNS 
(Schwarz et al., 1989).  
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Figure 1.2: Progesterone competition with [3H] (+) pentazocine in permeabilised 
MDA-MB-468 cells. The K50 (concentration of ligand occupying 50% of available 
receptors) for progesterone binding to the σ-1R in MDA-MB-468 cells is 64nM (nH -
0.61). Error bars indicate SEM from 3 independent competition binding assays. 
 
 
Tissue σ-1R K50 Radiolabelled ligand 
MDA-MB-468  64 nMa [3H] (+) pentazocine 
Brain membranes  268 nMb [3H] (+) SKF-10,047 
Spleenocytes 376 nMb [3H] (+) SKF-10,047 
 
Table 1.2: Affinity of Progesterone for the σ-1 R. a data obtained form 3 independent 
[3H] (+) pentazocine competition binding assays. b data obtained from Su et al., 1988. 
 
Progesterone however, along with other steroids still remain strong candidates for the 
endogenous ligand for the σ-1R (Bergeron et al., 1999), since progesterone binding shows 
as low nH value (Figure 1.2) there could be a multiple affinity site binding. Furthermore, 
the gonads express high levels of the σ-1R (Su, 1993). Other endogenous ligands have 
been suggested including the hallucinogen N,N-dimethyltryptamine. However, despite 
showing agonist activity at the σ-1R, its affinity is far lower than that of progesterone at 
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15µM, and in order to see an effect at voltage-gated sodium channels a dose of 100µM 
N,N-dimethyltryptamine is required (Su et al., 2009). Moreover no conclusive study has 
been conducted to quantify the amount of N,N-dimethyltryptamine found in blood or 
cerebrospinal fluid (Burchett and Hicks, 2006). N,N-Dimethyltryptamine also interacts 
with the 5-HT2A receptor (Gouzoulis-Mayfrank et al., 2005) at a concentration over 10 
times lower than required to interact with the σ-1R (Ki 4µM) (Cozzi et al., 2009) and 
therefore its is still unclear whether the effects are mediated through the σ-1R or the 5-
HT2A receptor. 
 
As more and more σ-1R ligands have been identified, and the study of the σ-1R furthered, 
some confusion in the classification of σ-1R ligands has emerged. As described above, the 
original behavioural experiments by Martin et al. (1976) using ligands such as (+) SKF-
10,047 and (+) pentazocine resulted in psychotomimesis (along with the effects previously 
described), and these ligands were classified as σ-1R agonists since they produced a 
response in the animals. It was only later when the σ-1R ligands were investigate more 
closely that it was discovered that the σ-1R antagonists modulate cytoplasmic calcium 
levels (Brent et al., 1996a, Brent et al., 1996b), block voltage-gated potassium channels 
(Aydar et al., 2002, Soriani et al., 1998), control plasma membrane cholesterol content 
(Hayashi and Su, 2003b, Hayashi and Su, 2004, Hayashi and Su, 2005b, Palmer et al., 
2007, Schwarz et al., 1989, Su et al., 1988) and induce apoptosis (Aydar et al., 2006, 
Aydar et al., 2004, Bem et al., 1991, Brent and Pang, 1995, Palmer et al., 2007, Spruce et 
al., 2004, Vilner et al., 1995b), whereas the σ-1R agonists block these effects. This is of 
course the reverse of the way in which receptor ligands are classified, however, this 
nomenclature is set in the literature such that ligands such as (+) pentazocine and (+) SKF-
10,047 are σ-1R agonists and ligands such as IPAG and rimcazole are σ-1R antagonists.  
1.4 σ-1 receptor structure and function 
 
The σ-1R has been cloned, originally from guinea pig (Hanner et al., 1996), and has now 
been cloned from a number of other species including humans, rats and mice (Kekuda et 
al., 1996, Mei and Pasternak, 2001, Pan et al., 1998). Currently there is still no crystal 
structure available; consequently the σ-1R structure has been predicted using sequence 
homology and hydrophobicity analysis. The original analyses have predicted at least one 
transmembrane region (Hanner et al., 1996, Kekuda et al., 1996, Seth et al., 1997) (Figure 
1.3A). More recently, however, Aydar et al. (2002) have provided evidence that the σ-1R 
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is found in the plasma membrane with both the N and C termini in the cytoplasm (Figure 
1.3B). They showed this by green fluorescent protein (GFP) tagging either the N or C 
terminal, followed by expression in a human cell line. Subsequently they were only able to 
see anti-GFP antibody binding having permeabilised the cell membranes (Aydar et al., 
2002). Therefore, both the N and C termini must reside inside the cell otherwise GFP 
antibody binding would have been observed in intact cells. It should be noted, however, 
that adding the bulky GFP tag to the relatively small σ-1R and expressing it in cells that 
otherwise do not express this receptor could have potentially altered its membrane 
topology. 
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A 
 
B  
 
Figure 1.3: Predicted σ-1R structures. A: σ-1R with single transmembrane region, with 
the N terminus on the outside. B: σ-1R with two transmembrane regions with both the N 
and C termini on the inside. Figures adapted from Aydar et al., 2004. 
 
 
Analysis of the σ-1R gene sequence has shown it to be a unique class of receptor, distinct 
from the opioid receptors and the NMDA receptor (Hanner et al., 1996, Seth et al., 1997).  
The σ-1R consists of a 223 amino acid long protein, which shares no homology with any 
other known mammalian protein. 
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In the N-terminus of the σ-1R protein sequence there is an arginine-arginine endoplasmic 
localisation signal (see appendix for sequence). The σ-1R is located at both endoplasmic 
reticulum and the cell membrane (Aydar et al., 2002), particularly lipid-rich areas (Aydar 
et al., 2006, Hayashi and Su, 2003b). It has been reported that σ-1R translocates from the 
endoplasmic reticulum to the plasma membrane on stimulation with σ-1R agonists such as 
(+) pentazocine (Hayashi and Su, 2001, Mavlyutov and Ruoho, 2007, Morin-Surun et al., 
1999) where they have been shown to block voltage-gated ion channels (Monnet et al., 
2003).  
 
Experiments using Ca2+-free buffers indicate that the σ-1R favours calcium influx 
mediated at the plasma membrane rather than Ca2+ release from intracellular stores 
(Mavlyutov and Ruoho, 2007, Morin-Surun et al., 1999, Novakova et al., 1998, Spruce et 
al., 2004). σ-1R agonists alone do not induce calcium influx into the cell, rather they are 
able to potentiate glutamate-induced Ca2+ increases (Monnet et al., 2003). σ-1R 
antagonists, including rimcazole and IPAG induce a rapid increase in cytoplasmic [Ca2+], 
which can be inhibited by σ-1R agonists such as (+) pentazocine and SKF-10,047, 
although a 30 minute pre-incubation is required (Spruce et al., 2004). The spike in 
intracellular [Ca2+] caused by σ-1R antagonists leads to caspase-dependent apoptosis, 
which suggests that the presence of the σ-1R acts as a survival signal to the cell (Spruce et 
al., 2004). 
 
1.5 σ-1 receptors, G-proteins and ion channels  
 
The debate as to whether σ-1Rs are G-protein coupled or not has been going back and forth 
and is yet to be satisfactorily concluded. Early σ-1R binding studies showed that the 
binding of σ-1R ligands could be altered by the addition of GTP and its analogues. Using 
rat brain membranes Itzhak (1989) showed that the σ-1R ligands (+) 3-PPP, (+) 
pentazocine and (+) SKF-10,047 bind the σ-1R at a high and a low affinity site in the 
presence and absence of GTP or its analogues. Other similar data showed that GTP and its 
analogues are able to modify the binding characteristics of σ-1R ligands (Beart et al., 1989, 
Connick et al., 1992). It has also been shown that σ-1R ligands can activate GTPase 
activity (Tokuyama et al., 1997). Furthermore, these studies have also shown that 
treatment with G-protein inhibitors such as pertussis toxin inhibits high-affinity (+)-3-PPP 
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binding, and removes the effect of GTP analogues on ligand binding (Itzhak, 1989). These 
data suggest that the σ-1R is Gi-protein coupled. However, cloning the σ-1R has revealed a 
223 amino acid protein that in no way resembles the classical 7 transmembrane G-protein 
coupled receptor. Other studies using GTPγS were unable to affect ligand binding at the σ-
1R (Hong and Werling, 2000). There has also been no evidence of σ-1R activating cyclic 
adenosine monophosphate (cAMP) production, suggesting it does not couple through Gs 
proteins (Odagaki et al., 2005). In order to explain this contradiction of results it has been 
proposed that the σ-1R could fall into further subtypes with one subtype acting though G-
proteins and another G-protein independent (Bermack and Debonnel, 2005).  
 
All the studies on the σ-1R’s link to G-proteins have used σ-1R agonists (Table 1.3), which 
with regard to the σ-1R do not behave biochemically in the same way true receptor 
agonists do.  They appear to behave more like typical antagonists, not having any effect at 
the σ-1R themselves other than possibly causing the translocation from the endoplasmic 
reticulum to the plasma membrane (Hayashi and Su, 2001, Mavlyutov and Ruoho, 2007, 
Morin-Surun et al., 1999) where the σ-1R can block ion channels (Monnet et al., 2003) or 
potentiate the response from other receptors (Monnet et al., 2003). The σ-1R antagonists 
on the other hand appear to have activity at the σ-1R, with rimcazole and IPAG causing an 
increase in cytoplasmic [Ca2+] which subsequently activates phospholipase C (PLC), and 
calcium dependent protein kinase B (PKB) inhibition, leading to caspase dependent 
apoptosis which could be inhibited with a 30min preincubation with σ-1R agonists (+) 
SKF-10,047 or (+) pentazocine (Spruce et al., 2004).  
 
Spruce et al. (2004) also showed that expressing the σ-1R alone was not enough to indicate 
sensitivity to σ-1R antagonists, as cerebellar granule neurons and human prostate epithelial 
cells showed no [Ca2+] increase in response to the σ-1R antagonists despite having high σ-
1R expression. This therefore suggests that the receptor can couple in different ways 
depending on the cell type, which could be a possible explanation for the discrepancy in 
the results seen in Table 1.3 
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Author Drug Agonist/ 
Antagonist 
Experimental 
output 
G-
Protein? 
Affect 
Hong and Werling, 
2000 
BD737 Agonist [35S]GTPγS No  
Hong and Werling, 
2001 
Neuropeptide 
Y 
Agonist [35S]GTPγS No  
Lupardus et al., 
2000 
(+) SKF-
10,047 
Agonist [K+] Current + GTPγS or 
GDPβS 
No  
Lupardus et al., 
2000 
(+) Pentazocine Agonist [K+] Current + GTPγS or 
GDPβS 
No  
Odagaki et al., 2005 (+) 3PPP Agonist [35S]GTPγS No  
Connick et al., 1992 DTG Agonist Gpp(NH)p effect 
competition binding 
Yes  nH of 
binding 
curve 
Itzhak, 1989 (+) 3PPP Agonist Gpp(NH)p effect 
competition binding 
Yes  nH of 
binding 
curve 
Itzhak, 1989 (+) Pentazocine Agonist Gpp(NH)p effect 
competition binding 
Yes  nH of 
binding 
curve 
Itzhak, 1989 (+) SKF-
10,047 
Agonist Gpp(NH)p effect 
competition binding 
Yes  nH of 
binding 
curve 
Schiess and 
Partridge, 2005 
Pregnenolone 
Sulphate 
Agonist Membrane potentials + 
pertussis toxin 
Yes  Neuron 
firing 
Ueda et al., 2001 DHEAS Agonist [35S]GTPγS + pertussis 
toxin 
Yes  GTPγS 
binding  
Ueda et al., 2001 Pregnenolone 
sulphate 
Agonist [35S]GTPγS + pertussis 
toxin 
Yes  GTPγS 
binding 
 
Table 1.3: σ-1R coupling to G-proteins in response to σ-1R agonists. 
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The σ-1Rs interaction with Ca2+ channels was demonstrated by the ability of (+) 
pentazocine to inhibit depolarization in rat forebrain synaptosomes (Brent et al., 1996b). It 
has been proposed that the modulation of calcium signalling by the σ-1R involves direct 
coupling in multi-protein complexes. σ-1Rs have been shown to anchor the cytoskeleton 
adaptor protein ankyrin to the endoplasmic reticulum membrane and modulate the function 
of ankyrin and the inositol 1,4,5-trisphosphate (IP3) receptor (Hayashi and Su, 2001). In 
the presence of the σ-1R agonist (+) pentazocine the σ-1R ankyrin complex dissociates 
from the IP3 receptor, leading to increased IP3 binding which in turn leads to increased 
Ca2+ efflux from the endoplasmic reticulum into the cytoplasm, whilst in the presence of 
the σ-1R antagonist NE-100 the σ-1R dissociates alone leaving the ankyrin associated to 
the IP3 receptor (Figure 1.4). These modulations of calcium currents implicates the σ-1R in 
various cell functions including neurotransmitter release (Hayashi and Su, 2001). 
 
 
 
 
 
 
Figure 1.4: Possible σ-1R regulation of the IP3 receptor and ankyrin (Hayashi and Su, 
2001). σ-1R agonists such as (+) pentazocine lead to σ-1R and ankyrin dissociation from 
the IP3 receptor leading to increased Ca2+ release whereas σ-1R antagonists such as NE-
100 lead to σ-1R dissociation alone, leaving ankyrin associated with the IP3 receptor 
reducing the Ca2+ release. 
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σ-1R ligands have been shown to inhibit numerous types of K+ channel including voltage-
gated K+ channels and Ca2+-activated K+ channels; these inhibitions are not sensitive to the 
G-protein inhibitor GDPβS or the G-protein activator GTPγS and in the absence of the σ-
1R the inhibition by σ-1R ligands did not occur (Lupardus et al., 2000). σ-1R agonists also 
cause the inhibition of Na+ channels, and again knocking down the σ-1R reduced the effect 
of the σ-1R agonists (Johannessen et al., 2009). However it should be noted that these 
experiments were looking at σ-1R agonists, not antagonists. 
 
1.6 σ-1 receptor distribution and knock-out. 
 
The σ-1R is expressed in many parts of the brain and central nervous system, and may also 
be found in many non-neuronal cells including the heart, liver, placenta, immune cells, 
kidney, gonads and pancreas (Ola et al., 2001, Seth et al., 1997, Zamanillo et al., 2000). 
The σ-1R has also been found to be expressed at high levels in embryonic stem cells, at all 
stages of embryogenesis, found at high levels in the CNS, developing spinal cord, 
developing limbs, and inside the thoracic and abdominal cavities (Langa et al., 2003). This 
is a period of rapid growth and cell division, the presence of σ-1Rs at this time reiterates 
the proposal that these receptors are part of a survival signal. 
 
σ-1R knock-down using σ-1R specific siRNAs in human lens cells resulted in cell death, 
compared to cells treated with the non-targeting control siRNA (Wang and Duncan, 2006). 
A similar study using σ-1R antagonists with the human lens cells resulted in cell 
pigmentation and death (Wang et al., 2005). These two studies and the study by Spruce et 
al. (2004) using σ-1R antagonists to selectively kill cancer cells, suggest that the σ-1R acts 
as a survival signal to the cells, and that switching it off either by stopping expression with 
siRNAs or by using σ-1R antagonists leads to death of the cell. 
 
A σ-1R knock-out mouse has been created (Langa et al., 2003). Despite the wide 
distribution of the σ-1R, the homozygous σ-1R knock-out mice were viable and fertile. 
Moreover, they do not appear to show any obvious phenotype when compared to wild-type 
mice (Langa et al., 2003). Acute knock-down of the σ-1R does have detrimental effects on 
a number of cell lines including cell death (Wang and Duncan, 2006, Wang et al., 2005) 
which suggests that there are some compensatory mechanisms which take over in the σ-1R 
knock-out mouse (Hayashi and Su, 2005). When the σ-1R knock-out mice were treated 
with σ-1R agonist SKF-10,047 it did not induce an increase in motility as seen in the wild 
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type mice, supporting the hypothesis that the σ-1R is involved in psycho-stimulant actions 
(Langa et al., 2003). 
 
There have been a number of studies looking at the involvement of σ-1Rs in pain and 
analgesia, including a number using the knock-out mice. It has been shown that formalin-
induced pain is reduced in σ-1R homozygous knock-out mice (Cendan et al., 2005), 
capsaicin-induced mechanical allodynia was abolished in the σ-1R knock-out mice 
(Entrena et al., 2009) and cold or mechanical allodynia does not develop in σ-1R knock-
out mice that have been exposed to partial sciatic nerve injury (De La Puente et al., 2009). 
The underlying mechanism through which the σ-1R modulates pain responses appears to 
be through the regulation of cytoplasmic calcium, and calcium dependent processes 
(Figure 1.5).  
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Figure 1.5 Activation of the σ-1R increases intracellular calcium (De La Puente et al., 
2009). σ-1R activation leads to increased cytosolic calcium through the potentiation of 
calcium entry at the plasma membrane through the N-methyl D-aspartate (NMDA) 
receptor and voltage-gated calcium channels (VGCC), as well as through calcium 
mobilisation from intracellular stores through phospholipase C (PLC) activation and the 
inositol trisphosphate (IP3) receptor. This is followed by kinase sensitization and rapid 
transcriptional activation of key gene products involved in pain hypersensitivity. Blocking 
σ-1R activation or the absence of the σ-1 receptor prevent the up regulation of calcium 
dependent signalling. GPCR - G-protein coupled receptor; TKR - tyrosine kinase receptor; 
DAG - diacylglycerol; BDNF - brain derived neurotrophic factor; PKC - protein kinase C; 
NR1 - NMDA receptor subunit 1; PIP2 - phosphatidylinositol 4,5-bisphosphate. 
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1.7 σ-1 receptors and cholesterol. 
 
Despite sharing no homology with any known mammalian protein, the C terminus of the 
σ-1R does share homology with a fungal C7-C8 sterol isomerase, a product of the ERG2 
gene, which shares a 30% identity with the σ-1R (Hanner et al., 1996). The ERG2 protein 
has high affinities for σ-1R ligands such as ifenprodil (also an NMDA receptor antagonist), 
haloperidol and pentazocine (Moebius et al., 1997). The isomerase catalyses the shift of 
the C8(9) double bond on the B ring of sterols to the C7(8) position in the ergosterol 
biosynthetic pathway (Figure 1.6). Yeast lacking or containing a mutation in the ERG2 
gene require exogenous ergosterol, as its precursors are not a substitute without other 
mutations (Silve et al., 1996). σ-1R ligands such as ifenprodil and haloperidol are able to 
inhibit the growth of yeast by interfering with the C7-C8 isomerase catalytic activity 
(Moebius et al., 1996, Silve et al., 1996).  The ERG2 has therefore be suggested to be an 
ancestor of the σ-1R (Moebius et al., 1996). However the σ-1R is unable to rescue ERG2 
negative strains of yeast (Hanner et al., 1996), which suggests that the σ-1R has by itself 
no isomerase activity.  
 
The mammalian protein, emopamil binding protein (EBP) shares pharmacological 
similarities with the σ1R, having moderate to high affinities for σ-1R ligands such as 
pentazocine, haloperidol and ifenprodil (Moebius et al., 1997)  and has C7-C8 isomerase 
activity and therefore is considered to be the mammalian homologue of the yeast ERG2 
gene  (Moebius et al., 2003). Interestingly despite sharing many pharmacological 
similarities with the σ-1 R, EPB shares no homology with the σ-1 R, and the 
transmembrane topology is different, with EPB having 4 transmembrane regions, and the 
σ-1R only 2 (Moebius et al., 1997a, Moebius et al., 1997b, Silve et al., 1996).  
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Figure 1.6: Fungal sterol biosynthesis pathway highlighting the C7-C8 Sterol 
isomerase step. Ergosterol plays a similar role in the membrane of yeast as cholesterol 
plays for mammals, The C7-C8 sterol isomerase is an important enzyme in ergosterol 
biosynthesis in yeast as yeast lacking the enzyme do not survive. 
 
The pharmacological similarity between the σ-1R and these other cholesterol binding 
proteins led to further research into cholesterol binding to the σ-1R (Figure 1.7) (Palmer et 
al., 2007). Two cholesterol binding domains were identified in the σ1R, located such that 
cholesterol docking takes place within the plasma membrane and sharing a number of 
amino acids which appear to be obligatory for other σ-1R ligand binding (Palmer et al., 
2007).  It has been hypothesised that the σ-1R is capable of inserting cholesterol into the 
plasma membrane (Hayashi and Su, 2003b, Palmer et al., 2007), modulating lipid raft 
formation (Hayashi and Su, 2005a, Hayashi and Su, 2003b, Hayashi and Su, 2004, Hayashi 
and Su, 2005b, Mavlyutov and Ruoho, 2007, Palmer et al., 2007, Takebayashi et al., 2004) 
Fecosterol 
Episterol 
Ergosterol 
C7-C8 Sterol Isomerase 
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Figure 1.7: Predicted σ-1R structure highlighting the amino acids involved in 
cholesterol binding. Adapted from Palmer et al., 2007. The σ-1R with 2 transmembrane 
regions and a 3rd membrane-associated region containing the amino acids essential for 
cholesterol binding. 
 
1.8 σ-1 receptors and lipid rafts 
 
It was once thought that the main function of phospholipid bilayers was as a solvent for 
membrane proteins which were free to move about randomly (Singer and Nicolson, 1972). 
It is now widely accepted that the plasma membrane plays a more functional role in 
cellular function. Free-moving, stable, lateral assemblies of sphingolipids and cholesterol 
form what are known as lipid rafts (Figure 1.8) (Edidin, 2003, Simons and Ikonen, 1997). 
Amongst other functions lipid rafts bring together and appear to be able to control a 
number of signalling proteins, including glycosylphosphatidylinositol (GPI)-anchored 
proteins (Hooper, 1999), double acetylated proteins such as the src-family kinases or the α-
subunit of the heterotrimeric G-proteins (Resh, 1999) and transmembrane proteins. Lipid 
rafts are involved in a number of cellular functions including cellular differentiation and 
programmed cell death (apoptosis) (Galbiati et al., 2001, Zhang et al., 2009). The 
distribution of lipid rafts over the cell membrane differs depending on the cell type. In 
neurons lipid rafts are more abundant on somal and axonal membranes than on dendritic 
membranes. Lipid rafts are also found on post-synaptic sites of neurones (Suzuki, 2002). 
Neuronal lipid rafts appear to play a role in cell adhesion, modulation of ion channels and 
neurotransmitter release (Chamberlain et al., 2001).  
Plasma membrane 
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Cholesterol plays an important part in lipid raft formation, maintaining membrane integrity 
and fluidity (Silvius, 2003), whilst also acting as a spacer between the hydrocarbon chains 
of the sphingolipids (London and Brown, 2000, Simons and Toomre, 2000). There is 
evidence to suggest that the σ-1R binds to cholesterol, as described above in (Figure 1.7) 
(Palmer et al., 2007), and that it associates with lipid rafts, modulating their cholesterol 
content changing their formation and therefore potentially affecting the signalling 
molecules that are associated with these lipid rafts (Hayashi and Su, 2003b, Hayashi and 
Su, 2003a, Hayashi and Su, 2004, Hayashi and Su, 2005b, Palmer et al., 2007, 
Takebayashi et al., 2004).  
 
Figure 1.8: Lipid raft formation. The lipid raft forms a stable domain separating it from 
the rest of the membrane, recruiting specific receptors and proteins to form scaffolds for 
signalling processes. 1: Raft associated membrane receptors 2: GPI-anchored protein 3: 
Glycolipid 4: Non-raft membrane 5: Cholesterol. Adapted from Edidin (2001).  
 
The cholesterol content of the plasma membrane is tightly regulated, involving the uptake 
of cholesterol rich low-density lipoproteins from the plasma and from synthetic pathways. 
Cholesterol accumulation has been shown to occur in a number of solid tumours including 
prostate (Freeman et al., 2005, Freeman and Solomon, 2004, Hager et al., 2006, Zhuang et 
al., 2002) and oral cancers (Kolanjiappan et al., 2003). Furthermore, cholesterol 
dysregulation has been identified in other malignancies including lung and breast cancers 
(Duncan et al., 2004). Given that cholesterol is an important component of lipid rafts, it is 
not surprising that lipid rafts appear to be up-regulated in a number of cancer cell lines, 
moreover disrupting lipid rafts by depleting cholesterol leads to apoptosis in certain breast 
cancer cell lines including MCF-7 and MDA-MB-231 cell lines and prostate cancer cell 
lines  including PC-3 (Li et al., 2006).  
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The σ-1R has been implicated in lipid and cholesterol transport from the endoplasmic 
reticulum to the plasma membrane. When functionally dominant negative σ-1Rs that are 
unable to interact with endoplasmic lipids or cholesterol, were transfected into NG108 
cells (a neuroblastoma cell line) there was a build up of lipid and cholesterol at the 
endoplasmic reticulum and a decrease cholesterol at the plasma membrane (Hayashi and 
Su, 2003). This, along with the evidence that the σ-1R can translocate from the 
endoplasmic reticulum to the plasma membrane (Hayashi and Su, 2001, Mavlyutov and 
Ruoho, 2007, Morin-Surun et al., 1999), suggests strongly that the σ-1R can modulate the 
cholesterol content of the plasma membrane, controlling the formation of lipid rafts and 
signalling domains.  
 
1.9 σ-1 receptors and cancer 
 
In normal healthy cells at any one time there are specific signals that prevent programmed 
cell death (apoptosis) and are likely to have evolved to maintain correct spatiotemporal 
patterning during development (Kerr et al., 1972, Raff, 1992). There are also signals that 
lead to apoptosis for example when a cell is damaged or has reached the end of its lifespan.  
 
Cancer is caused by abnormalities in the genetic material of cells, which can be caused by 
carcinogens such as tobacco smoke, radiation, chemicals, or infectious agents (e.g. 
viruses). Other cancer abnormalities can be caused by random mutations and errors during 
DNA replication, or can be inherited from a parent, therefore the abnormal gene will be 
found in every cell of the offspring. There are two classes of genes which are affected that 
go on to cause cancers. Oncogenes (under normal circumstances are called proto-
oncogenes) have roles in the promotion of cell division, if a mutation takes place in the 
proto-oncogene such that its expression is up regulated or its product is constantly active, 
driving cell division and growth, it becomes a tumour producing agent (Vogt, 1993). 
Examples of oncogenes include the GTPase Ras (Bracquart et al., 2009), tyrosine kinase 
receptors such as epidermal growth factor receptor (Lurje and Lenz, 2009) and 
transcription factors such as the Myc gene (Ruggero, 2009). The other class of genes that 
are affected that lead to cancers are known as tumour suppressor genes, these genes 
produce products that are responsible for preventing the cell from dividing. Examples 
include p53, which is mutated in 50% of human tumours (Hollstein et al., 1991) and acts to 
hold the cell in the G1 phase of the cell cycle such that damaged DNA can be repaired, and 
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is able to initiate apoptosis if the DNA damage is beyond repair (Zilfou and Lowe, 2009). 
Other examples include adenomatosis polyposis coli (APC), which when mutated leads to 
colorectal cancer (Markowitz and Bertagnolli, 2009), PTEN which works to negatively 
regulate the levels of phosphatidylinositol 3,4,5-trisphosphate preventing cells dividing too 
rapidly (Chu and Tarnawski, 2004) and CD95 (the Fas Receptor) which, on activation, 
leads to the formation of the death inducing signalling complex (DISC). Tumour 
suppressor genes usually require a mutation in both alleles in order to lead to a tumour-
forming mutation as usually the remaining allele is sufficient to protect the cell from 
tumourogenesis, whereas a single allele mutation of an oncogene is enough to allow the 
cell to avoid apoptosis (Knudson, 1971). 
 
Apoptosis can be triggered by an number of stimuli, including activation of death receptors 
(by cytokines such as tumour necrosis factor or Fas Ligand) and the formation of the 
DISC, oxidative stress, growth factor insufficiencies or calcium influx into the cytoplasm 
through channels in the plasma membrane or released from the endoplasmic reticulum 
(Mattson and Chan, 2003). The σ-1R has been shown to be involved in the influx of 
calcium into the cytoplasm (Spruce et al., 2004), and it is possible that the σ-1R can 
modulate lipid rafts, which have been linked with Fas receptor and DISC (Legembre et al., 
2006). The role of calcium in apoptosis is outlined in Figure 1.9, which shows an 
extracellular stimulus leading to cytoplasmic increases in calcium. With respect to σ-1R 
antagonist-induced apoptosis, this is likely to take place through the modulation of ion 
channels in the plasma membrane (Mavlyutov and Ruoho, 2007, Morin-Surun et al., 1999, 
Novakova et al., 1998, Spruce et al., 2004).  The increase in cytoplasmic calcium leads to 
an uptake of calcium into the mitochondria, which in turn leads to the release of 
cytochrome C into the cytoplasm, which activates caspase and nuclease enzymes. 
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Figure 1.9: The role of calcium and cytochrome C in cellular apoptosis (Mattson and 
Chan, 2003). Rapid increase in cytosolic calcium via calcium channels at the plasma 
membrane or via release from stores by phospholipase C activation and IP3 receptor 
activation, leads to calcium entry into the mitochondria, inducing the release of 
cytochrome C. Cytochrome C can cause further release of calcium causing more 
cytochrome C release from the mitochondria, forming apoptosomes and activating caspase 
cascades leading to DNA fragmentation. ER - Endoplasmic reticulum. 
 
Cells with limited access to nutrients and survival factors may have evolved by expressing 
σ-1Rs to prevent them from undergoing premature apoptosis (Goyagi et al., 2003, Maurice 
and Lockhart, 1997, Ola et al., 2001, Wang and Duncan, 2006, Wang et al., 2005). 
Avoiding apoptosis is also important to tumour cell survival, and one could suggest that 
tumours have hijacked the σ-1R as a potential driving force in cell survival (Wang and 
Duncan, 2006, Wang et al., 2005). Antagonising with σ-1R antagonists provides a 
potential way of releasing cells from an antiapoptotic drive (Spruce et al., 2004). 
Conversely, PRE-084, an agonist at the σ-1R, has been shown to prevent amyloid beta-
mediated toxicity in the rat retina. In this case, σ-1R agonists are preventing an apoptotic 
signal (Cantarella et al., 2007). 
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Cancer can affect people of all ages, and according to the World Health Organisation 
accounted for 13%  (7.4 million) of deaths world wide in 2004, and this figure is expected 
to rise to 12 million by 2030. Based on risk factors it is thought that 30% of cancers are 
preventable (Danaei et al., 2005), leaving 70% of cancers that require treatment. The 
principal treatment methods are a combination of surgery, chemotherapy and radiotherapy. 
Fundamental to adequate treatment is cancer imaging using ultrasound, endoscopy or 
radiography. σ-1Rs are highly expressed in a number of cancers and tumours, and have 
previously been shown to be useful in tumour imaging, using labelled σ-1R ligands in 
positron emission tomography (PET) scans (Kawamura et al., 2005).  A number of studies 
have shown, using radioligand binding, real time PCR, western blotting and 
immunohistochemistry techniques, that a wide range of human and mouse tumour cell 
lines express high levels of σ-1Rs (Aydar et al., 2004, Bem et al., 1991, Vilner et al., 
1995b). Using a range of cell lines Spruce et al. (2004) showed that the σ-1R antagonists  
such as rimcazole, haloperidol, BD1047, BD1067, cis-U50488 and IPAG were able to 
reduce tumour cell viability, moreover rimcazole and cis-U50488 were able to inhibit or 
reduce xenograft tumour growth. Wang et al. (2004) showed in a similar study that 
neoplastic breast epithelial cells expressed the σ-1R, and that haloperidol and progesterone 
inhibited tumour growth in a dose-dependent fashion at high concentrations. Aydar et al. 
(2006) also showed that silencing the expression of the σ-1R using an RNAi vector 
resulted in reduction of cell adhesion to the culture dish. This evidence appears to suggest 
that the σ-1R plays a role in cell survival and that the σ-1R is a potential target for cancer 
treatments.  
 
Interestingly, it has also been shown that σ-1R agonists can cause increases in tumour 
growth (Gardner et al., 2004, Zhu et al., 2003).  Both studies showed that σ-1R agonists 
such as cocaine and PRE-048 dose-dependently increased tumour growth. The growth was 
also dependent on IL-10, and could be blocked using either σ-1R antagonists or an IL-10 
antibody. However a immunohistochemical study of 95 patients with breast cancer showed 
no statistical correlation between σ-1Rs and tumour size or shape (Simony-Lafontaine et 
al., 2000). This study did however show that patients with a high σ-1R-expressing tumour 
lived longer in a disease-free state (81% showed no recurrence of the cancer within 5 
years) than those without σ-1R expression (Simony-Lafontaine et al., 2000). These results 
appear slightly paradoxical as it goes against the notion that the σ-1R is in some way 
promoting tumour growth and as yet these findings have yet to be explained. 
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1.10  σ-1 receptors and depression  
 
Depression is a seriously debilitating medical disorder, which can occur in early life and 
run a chronic course, adversely affecting the prognosis of a number of other medical 
conditions including diabetes (Charney and Manji, 2004), coronary vascular disease (Lett 
et al., 2004) and osteoporosis (Cizza et al., 2001). Common symptoms include long-lasting 
depressed mood, feelings of guilt, anxiety and it is not uncommon for patients with severe 
depression to commit suicide (Kessler et al., 2005); in 1999 the number of suicides in the 
USA was 30,000 and is the 3rd leading cause of death between 15 and 24 year olds 
(Charney and Manji, 2004).  
 
The main theory behind depression is the monoamine hypothesis (Schildkraut et al., 1965), 
which states that depression is caused by a functional lack of monoamine neurotransmitters 
such as serotonin (5-HT), dopamine and noradrenaline in specific parts of the brain. The 
hypothesis was borne out of clinical observations of various drugs that appeared to 
alleviate depression and were known to have effects on monoaminic neurotransmission in 
the brain. Early versions of antidepressants were monoamine oxidase inhibitors, such as 
phenelzine, which acutely increase monoamine function by preventing their metabolism 
(Manji et al., 2001, Morilak and Frazer, 2004) resulting in an increase in the cytosolic 
stores of 5-HT, noradrenaline and dopamine (Figure 1.10). Another early form of 
antidepressants were the tricyclics such as imipramine and clomipramine, these work by 
blocking the monoamine transporters, again resulting in an increase in available 
noradrenaline or 5-HT in the synaptic cleft. The tricyclic and the monoamine oxidase 
antidepressants have a number of undesirable side-effects, are incompatible with many 
other drugs, in the case of the monoamine oxidases foods (“The cheese effect” - 
monoamine oxidase inhibition in the gut results in the prevention of the breakdown of 
normally innocuous amines) and interactions with other neurotransmitter receptors result 
in toxicity in overdose (Stahl, 2005). Recent development of selective re-uptake inhibitors 
such as the selective 5-HT re-uptake inhibitors (SSRIs) have strengthened the monoamine 
hypothesis (Renard et al., 2001, Ressler and Nemeroff, 2000), and largely superseded the 
tricyclics and monoamine oxidase inhibitors (Stahl, 2005). SSRIs include fluoxetine, 
fluvoxamine, citalopram and sertraline; they act to selectively block 5-HT re-uptake over 
noradrenaline re-uptake and are less likely than the tricyclics to cause dangerous side 
effects, and do not cause “the cheese effect.”  
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Figure 1.10 The synapse. Neurotransmitter release from the axon in response to 
depolarisation passing the signal onto the adjacent cell.  Monoamine oxidase (MAO) 
inhibitors act to prevent neurotransmitter  breakdown resulting in an increased stock of 
transmitter waiting to be released. Tricyclic antidepressants nonspecifically block 
neurotransmitter re-uptake pumps. Selective re-uptake inhibitors prevent the specific 
uptake of a specific neurotransmitter.  
 
Despite the evidence for the monoamine hypothesis, such as the fact that nearly all 
effective antidepressant drugs result in noradrenaline or 5-HT increase in the synapse, 
either through blocking re-uptake or preventing breakdown of the neurotransmitters (Stahl, 
2005), there are problems with the monoamine hypothesis. The current antidepressant 
drugs are effective in less than 50% of patients (Nestler et al., 2002). Furthermore, chronic 
treatment with antidepressant drugs is required in order to see clinical effects, the reason 
for this is still unknown (Hyman and Nestler, 1996).  
 
A major problem in antidepressant activity is the lack of validated animal models as the 
symptoms of depression, such as depressed mood, feelings of worthlessness and suicidality 
are difficult to measure and quantify in laboratory animals (Nestler et al., 2002). The 
current animal models therefore measure one of two things, the effect of known 
antidepressants, or the response to stress. Despite this the available models such as the 
forced swim test, where a mouse or rat is made to swim in a container and lack of 
MAO 
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struggling is thought to represent a state of despair (Porsolt et al., 1977), have had some 
success in predicting the antidepressant efficacy of new drugs in humans. However, no 
novel (non-monoamine-based) antidepressants have been identified (Nestler et al., 2002). 
Another problem with the available animal models is that acute treatment with the current 
available antidepressants results in apparent antidepressant activity despite in a clinical 
setting chronic treatment is required to see a antidepressant effect (Hyman and Nestler, 
1996). It should also be noted that the animals used in these studies of depression are 
“normal” animals without a genetic or underlying depressive condition. As yet no animal 
model for depression has been produced, and until the genes that make a subject 
susceptible to depression are identified a model is unlikely to be produced (Nestler et al., 
2002).  
 
The interest in the σ-1R and its involvement in depression began when it was noted that the 
antidepressants fluvoxamine, fluoxetine, citalopram, sertraline, clorgyline, and imipramine 
all had nanomolar affinity for the σ-1R (Itzhak and Kassim, 1990, Narita et al., 1996). It 
has since been shown that these antidepressants can behave as σ-1R agonists. The SSRI 
sertraline and the monoamine oxidase inhibitor clorgyline selectively, in a haloperidol 
sensitive fashion, potentiated NMDA neurotransmissions.  Further evidence for the σ-1Rs 
involvement in depression comes from a study showing that the SSRI imipramine reduced 
the number of σ-1Rs without affecting their affinity for [3H] DTG (Shirayama et al., 
1993).  It has been reported that the σ-1R specific drug NE-100 may regulate the 5-HT2A 
receptor (Narita et al., 1995), suggesting that the σ-1R interacts with serotonergic neurons. 
Furthermore, direct evidence from behavioral studies demonstrated that the σ-1R agonists 
tested, including (+) pentazocine, DTG, SKF-10,047 dose-dependently decreased the 
immobility time in the forced swim test, and the effects were antagonized by the σ-1R 
antagonists NE-100 or BD1047 (Urani et al., 2004).  Other σ-1R agonists have been shown 
to have antidepressant properties using the tail suspension test, including SA4503 
(Matsuno et al., 1996b, Matsuno et al., 1997, Ukai et al., 1998).  Igmesine has been shown 
to have antidepressant properties in the forced swim test (Urani et al., 2001) tail 
suspension test (Ukai et al., 1998) and the conditioned fear stress test (Urani et al., 2004). 
Igmesine has been used in a clinical study, where patients were given either the placebo, 
igmesine (25mg or 100mg/day) or as a positive control, 20mg/day fluoxetine. Igmesine 
and fluoxetine both showed statistically significant effects superior to the placebo (Volz 
and Stoll, 2004), suggesting that igmesine is potentially a clinically active antidepressant. 
However, igmesine has not been developed further as an antidepressant. Interestingly 
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Urani et al. (2002, 2004) showed that the σ-1R agonists SKF-10,047, PRE-084, igmesine, 
and DHEA sulphate, were more effective than SSRI or tricyclic antidepressants. 
Venlafaxine is an inhibitor of both 5-HT and noradrenaline reuptake, has affinity for the σ-
1R (Dhir and Kulkarni, 2007), and chronic treatment with venlafaxine has a shorter delay 
before antidepressant effects can be seen compared to other antidepressants (Mitchell and 
Redfern, 2005), which could potentially be attributed to the σ-1R activity.  
 
A study utilizing σ-1R knock-out mice to investigate the involvement of σ-1Rs in 
depressive behaviour showed that σ-1R negative mice had an increased immobility time in 
the forced swim test, therefore indicating a potential increase in depressive like behaviour 
(Sabino et al., 2009). This is consistent with the studies showing σ-1R agonists reduce 
immobility time in the forced swim test, (Akunne et al., 2001, Dhir and Kulkarni, 2007, 
Dhir and Kulkarni, 2008, Matsuno et al., 1996a, Reddy et al., 1998, Ukai et al., 1998, 
Urani et al., 2001, Wang et al., 2007) and the binding studies that show currently clinically 
used antidepressants having σ-1R affinity (Dhir and Kulkarni, 2007, Dhir and Kulkarni, 
2008, Itzhak and Kassim, 1990, Narita et al., 1996, Wang et al., 2007). Sabino et al. 
(2009) suggest that the antidepressant effects seen though agonising the σ-1R (or 
depressant effects seen by knocking it out) are linked to serotonergic neurotransmission, 
since σ-1R agonists such as (+) pentazocine an DTG have been shown to increase 
serotonergic neurone firing (Bermack and Debonnel, 2001). This study further highlights 
the discrepancy in the nomenclature of σ-1R ligands, since knocking out the σ-1R has the 
same effect as using the σ-1R agonists such as SKF-10,047 begging the question are the σ-
1R agonists actually switching off the σ-1R?  
 
Another mechanism has been put forward to explain the antidepressant effects of σ-1R 
agonists, which involves the endoplasmic reticulum stress response (Sabino et al., 2009). 
Proteins synthesised at the endoplasmic reticulum are folded with the aid of chaperone 
proteins. Misfolded, malformed proteins are disposed of by endoplasmic reticulum-
associated protein degradation. When the amount of unfolded protein exceeds the 
endoplasmic reticulum’s capacity, cells can activate a defence mechanism known as the 
endoplasmic reticulum stress response (Yoshida, 2007). It is thought that deregulation of 
this stress response leads to a number of neurodegenerative and mood disorders including 
Alzheimer’s disease (Hoozemans et al., 2005, Katayama et al., 1999, Unterberger et al., 
2006) and bipolar disorder (Kakiuchi et al., 2005, Kakiuchi et al., 2004). Since the σ-1R, 
as described previously in relation to tumour formation, is cytoprotective it has been 
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hypothesised that the σ-1R is an endoplasmic reticulum chaperone protein that can 
counteract endoplasmic reticulum stress (Hayashi and Su, 2007) (e.g. controlling calcium 
signalling and possibly membrane cholesterol content). With respect to the Sabino et al. 
(2009) knock-out study, it could be the case that loss of the σ-1R results in a decreased 
ability to deal with endoplasmic reticulum stress, leading to cell death and impairment of 
neurotransmission, which results in the depressive like behaviour of the mice. 
 
1.11 Other aspects of the σ-1 receptor 
 
Addiction 
The σ-1 receptor has been known to have actions in addictive processes, despite the 
confusion with the NDMA and PCP receptors, selective σ-1 receptor drugs have been 
shown to modulate dopaminergic and serotoninergic systems. A number of recent studies 
have shown that σ-1R activation plays a role in the plasticity underlying reinforcement, 
and addictive processes (Maurice and Su, 2009). 
 
Cocaine 
Cocaine binds to the σ-1R with an affinity, depending on the enantiomer used, (+) 25.9µM 
(-) 6.7µM (Sharkey et al., 1988) and is able to activate the σ-1R producing its stimulant 
properties. Furthermore, pre-treatment with σ-1R antagonists blocks these stimulant 
effects. Also targeting the σ-1R with an antisense probe was able to inhibit the stimulant 
effects in the animals of cocaine (Matsumoto et al., 2002, Romieu et al., 2002). 
 
A second interesting connection between cocaine and the σ-1R is the link between 
cocaine, the σ-1R, HIV and immunity. Because cocaine binds the σ-1R and cocaine leads 
to enhanced HIV replication, the role of the σ-1 receptor in immune alteration has been 
investigated. Treatment of microglial cells with cocaine resulted in a dose-dependent 
increase in HIV expression, this increase was blocked by the σ-1R antagonist BD1047 
(Gekker et al., 2006).  
 
Amnesia 
The σ-1R has been studied extensively with respect to learning and memory, selective σ-
1R agonists when injected alone failed to improve learning, consolidation or retention 
phases of mnemonic processes but markedly improved the mnemonic process in animal 
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models of amnesia (Maurice and Su, 2009). In amnesia models induced by blocking 
cholinergic or glutamateric neurotransmissions the σ-1R agonists lowered the mnemonic 
deficits measured by behavioral processes assessing long term, short term and contextual 
or spatial memory (Maurice and Lockhart, 1997). A number of σ-1R ligands have been 
investigated mnemonic models including (+) pentazocine and (+) SKF-10,047, as well as 
more selective σ-1 receptor ligands such as PRE-084 and igmesine. In the water-maze test 
the impairment of spatial memory measured in aged rats could be reduced by σ-1R agonist 
treatment (Maurice et al., 1994).  
 
Alzheimer’s disease  
As described above, σ-1R expression and σ-1R agonists protect cells from apoptosis and 
there has been a number of studies that have looked into the use of σ-1R ligands for the 
protection of brain tissue in Alzheimer’s disease. The acetylcholinesterase inhibitor, 
donepezil, is used to treat Alzheimer’s disease and has been found to have high σ-1R 
affinity (15 nM) (Kato et al., 1999). Donepezil acts as a σ-1R agonist and has anti-amnesic 
effects against dizocilpine-, β-amyloid 25–35 peptide, or carbon monoxide-induced 
mnemonic impairment (Maurice et al., 2006). The σ-1R has been shown in vitro to be 
important in Alzheimer’s disease, β25–35 peptide-induced cell death in cultured cortical 
neurons could be inhibited by the σ-1R agonist PRE-084, and the agonist effects could be 
reversed by the σ-1R antagonist NE-100 (Marrazzo et al., 2005). Furthermore, when the σ-
1R agonists were injected into mice along with β25–35 peptide, the σ-1R ligands reduced 
β25–35 peptide damage to the hippocampus and reduced the learning and attention deficits in 
the mice (Goyagi et al., 2001). 
 
Schizophrenia  
Schizophrenia is characterised by positive symptoms (positive symptoms refers to 
symptoms that most individuals do not normally experience but are present in 
schizophrenia) that include delusions, hallucinations, paranoia and loss of touch with 
reality and negative symptoms (negative symptoms refer to the loss of traits found in 
normal/healthy individuals), which consist of loss of memory, lack of attention span and 
loss of motivation. The traditional antipsychotic, haloperidol, binds σ-1R with high affinity 
(Su et al., 1988), however, the link between schizophrenia and the σ-1R has yet to be 
satisfactorily demonstrated (Maurice and Su, 2009). Studies of polymorphisms in the σ-1R 
gene with relation to schizophrenia have yielded conflicting results. One study using 46 
randomly selected schizophrenic patients showed that the TT haplotype in the GC-241-
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240TT polymorphism and a substitution of A to C producing the substitution of a 
glutamine for a proline in the human σ-1R were significantly associated schizophrenia 
(Ishiguro et al., 1998). However, whilst other studies have identified these polymorphisms, 
they have not shown a significant correlation between these polymorphisms and an 
increased risk of schizophrenia (Ohmori et al., 2000, Uchida et al., 2003). 
 
Rimcazole was developed as a σ-1R targeting antipsychotic by the Wellcome Research 
Laboratories. Rimcazole was hypothesised as a novel antipsychotic which lacked the 
common side effects of other antipsychotics such as chronic blockade of dopamine 
receptors (Ferris et al., 1982). Clinical trials (in the 1980s) ended when at low doses 
limited efficacy was observed and higher doses resulted in grand mal seizures (Borison et 
al., 1991, Chouinard and Annable, 1984). 
 
1.12 Aims of this thesis 
 
The original pharmacophore of the σ-1R has been based on the original opioid receptor 
ligands, which often contain more than 1 nitrogen and have complex aromatic ring 
structures. A number of studies looking for a structure-activity-relationship between 
ligands and the σ-1R have been carried out before (Ablordeppey et al., 1998, Ablordeppey 
et al., 2000, Glennon et al., 1994). However all these studies have started with complex 
structures and not provided a simple new σ-1 ligand.  In this thesis I set out to reduce the 
complexity and identify a simple structure with σ-1R affinity and activity, without the 
minimum 7 synthetic steps required to make a new chemical entity (Baxendale et al., 2007, 
Ley and Baxendale, 2002). Furthermore, I sought to determine whether such a simple 
pharmacophore can be used as a basis for selective agonists and antagonists. 
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2 Materials and Methods. 
 
2.1 General materials 
 
General laboratory chemicals were purchased from Sigma-Aldrich Company Ltd (Dorset, 
UK). Tissue culture media, antibiotics, trypsin and serum were purchased from Invitrogen 
(Paisley, UK). Nunc tissue culture flasks and Nunc multiple well plates were purchased 
from Fisher Scientific (Loughborough, Leicestershire, UK). 
 
2.2 Tissue culture 
 
MDA-MB-468 (ATCC LGC Promotech, Middlesex, UK) and HEK 293 (ECACC) cells 
were grown in Dulbecco Modified Eagle’s minimum essential media (DMEM), 
supplemented with 4mM L-glutamine, 10% foetal calf serum (FCS), Fungizone 
(amphotericin B, 2.5µg/ml), penicillin (100 units/ml) and streptomycin (100µg/ml). MAC 
13 and MAC 16 cells were grown in RPMI media supplemented with L-glutamine, 10% 
FCS, Fungizone (amphotericin B, 2.5µg/ml) and penicillin (100 units/ml) /streptomycin 
(100µg/ml). The cells were incubated at 37 °C in a humidified air / 5% CO2 atmosphere. 
 
Materials and methods 
 37 
 
Figure 2.1: Phase contrast micrograph showing MDA-MB-468 cells growing in DMEM 
supplemented with FCS, L-glutamine, penicillin/streptomycin and Fungizone. 
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Figure 2.2: Phase contrast micrograph showing HEK 293 cells growing in DMEM 
supplemented with FCS, L- glutamine, penicillin/streptomycin and Fungizone. 
2.3 MDA-MB-468 propagation and storage 
 
MDA-MB-468 cells are human breast adenocarcinoma cells isolated from a 51-year-old 
black female. They were chosen for their high expression of the σ-1R (Spruce et al., 2004). 
MDA-MB-468 cells are adherent to tissue culture plastic. Cells were split having reached 
80% confluency, using 0.25% w/v trypsin 0.5mM ethylenediaminetetraacetic acid 
(EDTA), and incubated at 37°C until the cells had detached from the flask. An equal 
volume of DMEM 10% FCS was added to the cells before they were transferred to a sterile 
centrifuge tube and spun down at 240g. The pellet was resuspended in the required volume 
of DMEM 10% FCS, and transferred into tissue culture flasks.  
 
When freezing cells down for storage, the pellet would be resuspended in DMEM 10% 
FCS supplemented with 5% v/v DMSO, placed in to cryovials and the cells chilled down 
slowly to 4°C before being place at -20°C over night. The following day the vials were 
transferred to -80°C where they were stored until required.  
 
When thawing cells, vials were taken straight from the -80°C freezer, and placed into a 
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pre-warmed 37°C water bath to thaw. Once thawed the contents of the vial were 
transferred to a tissue culture flask containing DMEM 10% FCS that had been pre-warmed 
to 37°C in the humidified air incubator with 5% CO2. The flasks were incubated at 37°C 
overnight. The following day the media would be changed removing all cells that failed to 
adhere to the tissue culture plastic. 
 
2.4 General ligand preparation  
 
The simple amines were purchased from Sigma-Aldrich (Dorset, UK), Fluka (Sigma-
Aldrich, Dorset, UK) or Acros Organics (Fisher Scientific, Loughborourgh, UK) as either 
hydrochloride salts (HCl•) or as a free base (see Table 2.1). 
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Name Salt/Base Vender Chemical 
formula 
Structure 
Primary amines 
Propylammonium Free base Fluka C3H9N  
Butylammonium Free base Fluka C4H11N 
 
Pentylammonium Free base Fluka C5H13N 
 
Hexylammonium Free base Fluka C6H15N    
Branched-chain Primary amines 
1-Adamantlyammonium Free base Sigma 
Aldrich 
C10H17N NH2
 
2-Adamantlyammonium HCl•  Sigma 
Aldrich 
C10H17N NH2
 
Secondary amines 
Dimethylammonium HCl•  Sigma 
Aldrich  
C2H7N 
 
Diethylammonium HCl•  Sigma 
Aldrich 
C4H11N 
 
Dipropylammonium HCl•  Sigma 
Aldrich 
C6H15N 
 
Dibutylammonium Free base Sigma 
Aldrich 
C8H19N 
 
Dipentylammonium Free base Sigma 
Aldrich 
C10H23N 
 
Dihexylammonium Free base Sigma 
Aldrich 
C12H27N  
Secondary branched 
Diisopropylammonium Free base Sigma 
Aldrich 
C6H15N 
 
Diisobutylammonium HCl•  Sigma 
Aldrich 
C8H19N 
 
Bis(2-
ethylhexyl)ammonium 
Free base Sigma 
Aldrich 
C16H35N 
 
Di-sec-butylammonium Free base Sigma 
Aldrich 
C8H19N 
 
di-tert-amylammonium Free base Sigma 
Aldrich 
C10H23N 
N
H  
Tertiary amines 
Trimethylammonium HCl•  Fluka C3H9N  
 
 
Triethylammonium  HCl•  Fluka C6H15N 
 
Tripropylammonium HCl•  Sigma 
Aldrich 
C9H21N 
 
 
 
 
 
 
N  
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Table 2.1 continued  
Tributylammonium 
 
 
 
HCl•  Fluka C12H27N 
 
Tripentylammonium Free base  Sigma 
Aldrich 
C15H33N 
 
Trihexylammonium Free base Sigma 
Aldrich 
C18H39H 
 
Trioctylammonium Free base Sigma 
Aldrich 
C24H51N 
 
Tridodecylammonium Free base Sigma 
Aldrich 
C36H75N 
 
Branched-chain tertiary amines 
Triisopentylammonium Free base Fluka  C15H33N 
 
NN-diiso 
butylmethylammonium 
Free base  Sigma 
Aldrich 
C9H21N 
N
 
Quaternary amines  
Tetramethylammonium HCl•  Acros 
Organics 
C4H12N 
N
+
 
Tetraethylammonium HCl•  Sigma 
Aldrich 
C8H20N 
N
+
 
Tetrapropylammonium HCl•  Acros 
Organics  
C12H28N 
N
+
 
Tetrabutylammonium HCl•  Sigma 
Aldrich 
C16H36N 
N
+
 
 
Table 2.1: Simple ammonium salt structure, salt, and where it was purchased from. 
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The free base amines were made soluble in water by making the HCl salt. 5 ml of free base 
amine was dissolved in 15ml of ether, and hydrochloric acid (HCl) was added slowly until 
the mixture turned acidic, measured using universal indicator paper (Sigma-Aldrich, 
Dorset, UK). The resulting solid was filtered and any remaining solvent was removed 
under vacuum. If the solid did not come out of solution the solvents were removed under 
vacuum. 9-(3-((3R,5S)-3,5-dimethylpiperazin-1-yl)propyl)-9H-carbazole (rimcazole) 
(purchased from Sigma-Aldrich, Dorset, UK) was dissolved in DMSO, or methanol. 1-(4-
iodophenyl)-3-(2-adamantyl)guanidine (IPAG) (purchased form Tocris Bioscience, 
Bristol, UK) was dissolved in DMSO. [3H] (1S,9S,13S)-1,13-dimethyl-10-(3-methylbut-2-
en-1-yl)-10-azatricyclotrideca-2,4,6-trien-4-ol ((+)-pentazocine) (specific activity 32.2 
Ci/mmol) was purchased from Perkin-Elmer (Beaconsfield, UK). 
 
Rimcazole   (+) Pentazocine 
 
 
 
 
 
Figure 2.3: Structures of rimcazole and (+) pentazocine. 
 
2.5 General radioligand binding  
 
Cells were harvested prior to the experiments using 0.25% trypsin 1mM EDTA and stored 
at -20°C before use. On the day of the experiment cells were thawed and resuspended in 
10mM tris(hydroxymethyl)aminomethane (Tris) buffered saline (TBS) (10mM Tris 0.9% 
NaCl pH 7.4). The cells were permeabilised (5 pulses at 3.74KV/cm) and put on ice before 
use in the assay. Assays were set up in sets of 24 10ml tubes.  
2.6 Saturation binding 
 
The assay was set out as with the competition binding, other than the [3H] (+) pentazocine 
was made up 3000nM, 1000nM, 300nM, 100nM, 30nM, and 10nM, and 10 µl was added 
and to the 100µl final volume. The assays were carried out in duplicate and specific 
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binding calculated by subtracting the non-specific binding [3H] (+) pentazocine 
(determined with 0.1mM rimcazole in the assay) from the total [3H] (+) pentazocine 
binding.  
 
2.7 Competition assays 
 
 [3H] (+) Pentazocine was diluted in TBS to 300nM and 10µl were added to the tube giving 
a final assay concentration of 30nM. The competing ligand was prepared at 10 times the 
required concentration, and 10µl added to the tube. The volume was then made up to 50µl 
TBS, before adding 50 µl of the permeabilised cells to give a final volume of 100µl. The 
assay was then allowed to equilibrate for at least two hours at room temperature. After 
equilibration the cells were harvested using a Brandel M-24R cell harvester through 
untreated GF/B fired glass fibre filters (Semat International, St Albans. UK), washing with 
3 times 10ml room temperature TBS.  The glass fibre filters containing the cells with 
bound [3H] (+) pentazocine were placed into scintillation vial with 2ml of scintillant. The 
scintillant was allowed to soak into the filters overnight before counting in a Perkin Elmer 
Liquid scintillation analyzer Tricarb 2800TR (5min counts). Non-specific [3H] (+) 
pentazocine binding was determined using 0.1mM rimcazole. Under these conditions 
less than 10% of the [3H] (+) pentazocine was bound.  
 
Muscarinic receptor binding assays 
Rat brain membranes were prepared from freshly killed rats. The brain was immediately 
removed and placed on ice with TBS pH of 7.4. The brain was homogenised in 10ml of ice 
cold TBS by a Teflon-in-glass homogeniser for two 30s periods, the homogenates were 
weighed and then centrifuged at 40000g for 30 minutes at 4°C. The resultant supernatant 
was discarded and the pellets resuspended by homogenisation in fresh TBS. Protein 
concentrations were determined using the Bradford protein assay (Section 2.9). 1.35nM 
[3H] QNB (L-quinuclidinyl [phenyl-4-3H] benzilate; 48.0 Ci/mmol) (GE Healthcare), was 
incubated with rat brain membranes (0.5mg/ml) to which varying concentrations of 
ammonium salt compounds were added as with the σ-1R competition assays. The 
membranes were incubated and harvested as with the [3H] (+) pentazocine binding assays. 
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Competition binding with antagonists  
The assay was set as except that incubations were carried out for 6 hours to allow time for 
equilibration, since competing ligands with lower affinities require more time to reach 
equilibrium. The assay was also carried out on ice to prevent receptor internalization and 
preserve the 2 state nature of the receptor.  The cells were also washed 3 times in 10ml of 
TBS after permeabilisation to remove any native GTP. Cellular GTP concentration was 
checked using high performance liquid chromatography (HPLC). 
 
2.8 Cyclic AMP measurements  
 
MDA-MB-468 cells were cultured until confluent in a 175cm Nunc tissue culture flask 
before being harvested with 0.25% trypsin, EDTA 0.5mM. Cells were plated into 24-well 
multiplates at a confluency of 50%. The following day, DMEM was replaced with Tris-
buffer Krebs solution and cells were allowed to equilibrate for 30 minutes. Drugs were 
added for 30 minutes and the supernatant was removed before samples were quenched by 
the addition of 100µl 0.6M PCA. The supernatant was removed and neutralised with 18µl 
2M K2CO3. Further centrifugation allowed for the removal of potassium perchlorate 
precipitate. The supernatant was assayed for cAMP content using a commercially available 
kit (TRK432, GE Healthcare, Little Chalfont, UK). Assays were routinely performed at 
4oC in a total volume of 100µl. A 25µl portion of K2CO3-neutralised PCA containing 
standard amounts of cAMP (0.00625 to 4 pmoles) was added to 25µl buffer (Tris HCl 
50mM, EDTA 4mM, pH 7.5) containing trace levels of [3H] cAMP (approximately 
450fmol, 12.5nCi, 27,500 disintegrations per minute (DPM)). A soluble preparation of 
cAMP binding protein (50µl) was then added and assays were allowed to equilibrate. After 
2 hours at 4oC a 50µl aliquot of activated charcoal suspension was added and after 3 
minutes, samples were centrifuged at 15,000g for 3 minutes. Activated charcoal bound 
rapidly to the unbound cAMP thus separating it from that bound which remained in the 
supernatant The supernatant (100µl) was carefully removed and transferred into a 
scintillation vial, to which was added 2ml scintillation cocktail. Radioactivity was assessed 
using a liquid scintillation counter. 
 
In parallel, 25µl aliquots of cell extracts were treated in the same fashion. The amount of 
cAMP in each sample was calculated using GraphPad Prism by reading off the standard 
curve, fitted with linear regression. 
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2.9 Protein measurements  
 
Protein amounts were determined using BioRad Protein Dye Reagent, based on Coomassie 
Brilliant Blue G250. Bovine serum albumin (BSA) was dissolved in 0.1M sodium 
hydroxide. 10 µl were placed in a well of a 96-well plate at a concentration of 0-400µg/ml, 
followed by 200µl of the protein dye reagent (1:5 dilution). Following an incubation of 10 
minutes absorbance was measured at 595nm. 
2.10 MTS cell proliferation assay 
 
Cells were harvested with 0.25% trypsin and 1mM EDTA and spun down at 240g. The 
pellet was washed in fresh DMEM containing 10% FCS, before the cells were seeded onto 
a 96 well plate and allowed to adhere overnight. If cells were to be transfected, this took 
place on day 2 so they were left a further 24 hours before the addition of drugs, however if 
not then the drugs were added on day 2 and the cells incubated overnight (10X 
concentration and 10µl into 90µl of DMEM to give 1 X in the well).  
 
The day after drug addition the metabolic activity was measured using the CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS assay) (Promega, Southampton, 
UK). Metabolically active cells will convert 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) into media-soluble 
formazan, the absorbance of which can be measured at 490nm. The amount of formazan 
produced is directly proportional to the number of living cells in the well.  
 
 
MTS       Formazan 
Figure 2.4: Structures of MTS and formazan 
MTS from Promega and formazan which is produced by metabolically active cells from 
the MTS, images obtained from Promega MTS assay manual. 
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On the day of metabolic activity measurement, phenazine methosulfate (PMS) (an electron 
coupling reagent) was mixed with the MTS in a 1:20 ratio before 10µl of the MTS/PMS 
mix was added to the well of the 96 well plate containing 100µl of tissue culture media.  
Readings at 490nm were taken every 15 minutes for up to 2 hours until the readings 
levelled off. In between readings the 96 well plate was kept in the 37°C, 5% CO2 
humidified air incubator. Rates of cell metabolism were compared by taking the 
absorbance at the final time point at which the increase in absorbance is still linear (if the 
absorbance had reached a plateau by 2 hours then an earlier time point was used), minus 
the blank (well with media MTS/PMS but no cells) and taking away the absorbance at time 
0 minus the blank. The absorbance measured in untreated cells was designated as 100% 
and the absorbance in the blanks designated 0%.  
2.11 Fura-2 calcium measurements  
 
On the day of the experiment cells were harvested with 0.25% trypsin 1mM EDTA and 
spun down at 240g, the cell pellet was resuspended in a buffer containing 115mM NaCl, 
5mM KCl, 1mM NaH2PO4, 0.5mM MgSO4, 11mM glucose, 1.36mM CaCl2, 0.1% BSA, 
50mM Tris (note that Tris and not 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) was used to buffer the cells as HEPES has σ-1R affinity (Figure 2.5), with an 
affinity of approximately 10mM) pH 7.4. Approximately 20 million cells were 
resuspended in 2 ml of buffer. The cells were loaded with cell permeable Fura-2-
acetoxymethyl ester (Fura-2-AM) (5µM) (Invitrogen, UK) (a modified version of the 
calcium indicator developed in 1985 (Grynkiewicz et al., 1985), dissolved in DMSO and 
diluted 1/1000 in TBS) and incubated at room temperature for 45 minutes. Loading at 
room temperature rather than 37°C for 45 minutes reduced the cellular 
compartmentalization of the Fura-2 resulting in better loading of the cells (Roe et al., 
1990).  
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Figure 2.5: HEPES competition with [3H] (+) pentazocine. Error bars represent SEM 
from 3 independent radioligand competition experiments, using permeabilised MDA-MB-
468 cells. HEPES affinity for the  -1R was determined as (pKi + SEM) 1.9 ± 0.5. 
 
 
The cells were then spun down and washed in the warmed calcium buffer three times 
before being made up to 1 million cells per ml and incubated at room temperature for a 
further 30 minute to allow the acetoxymethyl groups to be removed by cellular esterases 
resulting in free Fura-2 in the cells. The cells were then kept in suspension in the dark at 
room temperature before use in calcium measurements. 2 ml of Fura-2 loaded cells were 
placed in a cuvette with a magnetic stirring bar and placed into the fluorometer, (Perkin 
Elmer luminescence spectrometer LS-50B) and were maintained at 37°C. The cells were 
excited at 340nm and 380nm and emissions were recorded at 510nm. When bound to Ca2+ 
Fura-2 undergoes an excitation shift between 335nm (calcium free) and 363nm (calcium 
saturated) whilst the emission wavelength remains unchanged. This can be visualized by 
scanning the excitation wavelength between 300nm and 400nm and recording the emission 
at 510nm Figure 2.6.  
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Figure 2.6: Fluorescence excitation spectra of Fura-2. Multiple solutions containing 
between 0 and 39.8 µM free [Ca2+], scanned between 250nm and 450nm and emission 
(Em) read at 510 nm. Data obtained from Invitrogen. 
 
The largest dynamic range for [Ca2+] dependent fluorescent signals is obtained by using 
the ratio of fluorescence emitted at 510 after excitation at 340nm and 380nm. At low 
concentrations of dye, taking 340/380 ratios allows accurate measurements of intracellular 
calcium and allows for differences in dye loading, cell thickness and other problems that 
can effect calcium measurements. 
 
Drugs were made up at 100 times concentration and pH balanced to 7.4 before 20µl was 
injected into the cuvette resulting in 1 x concentration in the cuvette. At the end of each 
individual experiment 20µl of 1mg/ml digitonin was added to the cuvette to permeabilise 
the cells allowing calcium to flood the dye giving a maximum fluorescence, followed by 
60µl of 0.5M EDTA pH 8.5 to chelate the calcium giving a minimum fluorescence. These 
values were then used to calculate the cytosolic calcium concentration of the cells, using 
the Grynkiewicz et al. (1985) equation.  
 
[Ca2+]i = Kd (R-Rmin) / (R-Rmax). 
 
Where the Kd for Fura-2 is 225nM, R is the ratio of emissions recorded at 340nm and 
380nm, Rmin is the minimum ratio of emissions recorded at 340nm and 380nm after the 
addition of EDTA chelating the calcium, and Rmax is the maximum ratio emissions 
recorded at 340nm and 380nm after the addition of digitonin causing the Fura-2 to be 
saturated with calcium. Unloaded cells were used to check autofluorescence and drug 
fluorescence.  
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2.12 High Performance Liquid Chromatography  
 
MDA-MB-468 cells were cultured until confluent in a 175cm Nunc tissue culture flask 
before being harvested with 0.25% trypsin, EDTA 0.5mM. Cells were spun down and 
washed in TBS containing 2mM MgCl2 before being permeabilised with 5 pulses of 
3.74KV/cm. The permeabilised cells were treated with drugs at 37ºC for 30 mins, in a 
200µl assay volume. The samples were quenched with 100µl 2M PCA and neutralized 
with 58µl K2CO3. 250µl samples were loaded on the following HPLC gradient through a 
Partisphere SAX 5µm column (Whatman, UK), dimensions 4.6mm x 125mm, with buffer 
A consisting of H2O, and Buffer B consisting of 1.3M (NH4)2HPO4, pH 4.8 with H3PO4. 
 
Time Buffer and gradient 
0-2 min         0% B, 1 ml/min 
 
2-15 min        linear gradient up to 39% B (3%/min) 
 
15.1 min        0% B 
16 min           1ml/min 
 
16-21 min      ramp volume from 1-1.5ml/min 
 
21.0 min 0.02ml/min 
 
 
Table 2.2: HPLC conditions. 
 
The absorbance at 260nm was measured throughout. The GTP control ran at 19.8 minutes 
and GDP at 14.2 minutes. Area under the curve was measured using Gilson Unipoint 
software (Anachem, Luton, UK). 
 
2.13  σ-1 GFP expression 
 
 
The pCMV6-AC-Sigma-1 GFP vector was purchased from Origene (Cambridge 
Biosciences, Cambridge, UK). The vector contains the CMV promoter driving 
heterologous expression of the σ-1R. The receptor is in frame with turbo Green fluorescent 
protein (tGFP) at the C-terminus. The tGFP allows positive identification of mammalian 
cells transfected with the plasmid. Mammalian cells were transfected with the σ-1 GFP 
vector using the transfection reagent, Jet PEI (Autogen Bioclear, Calne, UK).  
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Figure 2.7: Map of vector pCMV6-AC-GFP Origene TrueClone hand Book (Cambridge 
Biosciences, Cambridge, UK). The σ-1 cDNA was cloned into sites SGF I and Mlu I. 
 
2.14 Mammalian cell transfection 
 
 The following transient transfection protocol, modified from the Jet PEI handbook 
(Autogen Bioclear, Calne, UK), is for 24 well plates, if larger or smaller volumes of cells 
were required then the volumes of reagents were adjusted accordingly. Prior to transfection 
the HEK 293 cells were seeded at 50,000 cells/ well in 1ml of DMEM containing 10% 
FCS. The cells were allowed to adhere to the plate before being transfected. The 
transfection complexes were prepared as follows. Per well: 1µg of DNA was diluted in 
150mM NaCl to a final volume of 50µl, in a separate tube 2µl of Jet PEI was diluted in 
150mM NaCl to a final volume of 50µl. The Jet PEI was added to the DNA solution, 
mixed then incubated at room temperature for 30 mins. Jet PEI/DNA mixture (100µl per 
well) was added drop wise whilst swirling the plate. The plates were then returned to the 
humidified incubator at 37°C and 5% CO2 where they were left for 24 to 48 hours before 
transfection was assessed. 
2.15 Cloning and sub-cloning 
 
On receiving vectors containing σ-1Rs or siRNAs they were grown up by transforming 
chemically competent DH5α Escherichia coli using a heat shock method modified from 
Froger and Hall, 2007. DH5α E. coli were thawed slowly on ice and then transferred in to 
microcentrifuge tubes containing 50µl aliquots before the DNA that was to be transformed 
was added, the cells were then incubated on ice for up to 30 minutes, before being 
transferred to a 42°C water bath for 30 seconds then returned to the ice. 250µl of room 
temperature Super Optimal Broth with Catabolite repression (SOC) (consisting of 2% w/v 
bacto tryptone, 0.5% w/v yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, and 
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20mM glucose and sterilized by autoclaving at 121°C for 15 minutes) was added and the 
cells incubated for 1 hour (2 hours for kanamycin resistant vectors) at 37°C with shaking. 
The transformed E. coli were then plated onto Lysogeny Broth (LB) (10g/l tryptone, 5g/l 
yeast extract, 10g/l NaCl pH 7.5 and sterilized by autoclaving at 121°C) agar (1.5% w/v) 
plates containing the appropriate antibiotic, and incubated at 37°C overnight. The next day 
colonies were picked and grown in LB media containing the appropriate antibiotic 
(ampicillin 1µg/ml final concentration) at 37°C with shaking overnight. The following day 
the E. coli were pelletted by centrifugation and the plasmid extracted using a Qiagen 
(Crawley, UK) plasmid isolation kit. 
 
2.16  σ-1 knock-down 
 
The σ-1RNAi pSilencer vector and the non targeting RNAi control were obtained from Dr 
Christopher Palmer, Imperial College London described in Aydar et al., 2006.  MDA-MB-
468 cells were transfected with the σ-1RNAi pSilencer vector or the non-targeting RNAi 
control using the Jet PEI DNA transfection reagent, using the protocol described above. σ-
1R activity was assessed 24 to 48 hours later using radioligand binding, MTS cell 
proliferation assay, or by measuring calcium influx. 
2.17  σ-1 GFP mutagenesis  
 
Site directed mutagenesis is the addition, removal or substitution of a specific amino acid/s 
the method for which was modified from (Hutchison et al., 1978). Forward and reverse 
oligonucleotides (Sigma Genosys, Cambridge, UK) of approximately 30 base pairs were 
designed with a mutation in the middle as detailed in table 2.2 below. The oligonucleotides 
were used in a polymerase chain reaction (PCR) mutagenesis protocol using a high fidelity 
polymerase enzyme. The σ-1 GFP (approximately 15µl at 2ng/µl) construct was mixed 
with the oligonucleotides, dATP, dGTP, dCTP, dTTP (5µl at 2mM each), 5 times phusion 
polymerase buffer (10µl) and 1µl of phusion polymerase (NEB, Hitchin, UK). The PCR 
mix was then heated to 98°C for 5 minutes, followed by 18 cycles of 98°C for 30 seconds, 
60°C for 30 seconds and 68°C for 4.5 minutes. A final extension step at the end for 5 
minutes at 68°C was added to the protocol. After the PCR cycle was finished 5µl of Dpn1 
buffer and 1µl of the restriction enzyme Dpn1 was added to the tube and incubated at 37°C 
for 1 hour. Dpn1 will only cut were the recognition site (5’-GA*TC-3’) is methylated. The 
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σ-1 GFP construct grown up in E. coli is methylated, whilst the PCR product is not, 
therefore the Dpn1 treatment should remove any “parent” DNA leaving only the PCR 
product containing the desired mutation. After Dpn1 digestion 5µl of the resulting mixture 
was used to transform competent E. coli, which were then grown overnight at 37°C on LB 
agar plates containing ampicillin as the selection agent. The next day colonies were picked 
and grown up overnight in 10ml of LB media containing ampicillin at 37°C with shaking. 
The construct was then isolated using a Qiagen mini-prep kit before being sent for 
sequencing (Geneservice, Source Bioscience Cambridge, UK) to check the mutation had 
taken place and to make sure no PCR errors had occurred.  
 
Mutation Forward primer 
D126G 
 
5’-GGCTGAGATCTCGGGTACCATCATCTCTGG-3’ 
 
DEE76-
78GGG 
 
5’- CCACGTGCTGCCCGGCGGGGGGCTGCAGTGGGTG-3’ 
DHE53-
55GHG   
 
5’-GGGCTGGGCCACGGGCTGGCCTTCTCTCGTC -3’ 
E102G 
 
5’- CGCCTCGCTGTCCGGGTATGTGCTGCTCTTCGG-3’ 
E172G 5’-CCAAACACATGGATGGTGGGGTACGGCCGGGG-3’ 
 
E64G 
 
5’-CGTCTGATCGTGGGGCTGCGGCGGCTGCACC -3’ 
EE41/42GG 
 
5’-CGTCTTCCAGCGCGGAGGGATAGCGCAGTTGG-3’ 
Mutation Reverse primer 
D126G 
 
5’-CCAGAGATGATGGTACCCGAGATCTCAGCC-3’ 
 
DEE76-
78GGG 
 
5’-CACCCACTGCAGCCCCCCGCCGGGCAGCACGTGG-3’ 
DHE53-
55GHG   
 
5’- GACGAGAGAAGGCCAGCCCGTGGCCCAGCCC-3’ 
E102G 
 
5’-CCGAAGAGCAGCACATACCCGGACAGCGAGGCG-3’ 
 
E172G 5’- CCCCGGCCGTACCCCACCATCCATGTGTTTGG -3’ 
 
E64G 
 
5’-GGTGCAGCCGCCGCAGCCCCACGATCAGACG-3’ 
EE41/42GG 
 
5’- CCAACTGCGCTATCCCTCCGCGCTGGAAGACG -3’ 
 
 
Table 2.3: Table of forward and reverse primers  
Primers designed to induce specific mutations in the σ-1R. Mutated amino acids indicated 
in the first column, and the bases mutated to achieve these changes are highlighted in red 
in the next 2 columns with in the sequences of the PCR primers. 
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Once the sequence was verified and the desired mutation in place, the vector was grown up 
in E. coli, and isolated using a Qiagen midi prep kit. The vector was then transfected into 
HEK 293 cells using the Jet PEI transfection reagent. Expression was visualized using 
fluorescence microscopy, and quantified using flow cytometry, or western blotting. 
Affinity of the mutated receptor was measured using radioligand binding saturation 
experiments. 
2.18 Fluorescence microscopy of cholera toxin B treated cells 
 
The B subunit of the cholera protein complex is non toxic, and functions by binding to 
cellular surface via the polysaccharide chain of ganglioside GM1 (Merritt et al., 1994). The 
ganglioside GM1 is found in membrane microdomains enriched with cholesterol and 
sphingolipids called lipid rafts. Therefore, fluorescently labelled cholera toxin B is able to 
highlight lipid raft formation.  
 
MDA-MB-468 cells were plated out into 24 well plates and allowed to adhere to the tissue 
culture plastic overnight. On the day of the experiment cells were treated with the drug for 
30 minutes, control cells were treated with an equal volume of PBS or DMSO depending 
on which the drug was dissolved. After treatment the cells were washed with PBS and 
fixed using 4% paraformaldehyde for 15 minutes. The paraformaldehyde was washed off 
with PBS. The wells were then blocked with 1% bovine serum albumin for 15 minutes to 
prevent nonspecific binding of the cholera toxin to the well. The cells were again washed 
with PBS. 200 µl of PBS was then added to each well, and 2 µl of 1mg/ml Alexa Fluor 594 
cholera toxin subunit B conjugate (Invitrogen) was added to give a final concentration of 
10µg/µl. The cells were then incubated for 2 hours at 37°C. The excess cholera toxin B 
was then washed off using PBS and then kept in the dark until images were taken on the 
fluorescence microscope. 
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2.19 Mouse cancer model  
 
Testing for anti cancer activity in vivo was carried out on my behalf by Dr Steve Russell at 
Aston University Under Home Office Licence. 
 
Animals 
Naval Medical Research Institute (NMRI) mice weighing 25g were used for tumour 
transplantation, they were kept on a 12 hour day: night light cycle, at ambient temperature 
22 ± 2 °C and had free access to food (standard chow diet, Special Diet Services, Lillico, 
Wonham Mill, Bletchworth Surrey, UK) and water, the consumption of which was 
monitored throughout the experiments.  
 
Mac 13 transplant and treatment 
For each drug and the control 3 NMRI mice where transplanted with a fragment of mouse 
adenocarcinoma (MAC13) in the flank, by means of a trocar (Bibby et al., 1987). Twelve 
days after the tumour was implanted, animals were treated, on a daily basis, with either 
ammonium salt (10mg/kg i.v., via the tail vein) or control (100ul PBS i.v. via the tail vein). 
Animals were terminated before the tumour exceeded 1cm3. 
 
Analysis 
The tumour diameters were measured daily from day 12 using a micrometer. Statistical 
significance in tumour growth between control and treated mice was determined using 
GraphPad Prism (version4.0 for Macintosh). 
 
2.20 Test for antidepressant activity 
Testing for antidepressant activity was carried out in the Pharmacology Division, 
University Institute of Pharmaceutical Science, Panjab University, Chandigarh, India, by 
Mr. Kiran Kumar Akula, under the direction of Professor Kulkarni. 
 
Animals 
Male albino (laca strain) mice weighing between 22 and 30g (bred in the central animal 
house facility of the Panjab University) were housed under standard laboratory conditions 
with free access to food and water, and with a natural light dark cycle. The animals were 
acclimatised to the laboratory conditions before experiments, which were carried out 
between the hours of 09:00 and 15:00. Each animal was used only once. The experimental 
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protocols were approved by the Institutional Animal Ethics Committee (IAEC) and 
conducted according to the Indian National Science Academy Guidelines (INSA) for the 
use and care of experimental animals. 
 
Forced swim test 
Mice were individually forced to swim inside a rectangular glass jar (25 × 12 × 25 cm3) 
containing 15 cm of water maintained at 24±1˚C. An animal is considered to be immobile 
whenever it remained floating passively in the water in a slightly hunched but upright 
position, its nose above the water surface.  The total immobility period for a total period of 
6 min was recorded with the help of stop-watch and percentage decrease in immobility 
period was calculated with respect to vehicle control group. 
 
Tail suspension test 
Mice were suspended on the edge of a lever above the table top (58 cm) by using adhesive 
tape placed approximately 1 cm from the tip of the tail. The other side of the lever had a 
writing pen to record the activity on the moving drum. The duration of immobility period 
was recorded on a moving drum (speed previously standardized) rotating at a speed of 15 
cm/minute.  A mouse was considered to be immobile when it was suspended passively and 
completely motionless. The recordings were done for a total period of 6 min. The percent 
immobility period was calculated from the tracings. 
 
Drugs 
Dipentylammonium was made up at 1, 2.5, 5, and 10 mg/kg and tripentylammonium was 
made up at 2.5, 5 and 10 mg/kg, fluoxetine (a standard antidepressant for comparison) at 
10 mg/kg and BD1047 (N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-
(dimethylamino)ethylamine) (σ-1R antagonist) at 2 and 4 mg/kg. The drugs were 
dissolved in normal saline and different doses were administered 
intraperitoneally in a fixed volume of 1 ml/100g body weight 30 minutes before 
the animals were subjected to the test. 
 
Locomotive activity  
The total number of ambulations and rearing in 15 minutes was measured using a 
computerised actophotometer, as described in Dhir et al. (2005). The actophotometer 
consists of a chamber divided up into quadrants with light beams, when the mouse breaks a 
light beam that movement is recorded. 
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2.21 Data analysis 
Saturation data analysis were analysed using GraphPad Prism (version4.0 for Macintosh) 
non-linear regression analysis to fit saturation curves and calculate maximal radioligand 
binding and dissociation constants.  
 
Equation: S = Bmax· [L] / Kd + [L]  
 
Where S is the specific binding, [L] is the concentration of free radioligand, Bmax is the 
total number of receptors expressed in the same units as S (i.e sites/cell, cpm or fmol/mg 
protein) and Kd is the equilibrium dissociation constant expressed in the same units as [L] 
(usually nM). 
 
Scatchard plots were used only as a visual tool for comparing data, rather than for 
calculating maximal binding and equilibrium dissociation constants. Due to the fact that 
transforming the data to a linear form distorts the experimental error, whilst linear 
regression assumes that the scatter around the line follows the Gaussian distribution and 
that the standard error around X is the same for every point, this is not true for the 
transformed data, and there are much larger errors associated at the low concentrations of 
bound ligand, and therefore they have undue influence over the slope of the regression line 
resulting in a Kd and Bmax further from the true value than using non linear regression.  
 
Competitive binding data were analysed using GraphPad Prism non-linear curve fitting 
software. The equation used to fit competition binding data were the sigmoidal dose 
response (variable slope) model. 
 
Equation: Y=Bottom + (Top-Bottom) / 1+(10(LogIC50-X)Hillslope)  
 
Where X is the logarithm of the concentration of competing ligand, Y is the response (i.e 
counts per minute or % specific radioligand binding) and the Hillslope is the slope factor, a 
number that describes the steepness of the curve. A one site competitive binding curve that 
follows the law of mass action will have a slope of -1 (negative as the slope goes down).  
The IC50 is dependent on the Ki of the ligand for the receptor, but also dependent on the 
concentration of radiolabelled drug used in the assay (i.e increasing the radiolabelled drug 
concentration will change the IC50 whilst the Ki remains the same). In order to give a more 
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true representation of the drugs affinity for the receptor, the IC50 was converted to a Ki 
value using the Cheng Prusoff equation (Cheng and Prusoff, 1973). 
 
Equation: Ki=IC50/(1+ ([Radioligand] /Kd))  
 
The Ki value is derived from the IC50 which is on a log scale, therefore it does not make 
sense to present mean Ki values ± standard error of the mean (SEM) as the error is not 
symmetrical around the mean. Instead the mean Ki is displayed along with the 95% 
confidence interval (CI). The Ki was also converted into a pKi (-logKi), which is on a log 
scale, therefore the SEM is symmetrical about the mean pKi. 
 
When comparing two binding models to see which fits the data better the F test was 
employed to compare the models. The F test compares the increase in the sum of squares 
with the increase in degrees of freedom between the two models generating a ratio between 
the two. If the ratio (F value) is much greater than 1 you accept the more complicated 
model, a P value is also given showing the chance of this F value being a coincidence 
(Box, 1953). 
 
Fura-2 fluorescence data were collected using FL WinLab software (PerkinElmer, USA). 
The data were collected using the Ratio Data Application, and then converted to 
intracellular calcium ion concentrations using the ICBC Calibration Application, which 
uses the Grynkiewicz equation described earlier. The data were then transferred into 
GraphPad Prism for representation. 
 
MTS and protein assays were read using a Versamax plate reader, and the data collected 
using Softmax Pro software.  
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3 Simple straight-chain ammonium salts - high affinity 
agonists at the σ-1 receptor 
 
3.1 Background 
 
The σ-1R antagonists have been shown to induce apoptosis in mammary and colon 
adenocarcinoma cell lines (Brent et al., 1996a), whilst inhibiting the proliferation of colon 
and mammary carcinoma and melanoma cell lines (Vilner et al., 1995a). In 2004 Spruce et 
al. (2004) showed that σ-1R antagonists such as rimcazole could inhibit tumour growth 
(Figure 3.1). 
 
 
 
Figure 3.1: Effect of σ-1R antagonist rimcazole on tumour growth. MDA-MB-468 
xenographted immunocompromised mice treated with rimcazole showed a reduction in 
tumour growth compared to the control mice (Spruce et al., 2004). 
 
Around the same time Maffucci et al. (2005) published data showing similar effects with 
inositol 1,3,4,5,6 pentakisphosphate (IP5) (Figure 3.2) leading to the hypothesis that IP5 
could be a potential σ-1R ligand.  
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Figure 3.2: Effect of IP5 on tumour growth. Nude mice were implanted with SKOV-3 
tumour cells and treated with IP5, IP6 or cisplatin. IP5 reduces final tumour volume after 58 
days compared to the control, with a statistically significant P value < 0.05 as does the 
chemotherapy drug cisplatin used as a positive control P value < 0.01 (Maffucci et al., 
2005). 
 
The hypothesis that IP5 could be causing apoptosis in cancer cells through a σ-1R mediated 
pathway was tested using a radioligand binding assay. The assays were carried out with 
two different samples of IP5 containing different counterions. When the IP5 with the 
triethylammonium counterion was put into the radioligand binding assay (Figure 3.3) it 
appeared that the IP5 had σ-1R affinity. However when the binding assay was repeated 
with a sample of IP5 with a potassium counterion the affinity for the σ-1R disappeared. 
When triethylammonium was put into the assay alone it became clear that it was the 
triethylammonium with the σ-1R affinity and not the IP5.  
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Figure 3.3: IP5 Binding to the σ-1 Receptor. Binding of IP5 with different counterions to 
the σ-1R, reveals that it is in fact triethylammonium with σ-1R affinity and not IP5. IP5 
TEA+ appears to have a higher affinity for the σ-1R that triethylammonium alone, however 
there are 3 molecules of TEA for each IP5 accounting for this increase. 
 
These preliminary data led to the hypothesis that simple ammonium salts are σ-1R ligands. 
The purpose of this section of my thesis was to investigate the structure activity 
relationship of these simple ammonium salts and the σ-1R. The simple ammonium salts 
differ from commonly used σ-1R ligands, which often contain more than one nitrogen and 
have complex aromatic ring structures; the simple ammonium salts contain only one 
nitrogen, and have simple straight carbon chains. There have been a number of previous 
studies looking for a structural relationship between sigma receptor ligands and their 
affinity for the σ-1R (Ablordeppey et al., 1998, Ablordeppey et al., 2000, Glennon et al., 
1994). The importance of the nitrogen atom has been shown for the phenylalkylpiperidines 
and phenylalkylpiperazines (Ablordeppey et al., 2000) however no one has looked at such 
simple molecules as the simple ammonium salts discussed in this chapter.  
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3.2 Saturation [3H] (+) pentazocine binding in MDA-MB-468 cells 
 
In order to calculate the number of σ-1Rs expressed on the MDA-MB-468 cells (Bmax) and 
equilibrium dissociation constant (Kd) of [3H] (+) pentazocine in MDA-MB-468 cells, 
saturation binding experiments were carried out. Below (Figure 3.4) an example of a 
saturation binding curve for [3H] (+) pentazocine in permeabilised MDA-MB-468 cells can 
be seen with inset Scatchard plot for visualisation purposes only as the Bmax and Kd were 
calculated using nonlinear regression software (GraphPad Prism, California). 
0 100 200 300 400
0
250
500
750
1000
1250
1500
1750
 [3H] (+) pentazocine nM
0 500 1000 1500 2000
0
50
100
150
Scatchard
Bound
 
Figure 3.4: Saturation binding of [3H] (+) pentazocine in MDA-MB-468 cells 
Saturation binding curve for [3H] (+) pentazocine in MDA-MB-468 cells. Non specific 
binding was determined in the presence of 0.1mM rimcazole. This is a representative 
figure of 3 independent saturation experiments. 
 
The mean pKd ± SEM of [3H] (+) pentazocine from the σ-1R expressed on the MDA-MB-
468 cells was determined as 7.77 ± 0.56, Kd 16.97 nM and the Bmax as 2300 ± 200 fmol/mg 
protein (n=3). 
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3.3 Primary ammonium salt affinity for the σ-1 receptor 
 
The primary ammonium salts consist of a single nitrogen and a single carbon chain. 
Primary ammonium salts have previously been shown to be able to selectively cause the 
release of 5-HT and histamine from rabbit platelets (May et al., 1967). Also 
pentylammonium and hexylammonium have been shown to have behavioural effects in 
mice, with lower doses (3mg/kg) resulting in motor stimulation, and higher doses 
(100mg/kg) giving a motor depressing action (Widy-Tyszkiewicz and Czlonkowski, 1983, 
Widy-Tyszkiewicz and Sourkes, 1980). Due to the σ-1R’s proposed link to 5-HT 
signalling in depression models, the affinity of primary ammonium salts for the σ-1R was 
investigated using radioligand binding (Figure 3.5). The data have been normalized to % 
specific [3H] (+) pentazocine binding. Each curve represents the average of four 
independent binding experiments. 
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Figure 3.5: Binding of primary ammonium salts to the σ-1R in MDA-MB-468 cells. 
Competition assays using 30nM [3H] (+) pentazocine and increasing doses of amine. Data 
are represented as percentage specific binding of [3H] (+) pentazocine; error bars represent 
SEM from 4 independent competition binding assays. 
 
The Ki values for the binding of the primary ammonium salts ranged from 6mM (0.01mM 
– 1000mM) (propylammonium) to 0.3mM (0.05mM – 2mM)  (hexylammonium). In order 
to visualise the affinities for the σ-1R more clearly with symmetrical errors, the Ki values 
obtained from the above competition binding curves were converted into pKi values (-
log10Ki) shown in Figure 3.6 below. 
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Figure 3.6: Summary of primary ammonium salt binding to the σ-1R.  The affinities 
of the primary ammonium salts for the σ-1R (pKi ± SEM) n=4 were: propylammonium 
2.25 ± 0.22, butylammonium 2.19 ± 0.11, pentylammonium 2.59 ± 0.43, and 
hexylammonium 3.54 ± 0.23. 
 
There is a slight increase in affinity for the σ-1R in the primary ammonium salts as the 
carbon chain length increases from 3 to 6; however the increase was not large enough to 
warrant continuing investigating longer chain lengths in this series of ammonium salts. 
 
3.4 Secondary ammonium salt affinity for the σ-1 receptor 
 
The secondary ammonium salts described in this chapter consist of a single nitrogen and 
two carbon chains. Dimethylammonium is a normal component of human urine (Asatoor 
and Simenhoff, 1965, Zhang et al., 1995) and has been shown to interfere with cell growth, 
causing a decrease in cell size, and have a toxic effect on tumour cells (Guest and Varma, 
1991). The mechanism by which dimethylammonium causes these effects has never been 
investigated, with this in mind, and knowing from the preliminary data that 
triethylammonium has σ-1R affinity, the secondary ammonium salts affinity for the σ-1R 
was investigated using radioligand competition assays (Figure 3.7). The data are 
normalised to % specific [3H] (+) pentazocine binding, and each curve is the average of six 
independent competition binding assays. 
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Figure 3.7: Secondary ammonium salt binding to the σ-1R in MDA-MB-468 cells. 
Competition assays using 30nM [3H] (+) pentazocine and increasing doses of ammonium 
salt. Data are represented as percentage specific binding of [3H] (+) pentazocine. Error bars 
represent SEM from 6 independent competition binding assays. 
 
Dimethylammonium had no affinity for the σ-1R within the range tested (highest dose 
10mM). The mean Ki (95% CI) values ranged from diethylammonium 98 µM (30 µM – 
320µM) to dipentylammonium 0.3µM (0.2µM - 0.5µM). In order to visualise the affinities 
for the σ-1R more clearly, Ki values obtained from the above competition binding curves 
were converted into pKi values. The pKi values (±SEM) are shown below in Figure 3.8. 
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Figure 3.8: Summary of secondary ammonium salt binding to the σ-1R 
pKi values for secondary ammonium salts (n=4). The mean pKi values ± SEM are 
diethylamine 4.73 ± 0.49, dipropylammonium 5.58 ±0.19, dibutylammonium 6.86 ± 0.40, 
dipentylammonium 7.37 ± 0.48, dihexylammonium 6.84 ± 0.63.  
 
The dimethylammonium had no affinity in the range tested (highest dose 10mM). There is 
an increase in affinity for the σ-1R from the two carbon long chain length 
(diethylammonium pKi 4.73 ± 0.49) to the five carbon long chain length 
(dipentylammonium). At the six carbon long chain length (dihexylammonium pKi 7.37 ± 
0.48) the affinity began to decrease and therefore this series was not investigated further. 
 
3.5 Tertiary ammonium salt affinity for the σ-1 receptor 
 
The tertiary ammonium salts discussed in this chapter consist of a single central nitrogen 
and three straight carbon chains. The preliminary data showed that triethylammonium has 
σ-1R affinity, therefore, the tertiary ammonium salt series from trimethylammonium with 
three single carbons to tridodecylammonium with three twelve carbon chains. The affinity 
of the tertiary ammonium salts were investigated using radioligand binding competition 
assays (Figure 3.9), the data are normalised to % specific [3H] (+) pentazocine binding. 
Each curve is made up of six or more independent competition binding assays. 
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Figure 3.9: Tertiary ammonium salt binding to the σ-1R in MDA-MB-468 cells. 
Competition assays using 30nM [3H] (+) pentazocine and increasing doses of ammonium 
salt, represented as percentage specific binding of [3H] (+) pentazocine. Error bars 
represent SEM from 6 independent competition binding assays. 
 
Trimethylammonium had no affinity for the σ-1R within the range tested (highest dose 
10mM). The mean Ki (95% CI) values ranged from triethylammonium 420µM (313µM -
620µM) to trihexylammonium 6.4nM (0.4nM-94.4nM). 
 
In order to visualise the affinities for the σ-1R more clearly, Ki values obtained from the 
above competition binding curves were converted into pKi values (-log10Ki). The pKi 
(±SEM) values are represented in Figure 3.10 below. 
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Figure 3.10: Summary of tertiary ammonium salts binding to the σ-1R. The mean pKi 
values for tertiary ammonium salts (n=6) are triethylammonium 3.38 ± 0.05, 
tripropylammonium 5.46 ± 0.11, tributylammonium 6.88 ± 0.11, tripentylammonium 7.83 
± 0.16, trihexylammonium 8.05 ± 0.41, trioctylammonium 4.72 ± 0.87, and 
tridodecylammonium 4.26 ± 0.04. 
 
Trimethylammonium had no affinity in the range tested (highest dose 10mM). There was 
an increase in affinity from the two carbon long chain (triethylammonium pKi 3.38 ± 0.05) 
to the six carbon long chain (trihexylammonium pKi 8.05 ±0.41). There was a decrease in 
affinity from the six to the twelve carbon long chain (tridodecylammonium pKi 4.26 ± 
0.04) therefore no ammonium salts were tested with carbon chains longer than twelve.  
 
3.6 Quaternary ammonium salt affinity for the σ-1 receptor 
 
The quaternary ammonium salts discussed in this section consist of a single positive 
nitrogen and 4 straight carbon chains. Tetraethylammonium is a well known voltage-
activated potassium channel blocker (Fukushima et al., 1996). With this in mind the series 
of quaternary ammonium salts from one carbon to four carbons in chain length were tested 
for σ-1R affinity using radioligand competition assays (Figure 3.11). The data are 
represented as % specific [3H] (+) pentazocine binding, and each curve is the average of 
three independent competition assays.  
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Figure 3.11: Quaternary ammonium salt binding to the σ-1R. Binding of simple 
straight-chain quaternary ammonium salts, the data are represented as % specific (+) 
pentazocine binding. Error bars represent SEM from 3 independent competition binding 
assays. 
 
 
Tetramethylammonium had no affinity with in the range tested (highest dose 10mM). The 
mean Ki values for the quaternary ammonium salts ranged from tetraethylammonium 7mM 
(2 mM – 19 mM) to tetrabutylammonium 2mM (0.8mM –  28mM). In order to visualise 
the affinities for the σ-1R more clearly, Ki values obtained from the above competition 
binding curves were converted into pKi values (-log10Ki) shown in Figure 3.12 below. 
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Figure 3.12: Summary of quaternary ammonium salt binding to the σ-1R. The mean 
pKi values for the quaternary ammonium salts (n=3) are tetraethylammonium 2.34 ± 0.18, 
tetrapropylammonium 2.49 ± 0.07, and tetrabutylammonium 2.77 ± 0.05. 
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The quaternary ammonium salts showed only little affinity for the σ-1R, and there was 
little increase in affinity as the carbon chain length increased, therefore no larger 
quaternary amines were tested for σ-1R affinity. 
 
3.7 Calcium response to simple straight-chain ammonium salts 
 
σ-1R antagonists have been shown to induce a rapid influx of calcium into the cytoplasm 
in cancer cell lines (Spruce et al., 2004). Using this as a selection criterion for a σ-1R 
antagonist the simple straight-chain amines were tested to see if they induced a σ-1R 
mediated calcium influx into the cells. All the straight-chain amines were put into this 
assay, and below are some examples from the amines with the highest affinity for the σ-
1R. 
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Figure 3.13: Calcium influx in response to simple straight-chain ammonium salts  
A: 2µM trihexylammonium followed by a dose of the known σ-1R antagonist IPAG as a 
positive control, in a stirred suspension of Fura-2 loaded MDA-MB-468 cells. B: 2µM 
dipentylammonium followed by a dose of 10 µM IPAG, in a stirred suspension of Fura-2 
loaded MDA-MB-468 cells. C: 2µM tripentylammonium followed by a dose of 10µM 
IPAG, in a stirred suspension of Fura-2 loaded MDA-MB-468 cells. D: 20µl of TBS 
followed by 10µM IPAG in a stirred suspension of Fura-2-AM loaded MDA-MB-468 
cells. 
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Of all the simple straight-chain ammonium salts put into the calcium influx assay, not one 
induced an influx of calcium into the cells, even when a concentration 100 times the 
affinity of the amine for the σ-1R was added to the assay. 
 
3.8  Simple straight-chain ammonium salt effect on cellular metabolic 
activity 
 
It has been shown previously that σ-1R antagonists induce cell death in cancer cell lines 
(Brent et al., 1996a, Spruce et al., 2004, Vilner et al., 1995a). The MTS assay was used to 
measure cellular metabolic acitivity induced by σ-1R ligands. IPAG, a well-known σ-1R 
antagonist was used as a positive control as all the simple straight-chain ammonium salts 
were tested. Below is an example of an ammonium salt with high σ-1R affinity, 
tripentylammonium.  
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Figure 3.14: Tripentylammonium in MTS assay dose response. The effect of the simple 
straight-chain ammonium salt, tripentylammonium, on MDA-MB-468 metabolic activity 
Error bars represent SEM from 4 independent MTS assays. 
 
Of all the simple straight-chain ammonium salts put into the MTS assay not one reduced 
cell metabolism of the MDA-MB-468 cancer cell line with in the range of concentrations 
tested (up to 100µM). 
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In order to assess they toxicity of ammonium salts with the highest affinity for the σ-1R, σ-
1R negative HEK 293 cells (Figure 3.15a) were used in the MTS assay. Below are 
examples of the highest affinity simple straight-chain ammonium salts effect on σ-1R 
negative cell metabolism (Figure 3.15). 
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Figure 3.15: Effect of high σ-1R affinity ammonium salts on HEK 293 cell 
metabolism. A: Saturation binding of [3H] (+) pentazocine in permeabilised HEK 293 
cells, Kd 453nM Bmax 475 fmol/mg (n=3). B: MTS assay showing the metabolic activity of 
HEK-293 cells after treatment with 10nM and 100nM trihexylammonium compared to the 
control treated with TBS. (n=3) C: MTS assay showing the metabolic activity of HEK-293 
cells after treatment with 10nM and 100nM tripentylammonium. (n=3) D: MTS assay 
showing the metabolic activity of HEK-293 cells after treatment with 10nM and 100nM 
tripentylammonium (n=3). 
 
 
The metabolism of the HEK 293 cells treated with the 10nM and 100nM doses of 
tripentylammonium, dipentylammonium and trihexylammonium, showed no difference 
compared to the cell metabolism of the untreated HEK 293 cells. 
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3.9 Straight-chain ammonium salt specificity for the σ-1 receptor: 
histamine receptors 
 
Histamine receptors, H1 receptor, H2 receptor, H3 receptor and H4 receptor have all been 
shown to express in breast cancer cell lines (Medina et al., 2008). Histamine exerts its 
function by binding to G-protein coupled histamine receptors. The H2R is coupled to 
adenylyl cyclase via the Gs G-protein. The H1 receptor is coupled to phospholipase C via 
the Gq G-protein. Activation of the H1 receptor and H2 receptor results in an increase in 
cytosolic calcium and therefore the MDA-MB-468 cell line was used to measure the 
effects of the simple ammonium salts on the histamine receptors. The ammonium salts 
with the highest affinity for the σ-1R were tested in the calcium assay, including 
dipentylammonium, tripentylammonium and trihexylammonium. A dose response to 
histamine in the calcium response assay was carried out and some examples of the calcium 
peaks a represented below. 
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Figure 3.16: Increase in cytosolic [Ca2+] in Fura-2-AM loaded MDA-MB-468 cells in 
response to histamine. Calcium response in stirred MDA-MB-468 cells loaded with Fura-
2-AM, to 1µM and 10µM histamine, having been pre-treated with 20 µl of buffer. This is a 
representative figure of 3 independent experiments, the mean increase in [Ca2+]i in 
response to 1µM histamine was 0.55 ± 0.08 µM and for 10µM histamine was 4± 1µM.  
 
Histamine (1µM) induced a peak calcium response of 0.55 ± 0.08 µM and 10µM histamine 
induced a peak calcium response of 4± 1.1 µM. Pyrilamine maleate (Figure 3.17) is a 
histamine receptor antagonist acting on the H1 R. Pyrilamine maleate was used as a 
positive control in the calcium assay (Figure 3.18). 
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Figure 3.17: Structure of pyrilamine maleate, H1 receptor antagonist. 
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Figure 3.18: Increase in cytosolic free [Ca2+] in Fura-2-AM loaded MDA-MB-468 
cells. Calcium response in stirred MDA-MB-468 cells to 10µM histamine after a pre-
treatment with 10µM pyrilamine maleate. This is a representative figure of 3 independent 
experiments. No calcium peak was observed in response to histamine after pre-treatment 
with pyrilamine maleate. 
 
A 10µM dose of pyrilamine maleate was enough to completely wipe out the calcium 
response in the MDA-MB-468 cells in response to 10µM histamine. Once the agonist 
antagonist relationship for histamine and pyrilamine maleate was established in the MDA-
MB-468 cell line, the simple straight-chain ammonium salts were tested to see if they 
could antagonise the histamine-induced calcium influx into the cells (Figure 3.19). A 
histamine dose response was carried out in the presence of a high dose of simple straight-
chained ammonium salt. 
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Figure 3.19: Effect of dipentylammonium on the increase of cytosolic [Ca2+] in 
response to histamine. Calcium response in stirred MDA-MB-468 cells loaded with Fura-
2-AM in response to 1µM and 10µM histamine after pre-treatment with 1mM 
dipentylammonium (DPA). This is a representative figure of 3 independent experiments, 
the mean calcium influx in response to 1µM histamine was 0.36 ± 0.04µM 10µM 
histamine in the presence of 1mM dipentylammonium was 0.9± 0.6µM. 
 
1mM dipentylammonium caused approximately a 50% reduction in the calcium response 
to 1µM histamine, dropping from 0.55 ± 0.08µM to 0.36 ± 0.04µM calcium and in 
response to 10µM histamine in the presence of 1mM dipentylammonium there was 
approximately an 80% drop in calcium influx, dropping from 4 ± 1µM to 0.9 ± 0.6µM 
calcium. The full dose response curve for calcium influx in response to histamine in MDA-
MB-468 cells in the presence and absence of 1mM dipentylammonium is shown below 
(Figure 3.20). 
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Figure 3.20: Histamine dose response in Fura-2-AM loaded MDA-MB-468 cells with 
and without 1mM dipentylammonium (DPA). Histamine dose response in the presence 
and absence of 1mM dipentylammonium. Data from 3 independent experiments are 
normalised to percentage maximal response to histamine. The pEC50 values for histamine 
in presence and absence of 1mM dipentylammonium were 6.0 ± 0.2 and 5.5 ±0.7 
respectively. The maximum response for the cells treated with 1mM dipentylammonium 
was 62 ± 8 % of the untreated cells. 
 
Dipentylammonium (1mM) had no effect on the EC50 of the calcium response in response 
to histamine (t test P value 0.33). However, it did decrease the maximal response by 
approximately 40% (t test P value 0.015). Of the other ammonium salts tested none had 
any effect on the calcium response to histamine, below is an example of 100µM 
tripentylammonium and 100µM trihexylammonium pre-treatment before 1µM histamine 
was added to the assay. 
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Figure 3.21: Effect of A: Tripentylammonium and B: trihexylammonium on 
histamine-induced cytosolic [Ca2+] increase. Calcium response in stirred MDA-MB-468 
cells loaded with Fura-2-AM in response to 1µM histamine after pre-treatment with 100 
µM tripentylammonium (TPA) or 100µM trihexylammonium (THA). This is a 
representative figure of 3 independent experiments. 
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The mean peak calcium response to 1µM histamine after pre-treatment with 100µM 
tripentylammonium was 532 ± 3 nM and for trihexylammonium 0.69 ± 0.07 µM, these 
values were not significantly different from the control (t test P values 0.73 and 0.26 
respectively) and were not investigated further. 
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3.10 Straight-chain ammonium salt specificity for the σ-1 receptor: 
Muscarinic receptors 
 
It has been shown previously that σ-1R ligands such as (+) pentazocine and 1S,2R-cis-N-
[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)- cyclohexylamine (BD737) are 
capable of affecting muscarine-induced intracellular calcium changes in SH-SY5Y 
neuroblastoma cells which have been shown to express the M1 and M3 subtypes of the 
muscarinic acetylcholine receptor (mACh) (Hong and Werling, 2002). These changes 
however could not be reversed by σ-1R antagonist haloperidol, therefore it was deduced 
that (+) pentazocine and BD737 had affinity for the mACh. This was confirmed with 
radioligand binding using the muscarinic specific radioligand [3H]-QNB (pKd of 9.5 ± 0.1). 
The affinities of pentazocine, haloperidol and BD737 for the muscarinic receptor were 
identified as (pKi ± SEM) 6.29 ± 0.06, 6.4 ± 0.07, 5.35 ± 2.3, respectively (Hong and 
Werling, 2002). With this in mind the simple ammonium salts were assessed for 
muscarinic receptor affinity using rat brain membranes. 
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Figure 3.22: σ-1 Ligand binding to the mACh receptor. Binding of σ-1 ligands and 
simple amines compared to atropine. Example selection of data represented as % specific 
binding of QNB from between 4 and 7 binding assays.  
 
The full list of compounds tested for muscarinic receptor affinity can be seen in table 3.1 
below. 
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Compound name Type of compound σ-1R  
affinity pKi 
± SEM 
(MDA-MB-
468 cells) 
mAChR 
Affinity pKi 
± SEM 
(Rat Brain) 
mACh 
Ki/σ-1Ki 
Number 
of assays 
(n) 
Atropine Muscarinic 
antagonist 
4.51±0.42 9.40±0.34 0.000012 4 
Rimcazole σ-1R ligand 6.22±0.23 4.49±0.10 53 7 
IPAG* σ-1R ligand 8.62±0.67 4.3 20000 1 
Tripentylammonium Straight-chained, 
tertiary amine 
7.83±0.10 4.33±0.38 2000 4 
Dipentylammonium  Straight-chained, 
secondary amine 
8.03±0.48 3.42±0.24 7940 5 
Pentazocine σ-1R agonist 8.50a 6.29 ± 0.06b 162 ** 
BD737 σ-1R agonist 8.54b 5.35 ± 2.30b 1550 ** 
Haloperidol σ-1R Antagonist 
and antipsychotic 
8.43a 6.40 ± 0.07b 107 ** 
 
Table 3.1: The affinity of ligands for the σ-1R and the mAChR 
(pKi ± SEM), number of assays refers to the QNB binding assays. *IPAG was only 
assayed on one occasion with QNB, and the affinity for the σ-1R is represented as pK50 ± 
SEM as the nH differs significantly from -1. aWhittemore et al., 1997, bHong and Werling, 
2002 ** data obtained from Hong and Werling, 2002. 
 
Dipentylammonium and tripentylammonium (pKi ± SEM, 8.03 ± 0.48 and 7.83 ± 0.10 
respectively) both have higher affinities for the σ-1R than the well known σ-1R antagonist 
rimcazole (pKi ± SEM, 6.22 ± 0.23). Moreover rimcazole has a higher affinity for the 
mAChR. The pKi data for rimcazole compared to dipentylammonium and 
tripentylammonium for the σ-1R is represented below in Figure 3.23.   
 
 
 
 
 
Simple straight-chain ammonium salts  
high affinity σ-1R agonists 
 80 
0
1
2
3
4
5
6
7
8
9 **
 
Figure 3.24: Ligand Affinity for the σ-1R. Affinity of rimcazole, tripentylammonium 
and dipentylammonium for the σ-1R ANOVA P value 0.0238 (n=3). * Dunnett’s post test 
< 0.05. 
 
Both dipentylammonium and tripentylammonium have statistically significant higher 
affinities for the σ-1R than the well-characterised σ-1 ligand rimcazole, with ANOVA 
Dunnett’s post test P values < 0.05. The affinities of the simple straight-chain ammonium 
salts with a high affinity for the σ-1R, tripentylammonium and dipentylammonium, for the 
mAChR compared to the affinity of rimcazole for the mACh are represented in figure 3.25. 
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Figure 3.25: Affinity of σ-1R ligands for the mAChR. Affinity of rimcazole, 
dipentylammonium and tripentylammonium for the mAChR (n=4). ANOVA P value 
0.008. ** Dunnett’s post test rimcazole vs dipentylammonium P < 0.01. 
 
Dipentylammonium has a statistically significant lower affinity for the mAChR than the 
well known σ-1R antagonist rimcazole (P<0.01). Tripentylammonium shows no 
significant difference from rimcazole in affinity for the mAChR (ANOVA Dunnett’s post 
test rimcazole vs tripentylammonium P >0.05). 
 
3.11 Straight-chain ammonium salt specificity for the σ-1 receptor: 
dopaminergic and adrenergic receptors. 
 
Since their original description the σ-1R has been linked with dopaminergic 
neurotransmission (Martin et al., 1976), although in the original studies the ligands used 
had affinities for the dopamine receptor besides the σ receptor. In electrophysiological 
models (+) pentazocine and (+) SKF-10,047 increases the firing of dopaminergic neurons 
whilst DTG and (+) 3 PPP reduce it (Clark et al., 1985, French and Ceci, 1990, Steinfels 
and Tam, 1989, Zhang et al., 1992). Biochemical tests show that high doses of (+) 
pentazocine and DTG cause dopamine release (Ebert et al., 1991, Kanzaki et al., 1992) and 
direct interaction of σ-1R ligands with dopaminergic neurons has been shown using 
radioligand binding studies (Gundlach et al., 1986, Quirion et al., 1987). 
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The dopamine receptor can be split into 5 subtypes D1-D5, D1 (Dearry et al., 1990, 
Monsma et al., 1990, Zhou et al., 1990) and D5 (Grandy et al., 1989, Sunahara et al., 1991, 
Tiberi et al., 1991, Weinshank et al., 1991) couple through Gs G-protein to activate 
adenylyl cyclase (AC), which causes an increase in cellular cAMP. The D2 receptor can 
inhibit cAMP production through Gi G-protein inhibition of AC (De Camilli et al., 1979, 
Enjalbert and Bockaert, 1983, Mcdonald et al., 1984, Onali et al., 1985, Onali et al., 1981), 
D3 (Chio et al., 1994b, Mcallister et al., 1995, Potenza et al., 1994, Robinson and Caron, 
1996, Tang et al., 1994) and D4 (Chio et al., 1994a, McAllister et al., 1995, Tang et al., 
1994) receptors also have been shown to reduce cAMP production.  
 
The β adrenergic receptor is also coupled through Gs G-protein stimulation of AC causing 
an increase in cAMP (Skeberdis et al., 1997). MDA-MB-468 cells have been shown to 
express both dopaminergic and adrenergic receptors (Drell et al., 2003, Lang et al., 2004), 
therefore the MDA-MB-468 were used to assess the ammonium salts for dopaminergic or 
adrenergic receptor affinity. Lang et al. (2004) show the presence of D2 receptors on the 
MDA-MB-468 cells, however they do not rule out the presence of D1 or D5 receptors. 
They show that dopamine treatment of MDA-MB-468 cells leads to the activation of 
cAMP response element binding (CREB) protein. This is unlikely to be due to the D2 
receptor as it is coupled through Gi, which would reduce cAMP, rather it is more likely to 
be due to D1 or D5 but with the D2 present the signal will be reduced.  
 
Isoprenaline (Figure 3.26) is an adrenergic β1 and β2 agonist, and on addition to MDA-
MB-468 cells dose dependently causes an increase in cAMP production (Figure 3.27).  
 
A      B 
   
 
Figure 3.26: Structure of A: isoprenaline and B: dopamine. 
Simple straight-chain ammonium salts  
high affinity σ-1R agonists 
 83 
-11 -10 -9 -8 -7 -6 -5 -4 -3 -2
0
10
20
30
Dopamine
Isoprenaline
Log10 [Drug]
 
Figure 3.27: cAMP production in response to dopamine and isoprenaline in MDA-
MB-468 cells. Measured using commercially available cAMP assay kit. Error bars 
represent SEM from 8 independent cAMP assays. 
 
MBA-MD-468 cells were treated with the range of amines along with IPAG and 
pentazocine. Control level of cAMP was 9 ± 1 pmol/mg protein. None of the agents tested 
(at 100µM) caused a significant change in cAMP levels (one-way ANOVA P value 0.37 
(table 3.2)). Isoprenaline raised cAMP levels in MDA-MB-468 cells in a dose-dependent 
fashion, with EC50 of 5.8nM (pEC50 8.2 ± 0.3, mean ± SEM, n=5). None of the agents 
tested (at 100µM) affected the response to isoprenaline (100nM) (table 3.2). Dopamine 
also raised cAMP levels in MDA-MB-468 cells in a dose-dependent fashion (Figure 3.27), 
with EC50 of 14µM (pEC50 4.8 ± 0.2, mean ± SEM, n=5). None of the agents tested (IPAG, 
(+) pentazocine, dipentylammonium or tripentylammonium at 100µM) affected the 
response to dopamine (100µM) (table 3.2), one-way ANOVA P value 0.95. 
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Drug  
 
cAMP (pmol/mg) Number of assays 
Control (no drug) 8.7 ± 1.4 8 
Dopamine (100µM) 17.63 ± 2.5 8 
Isoprenaline (100nM) 22 ± 2.9 8 
IPAG 8.9 ± 1.9 7 
(+) Pentazocine 11.7 ± 2.0 3 
Tripentylammonium 8.5 ± 1.5 4 
Dipentylammonium 7.8 ± 1.9 4 
Dopamine + IPAG 13.2 ± 1.4 6 
Dopamine + tripentylammonium 15.5 ± 4.8 4 
Dopamine + dipentylammonium  17.3 ± 3.1 6 
Isoprenaline + IPAG 20.4 ± 4 5 
Isoprenaline + tripentylammonium 30.8 ± 6.3 5 
Isoprenaline + dipentylammonium 19.5 ± 4.6 6 
 
Table 3.2: cAMP production in response to dopaminergic, adrenergic and σ-1R 
ligands. 
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3.12 Straight-chain ammonium salts as σ-1 receptor agonists and 
antidepressants 
 
There has been much published evidence that σ-1R agonists including (+) pentazocine, (+) 
SKF-10,047 and DTG have antidepressant properties (Urani et al., 2001), as well as σ-1R 
antagonists, including progesterone, rimcazole and BD1047, reversing the effects of 
venlafaxine (a 5-HT and noradrenaline transporter inhibitor (Redrobe et al., 1998, Dhir and 
Kulkarni, 2007). 
 
Dipentylammonium 
Simple ammonium salts have been tested for behavioural effects before, low doses of the 
primary ammonium salt, pentylammonium resulted in motor stimulatory effects (Widy-
Tyszkiewicz and Czlonkowski, 1983, Widy-Tyszkiewicz and Sourkes, 1980), and 
treatment of rabbit platelet cells with pentylammonium resulted in 5-HT production (May 
et al., 1967). Dipentylammonium is a high affinity σ-1R ligand with nanomolar affinity 
(1,000,000 times higher affinity than pentylammonium), therefore its behavioural effects 
were assessed using the forced swim test (Porsolt et al., 1977) (one of the most used 
animal models for screening antidepressants (Petit-Demouliere et al., 2005)) (Figure 3.28), 
which assesses despair behaviour and the tail suspension test which relies on similar 
despair behaviour. The following behavioural studies (Figures 3.28 to Figure 3.31) were 
carried out on my behalf, at The University Institute of Pharmaceutical Science, Panjab 
University, Chandigarh, India, under the direction of Professor Kulkarni. 
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Figure 3.28: The effect of dipentylammonium (DPA) on despair behaviour in mice 
subjected to the forced swim test. The control consisted of 10ml/kg saline, fluoxetine 
(SSRI) 10mg/kg was used as a positive control (ANOVA P value 0.014). * Dunnett’s 
multiple comparison post test vs control P < 0.05. 6 to 8 mice were used for each data 
point, error bars represent SEM. 
  
When submitted to the forced swim test the control (10 ml/kg saline) mice exhibited 
despair behaviour, remaining still in the water (only making movements to keep their head 
above the water) for 238 ± 17 seconds out of a total of 6 minutes in the water. The SSRI, 
fluoxetine at 10mg/kg, significantly reduced the time spent immobile in the water to 152 ± 
19 seconds (ANOVA post test, Dunnett’s multiple comparison P<0.05). Similarly, 
dipentylammonium (1mg/kg, 5mg/kg and 10mg/kg) significantly reduced the time spent 
immobile in the water (all having ANOVA post test, Dunnett’s multiple comparison 
P<0.05).  
 
In order to assess whether dipentylammonium is reducing time spent immobile in the water 
through a σ-1R mediated mechanism, dipentylammonium was reassessed in the forced 
swim test in the presence and absence of the σ-1R antagonist BD1047 (Figure 3.29). 
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Figure 3.29: The effect of dipentylammonium (DPA) and σ-1R antagonist BD1047 on 
despair behaviour in mice subjected to the forced swim test. 6 to 8 mice were used for 
each data point, error bars represent SEM. (ANOVA P value, 0.0001). (**ANOVA post 
test, Tukey’s multiple comparison, control vs DPA P< 0.01, ##ANOVA post test, Tukey’s 
multiple comparison, DPA vs DPA+ BD1047 p<0.01)  
 
Control mice (10ml/kg saline) subjected to the forced swim test remained immobile for 
232 ± 10 out of the 6 minute test. Again a 5 mg/kg dose of dipentylammonium resulted in 
a significant decrease in time spent immobile, 80 ± 13 (**ANOVA post test, Tukey’s 
multiple comparison, control vs DPA P< 0.01), whereas the σ-1R antagonist BD1047 
alone at 4mg/kg had no significant effect on time spent immobile in the water. However, 
when a 4 mg/kg dose of the σ-1R antagonist BD1047 was injected along with a 5mg/kg 
dose of dipentylammonium, the effect of the dipentylammonium was reversed (##ANOVA 
post test, Tukey’s multiple comparison, DPA vs DPA+ BD1047 p<0.01). 
 
Dipentylammonium was also tested in another behavioural test, which also tests despair 
behaviour, the tail suspension test (Figure 3.30). The mouse is suspended by its tail 58 cm 
above the table top (such that the mouse cannot sense the table) for a period of 6 minutes. 
Despair behaviour is interpreted as time spent completely immobile (not struggling to 
escape). 
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Figure 3.30: The effect of DPA and σ-1R antagonist BD1047 on despair behaviour in 
mice subjected to the tail suspension test. The control consisted of an injection of 
10ml/kg saline, fluoxetine was used as a positive control at 10mg/kg. 6 to 8 mice were 
used for each data point, error bars represent SEM. (ANOVA P value <0.0001). * 
ANOVA post test, Tukey’s multiple comparison, vs. control 5mg/kg P<0.05, # ANOVA 
post test Tukey’s multiple comparison vs. fluoxetine P<0.05. 
 
Control mice (10ml/kg saline) subjected to the tail suspension test exhibited despair 
behaviour remaining immobile for 235 ± 12seconds, as with the forced swim test the SSRI, 
fluoxetine (10mg/kg), resulted in a significant decrease in time spent immobile, 126 ± 22 
seconds (ANOVA post test, Tukey’s multiple comparison, Control vs Fluoxetine p< 0.05). 
Dipentylammonium at 2.5 mg/kg did not have a significant effect on immobility time in 
the tail suspension test, however dipentylammonium at 5mg/kg resulted in a significant 
decrease in time spent immobile in the tail suspension test 115 ± 7 seconds (ANOVA post 
test, Tukey’s multiple comparison, Control vs DPA 5mg/kg p<0.05). Injecting the σ-1R 
antagonist BD1047 (4mg/kg) along with the 5mg/kg dipentylammonium reverses the 
effect of the dipentylammonium on the immobility time of the mice, resulting in an 
immobility time of 182± 30 seconds (ANOVA post test, Tukey’s multiple comparison, 
DPA vs BD1047 4mg/kg + DPA 5mg/kg p<0.05). DPA alone or in combination with 
BD1047 had no effect on locomotion (Table 3.3). 
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Treatment Dose 
(mg/kg) 
Total Locomotive activity 
(Ambulations and rearing /15mins) 
Vehicle Control 10 ml/kg 140 ± 15 
DPA 5 128 ± 19 
DPA + BD1047 5 + 4 114 ± 14 
 
Table 3.3 Effect of σ-1R agonists on locomotive activity. Locomotive activity measured 
using an actophotometer (n=6 to 8). 
 
Tripentylammonium 
Tripentylammonium is a high affinity σ-1R ligand with nanomolar affinity, which is 
comparable with dipentylammonium. Tripentylammonium was therefore tested for 
antidepressant activity in the forced swim test (Figure 3.31). 
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Figure 3.31: The effect of tripentylammonium (TPA) on despair behaviour in mice 
subjected to the forced swim test. The control consisted of 10ml/kg saline, 6 to 8 animals 
were used for each data point and the error bars represent SEM (*ANOVA Dunnett’s post 
test P <0.05). 
 
Tripentylammonium did not have any significant effect on the despair like behaviour of the 
mice, as measured by the immobility time in the forced swim test, at any of the doses 
tested (ANOVA Dunnett’s post test P value >0.05).  
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3.13  Straight-chain ammonium salts discussion 
 
Twenty two straight simple chain amines were tested for σ-1R affinity, all of which had 
never been tested for σ-1 affinity previously, and differ greatly from all previously know 
σ-1 ligands in their simplicity.  
 
Primary ammonium salts 
The simplest of ammonium salts tested were the primary ammonium salts, 
pentylammonium and hexylammonium have been shown previously to have antidepressant 
like activity in mouse models when administered at low doses (3mg/kg) and a depressant 
like affect at higher doses (100mg/Kg) (Widy-Tyszkiewicz and Czlonkowski, 1983, Widy-
Tyszkiewicz and Sourkes, 1980). Widy-Tysziewiez et al. (1980) suggests that the amines 
cause their behavioural effects through the 5-HT and dopamine receptors, however Widy-
Tyszkiewicz et al. (1980) had shown that the amines do not displace [3H] spiperone (a 5-
HT1A, 5-HT2A, 5-HT7, and D2 receptor antagonist). Of the primary amines tested 
pentylammonium and hexylammonium had the highest affinity for the σ-1R. The affinity 
of hexylammonium for the σ-1R is 6mM, which is in the range the doses used by Widy-
Tyszkiewiez et al., in the behavioural experiments suggesting that the amines might be 
causing their effect via the σ-1R. The affinity of these primary ammonium salts, for the σ-
1R is low. However, there have been recent publications suggesting endogenous σ-1R 
ligands that have σ-1R activity despite their low affinity (Burchett and Hicks, 2006, Su et 
al., 2009). 
 
Secondary ammonium salts 
Six secondary amines were tested in the [3H] (+) pentazocine competition assay, from the 
dimethylammonium with a 2 single carbon chains, to dihexylammonium with 2 six carbon 
long chains. Dimethylammonium, which has previously been shown to have anti tumour 
properties (Guest and Varma, 1991), and be present in human urine (Asatoor and 
Simenhoff, 1965, Zhang et al., 1995), has an affinity for the σ-1R below 10mM and 
therefore it is unlikely that the anti tumour effects of dimethylammonium described by 
Guest and Varma (1991) are caused by an interaction with the σ-1R.  However with each 
addition of a carbon to the chain there was an increased affinity for the σ-1R up until the 
five carbon long chain dipentylammonium (one way ANOVA P value 0.016), after which 
the affinity does not increase significantly for dihexylammonium. Dipentylammonium has 
a pKi of 7.37 ± 0.48, which is significantly higher than that of the well known σ-1R ligand, 
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rimcazole which as a pKi (± SEM) 6.22 ± 0.23 and at the same time it has a significantly 
lower affinity for the mAChR with a pKi (± SEM) 3.42 ± 0.24 compared to rimcazole with 
a pKi (± SEM) for the mAChR of 4.49 ± 0.10. Dipentylammonium is 7940 times more 
selective for the σ-1R then the mAChR, whereas σ-1R ligands such as (+) pentazocine are 
162 times more selective, haloperidol 100 times more selective and rimcazole only 53 
times more selective. 
 
Dipentylammonium also has a lower affinity for the mAChR than another well known σ-
1R ligand IPAG pKi 4.3 (IPAG was not tested more than once in the QNB competition 
assay). Dipentylammonium has a 10 times lower affinity for the σ-1R than (+) pentazocine 
(the radioligand of choice in σ-1R binding assays), and haloperidol but has a 1000 times 
lower affinity for the mAChR than both (+) pentazocine and haloperidol. 
Dipentylammonium did have an effect on the calcium response induced by histamine, 
although dipentylammonium did not affect the EC50, it did reduce the maximal response, 
however the dose required to cause this was 1mM, 1000 times that of dipentylammonium’s 
affinity for the σ-1R. This shows that dipentylammonium is not binding to histamine 
receptor at the orthosteric site; rather it is either acting allosterically, or behaving as a 
functional antagonist, lowering calcium through another mechanism. Since the σ-1R 
agonists have been previously shown to cause σ-1 inhibition of calcium channels (Brent et 
al., 1996b, Katnik et al., 2006, Monnet et al., 2003) this could be the explanation for the 
reduction in histamine-induced increase in cytoplasmic Ca2+, and if so would be further 
suggest that dipentylammonium is a σ-1R agonist, either causing the movement of σ-1Rs 
to the cell surface (Hayashi and Su, 2001, Mavlyutov and Ruoho, 2007, Morin-Surun et 
al., 1999) where they can prevent Ca2+ influx via interaction with ion channels (Monnet et 
al., 2003) or preventing release of calcium from intracellular stores.  
 
Dipentylammonium (100µM) alone did not raise cellular cAMP, nor did it inhibit the 
increase in cAMP caused by dopamine (100µM) or isoprenaline (100nM), which shows 
that it does not have affinity for the dopaminergic D1 or D5 receptors or the adrenergic β2 
receptors, which are coupled through Gs. Since dipentylammonium did not cause a 
decrease in dopamine-induced cAMP production it is possible to also rule out the D2, D3, 
and D4 receptors, which are coupled through Gi. Dipentylammonium had no effect on the 
metabolism of the σ-1R negative HEK 293 cells, even when added at a dose 100 times its 
affinity for the σ-1R, indicating that it is non-toxic at these concentrations.  
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Our in vitro results suggest that these ligands are potential antidepressants. To determine 
whether they can be effective in vivo, we were able to have them tested in two animal 
models. Mice when subjected to the forced swim test exhibited despair behaviour, which 
was reduced significantly by dipentylammonium at 1, 5 and 10 mg/kg, having much the 
same effect on the despair behaviour as the SSRI antidepressant fluoxetine. There does not 
appear to be a dose dependent decrease in despair behaviour, however this maybe due to 
the lowest dose tested giving a maximal response. This suggests that dipentylammonium 
exhibits antidepressant activity equal to that of the SSRI fluoxetine. Furthermore when the 
σ-1R antagonist BD1047 (which has no affect on behaviour alone) was administered with 
the dipentylammonium, the antidepressant effect seen by dipentylammonium alone was 
reversed. The same antidepressant effect was seen in the tail suspension test, which is 
similar to the forced swim test in that it measures the despair behaviour exhibited by the 
mice suspended by their tail. The time where the mice remained immobile, not struggling 
to escape was decreased by a 5mg/kg dose of dipentylammonium to the same extent as the 
mice treated with the SSRI fluoxetine (10mg/kg). The effect of dipentylammonium on the 
immobility time of the mice in the tail suspension test was reversed when it was added in 
conjunction with the σ-1R antagonists BD1047, which further adds to the evidence that 
dipentylammonium is acting as a σ-1R agonist, and causing an antidepressant effect in the 
mice. Neither dipentylammonium per se nor in combination with BD1047 had an effect on 
locomotion suggesting that neither have psychostimulant or psychoinhibitory effects, 
providing strong evidence for dipentylammonium having antidepressant activity causing 
its antidepressant effects through a σ-1R mediated mechanism.  
 
Tertiary ammonium salts 
Eight tertiary ammonium salts were tested in the [3H] (+) pentazocine competition assay, 
of these the two highest σ-1R affinity simple straight-chain amines were identified, 
tripentylammonium and trihexylammonium, with affinies of (pKi ± SEM) 7.83 ± 0.16 and 
8.05 ± 0.40 respectively, both of which having higher affinities for the σ-1R than 
rimcazole, and both have no effect on the calcium response induced by histamine. 
Tripentylammonium also has an affinity for the mAChR (pKi ± SEM) 4.33 ± 0.38 that is 
statistically not different to that of rimcazole, however it is 2000 times more selective for 
the σ-1R over the mAChR where as rimcazole is only 53 times more selective, therefore 
tripentylammonium is a σ-1R ligand with a higher affinity for the σ-1R than rimcazole, 
and is more selective for the σ-1R over the mAChR than rimcazole .  
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Tripentylammonium (100µM) alone did not raise cellular cAMP, nor did it inhibit the 
increase in cAMP caused by dopamine (100µM) or isoprenaline (100nM), which shows 
that it does not have affinity for the dopaminergic D1 or D5 receptors or the adrenergic β2 
receptors, which are coupled through Gs. Since tripentylammonium did not cause a 
decrease in dopamine-induced cAMP production it is possible to also rule out the D2, D3, 
and D4 receptors, which are coupled through Gi. Furthermore the cAMP assay provides 
evidence that the σ-1R itself is not coupling through Gs or Gi G-proteins since neither the 
σ-1R agonist (+) pentazocine or the antagonist IPAG raised cAMP levels alone, nor did 
they affect on the cAMP increase caused by dopamine or isoprenaline, there is also no 
suggestion of functional antagonism as the responses to dopamine and isoprenaline 
remained the same.  
 
Neither dipentylammonium nor tripentylammonium had an effect on the growth of HEK 
293 cells (σ-1R negative), measured using the MTS assay, at doses 100 times their affinity 
for the σ-1R, indicating that it is non-toxic at these concentrations. 
 
Tripentylammonium despite having an affinity similar to that of dipentylammonium for the 
σ-1R failed to reduce despair behaviour in mice subjected to the forced swim test, this 
could be due to tripentylammonium not crossing the blood brain barrier, rapid metabolism 
or excretion and therefore not being accessible to the brain. It could equally be due to 
tripentylammonium having no activity at the σ-1R despite its high affinity for the σ-1R and 
its structural similarity to dipentylammonium, since tripentylammonium also did not have 
an effect on the histamine-induced calcium response, whereas dipentylammonium did. It 
has been shown previously that many antidepressant drugs including the tricyclic 
antidepressant imipramine and the SSRI citalopram (both of which have σ-1R affinity) 
along with other antidepressants that don’t have reported σ-1R affinity (although that isn’t 
to say they have no σ-1R affinity) maprotiline, amitripyline and clomipramine are able to 
inhibit L-type calcium channels (Zahradnik et al., 2008). This modulation of ion channels 
is a possible mechanism for the antidepressant effects. Stimulation of neuron growth, 
which has previously been reported for the SSRI fluoxetine (which has σ-1R affinity) 
(Wang et al., 2008) could be controlled by ion channel modulation by the σ-1R which 
would explain the shorter delay in effect of antidepressants such as chronic treatment with 
venlafaxine (Mitchell and Redfern, 2005), which has σ-1R affinity (Dhir and Kulkarni, 
2007). 
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Quaternary ammonium salts 
Four quaternary, positively charged ammonium salts were tested in the [3H] (+) 
pentazocine competition assay, all of which had low affinities for the σ-1R, with pKi 
values between 2 and 3, with the exception of tetramethylammonium, which had no 
affinity with in the range tested (maximum dose 10mM). From the quaternary ammonium 
salt binding data it is possible to conclude that a positively charged nitrogen results in a 
reduction in the affinity of a ligand for the σ-1R. 
 
None of the simple straight-chain ammonium salts were able to cause a calcium response 
in Fura-2-AM loaded MDA-MB-468 cells when added at 100 times their affinity for the σ-
1R, which means the straight-chain amines are unlikely to act as σ-1R antagonists. 
Tripentylammonium also has no effect on cell metabolism of the MDA-MB-468 cells, 
another indication that the simple straight-chain amines are not acting as σ-1R antagonists 
and are in fact σ-1R agonists. 
 
Summary  
To summarise and conclude this chapter, the straight-chain simple primary, secondary and 
tertiary ammonium salts have σ-1R affinity (the positively charged quaternary ammonium 
salts showed little affinity), which increases as the carbon chain length is increased 
between 2 carbons and 6 carbons. Beyond this the affinity for the σ-1R falls away. The 
high affinity straight-chain amines appear to be non toxic at doses 100 times their affinity 
for the σ-1R in σ-1R negative HEK 293 cells although none were able to induce a calcium 
response in the σ-1R expressing MDA-MB-468 cell line. Dipentylammonium (one of the 
ammonium salts with the highest affinity for the σ-1R), whilst being more selective for the 
σ-1R than the σ-1R ligands (+) pentazocine, IPAG, rimcazole and haloperidol, however 
was the only ammonium salt to reduce the maximal response to histamine. Furthermore 
dipentylammonium reduced the immobility time of mice in both the forced swim test and 
the tail suspension test whereas the structurally similar tripentylammonium did not, 
suggesting that dipentylammonium has antidepressant effects, which are reversed on 
addition of the σ-1R antagonist BD1047.  
 
In summary, I have identified a non-toxic, high affinity σ-1R ligand, dipentylammonium 
that possesses potent antidepressant activity in animal in vivo assays. Further development 
of this molecule should be carried out to determine whether this compound can proceed 
into clinical trials, as an antidepressant, or a neuroprotective agent. 
 Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  96 
4 Simple branched-chain ammonium salts - antagonists at the 
σ-1 receptor 
4.1 Background 
 
In Chapter 3 I have identified 3 high affinity σ-1R ligands, dipentylammonium, 
tripentylammonium and trihexylammonium, all of which show better or equal selectivity 
for the σ-1R over the mACh compared to rimcazole, haloperidol, and pentazocine. 
Furthermore, dipentylammonium showed antidepressant properties in the animal models. 
Their affinity for the σ-1R was higher than that of rimcazole. However, their affinity for 
the σ-1R is lower than that of pentazocine and haloperidol. Therefore, in order to try and 
find some higher affinity ligands for the σ-1R, or alter the activity at the σ-1R, and also try 
and keep the higher selectivity, whilst keeping to the original scope of the investigation 
with the simple single nitrogen ammonium salts, I moved on to investigate branched-chain 
ammonium salts. The branched-chain ammonium salts remain simple ammonium salts, 
and are the simplest variation on the theme that could alter the affinity for the σ-1R whilst 
staying within the original remit of the investigation. 
4.2 Primary branched-chain ammonium salt affinity for the σ-1 
receptor  
 
Despite the straight-chain primary ammonium salts having low affinity for the σ-1R, the 
branched-chain primary ammonium salts described in this chapter were investigated, as 
they resemble part of IPAG, a known σ-1R antagonist. 
 
 A   B   C 
NH
2
 
 
 
Figure 4.1: Structures of primary branched amines and IPAG 
A 1-adamantylammonium, B 2-adamantylammonium, C IPAG. 
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The affinities of 1-adamantylammonium and 2-adamantylammonium (Figure 4.1a and 
4.1b) for the σ-1R were assessed using radioligand competition binding (Figure 4.2), and 
the data are normalised to % specific [3H] (+) pentazocine binding, the curve in Figure 4.2 
is made up of 6 independent binding assays.  
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Figure 4.2: Binding of primary branched-chain ammonium salts to the σ-1R. Data 
represented as % Specific [3H] (+) pentazocine binding competing with 1-
adamantylammonium and 2-adamantylammonium. Affinity (Ki 95% CI) for the σ-1R of 1-
adamantylammonium is 0.73mM (0.48-1.11) and 2-adamantylammonium is 0.57mM 
(0.33-0.99). Error bars represent SEM from 4 independent radioligand competition assays. 
 
In order to visualise the affinities for the σ-1R more clearly, Ki values obtained from the 
above competition binding curves were converted into pKi values (-log10Ki) shown in 
Figure 4.3 below. 
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Figure 4.3: Summary of Branched-chain Primary ammonium salt binding to the σ-
1R. pKi (± SEM) for the primary ammonium salts 1-adamantylammonium and 2-
adamantylammonium were pKi 3.13 (± 0.06) and 2-adamantylammonium was pKi 3.23 (± 
0.09) respectively. 
 
1-adamantylammonium and 2-adamantylammonium show similar binding properties with 
low affinities. The affinity of 1-adamantylammonium for the σ-1R was pKi 3.13 (± 0.06) 
and 2-adamantylammonium was pKi 3.23 (± 0.09). No other primary branched-chain 
ammonium salts were assessed for binding to the σ-1R.   
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4.3 Secondary branched ammonium salt affinity for the σ-1 receptor 
 
In order to assess the structure activity relationship of the simple ammonium salts with the 
σ-1R, some simple branched-chain ammonium salts that were of similar chain length to the 
straight-chain ammonium salts with high affinity for the σ-1R, were tested for σ-1R 
affinity using [3H] (+) pentazocine in the radioligand competition assay. The binding data, 
normalised to % specific (+) pentazocine, are shown below in Figure 4.4. 
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Figure 4.4: Binding of secondary branched-chain ammonium salts to the σ-1R. 
Binding of simple branched-chain secondary amines to the σ-1R, data represented as % 
specific binding of (+) pentazocine. Error bars represent SEM from 5 independent 
radioligand competition assays. 
 
The Hill slope (nH) for the binding curves of diisobutylammonium and bis(2-
ethylhexyl)ammonium differ significantly from -1 (one sample t-test P values 0.049 and 
<0.0001 respectively), therefore the binding of diisobutylammonium and bis(2-
ethylhexyl)ammonium does not follow the law of mass action and the affinities can not be 
represented as Ki, instead the affinities are referred to as K50 values (the concentration of 
competing ligand that occupies 50% of the receptors). As for the other simple secondary 
branched-chain ammonium salts, diisopropylammonium (P value: 0.212), di-sec-
butylammonium (P value: 0.359), di-tert-amylammonium (P value 0.106) and 
dicyclohexylammonium (P value 0.52), there was no significant deviation from the nH of -
1.  The nH values are represented in table 4.1 along with the comparison of binding models 
and F test values. 
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Ammonium salt nH +/- SEM Preferred binding 
model  
F value and P 
value 
Diisopropylammonium -1.47 ± 0.33 One site F=1.1 and P = 0.6 
Diisobutylammonium -0.51 ± 0.11 One site F=2.2 and P=0.19 
Di-sec-butylammonium -0.75 ± 0.21 One site F=0.4 and P=0.5 
Bis(2-
ethylhexyl)ammonium 
-0.47 ± 0.07 Two site F=4.0 and P=0.049 
Dicyclohexylammonium -0.43 ±0.18 One site F=0.3 and P=0.5 
Di-tert-amylammonium -0.43 ± 0.18 One site F=1.2 and P=0.2 
Table 4.1: Hill coefficient and preferred binding model for branched-chain secondary 
ammonium salts at the σ-1R. P value refers to the chance of random error leading to 
accepting the alternative hypothesis (2 site model) rather than the null hypothesis (1 site 
model) (n=4). 
 
In order to compare the affinities of the simple branched-chain ammonium salts that had 
nH values that differed significantly from -1 (diisobutylammonium and bis(2-
(ethylhexyl)ammonium) the K50 values were converted to –logK50 (pK50) values. These 
values are represented in Figure 4.6. 
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Figure 4.5: Summary of secondary branched-chain ammonium salts to the σ-1R 
Summary of simple secondary branched-chain ammonium salts with nH values that differ 
significantly from -1, affinity for the σ-1R. The Mean pK50 ± SEM (n=4) for 
diisobutylammonium is 3.14 ± 0.02 and for bis(2-ethylhexyl)ammonium 4.54 ± 0.26. 
 
In order to compare the affinities of the simple branched-chain ammonium salts, which 
have nH values that do not differ significantly from, -1 (and therefore the binding is 
assumed to follow the law of mass action) the Ki values were converted to pKi values and 
represented in Figure 4.6. 
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Figure 4.6: Summary of the binding of the simple branched-chain ammonium salts to 
the σ-1R. The affinity (pKi ± SEM) of the secondary branched-chain ammonium salts for 
the σ-1R are, diisopropylammonium 3.14 ± 0.02, di-sec-butylammonium 3.81 ± 0.33, di-
tert-amylammonium 4.1 ± 0.5 and dicyclohexylammonium 5.76 ± 0.75. (n=4). 
 
 
Bis(2-ethylhexyl)ammonium has the highest affinity for the σ-1R of the simple secondary 
branched-chain ammonium salts that have a statistically significant low nH value. 
Dicyclohexylammonium has the highest affinity for the σ-1R of the simple secondary 
branched-chain ammonium salts, which have an nH of 1. However, these affinities are 
much lower than the affinities of the straight-chain ammonium salts in the previous 
chapter, with the highest σ-1 affinity straight-chain secondary ammonium salt being 
tripentylammonium with a pKi of 7.34 ± 0.48 compared to the branched-chain ammonium 
salt bis(2-ethylhexyl)ammonium with a pK50 of 4.54 ± 0.26 and dicyclohexylammonium 
with a pKi of 5.78 ± 0.74. 
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4.4 Tertiary branched-chain ammonium salt affinity for the σ-1 
receptor  
 
The simple straight-chain tertiary ammonium salts with carbon chain length between five 
and six carbons had the highest affinity for the σ-1R, therefore triisopentylammonium was 
tested for σ-1R affinity (being the longest simple branched-chain ammonium salt 
commercially available at the time along with N,N diisopropylethylammonium, which 
consists of two branched-chains and one straight-chain. The binding curves are represented 
in Figure 4.7. 
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Figure 4.7: Tertiary branched-chain ammonium salt competition with [3H] (+) 
pentazocine in permeabilised MDA-MB-468 cells. Binding of simple branched-chain 
tertiary amines to the σ-1R, represented as % specific (+) pentazocine binding. Error bars 
represent SEM from 6 independent radioligand competition assays. 
 
Once again the nH values for the binding curves of triisobutylammonium and 
triisopentylammonium differ significantly from -1 (nH values represented in Figure 4.8) 
(one sample t-test P values, 0.0011 and 0.0002 respectively), meaning that the binding of 
these two ammonium salts does not follow the law of mass action, and therefore the 
affinities are represented as K50 values. Triisobutylammonium has a K50 (95% CI) of 9.7 
µM (6.9 to 80.1) and triisopentylammonium has a K50 (95% CI) of 196 µM (62 to 624). 
N,N-diisopropylethylammonium did not have affinity for the σ-1R within the range tested 
(highest dose 10mM). 
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Ammonium slat nH +/- SEM Preferred binding model F value and P value 
Triisobutylammonium -0.33 ± 0.10 One site F=0.3 and P=0.58 
Triisopentylammonium -0.36 ± 0.07 Two site F=4.22 and P=0.047 
 
Table 4.2: Hill coefficient and preferred binding model for branched-chain tertiary 
ammonium salts at the σ-1R. (n=6). 
 
In order to compare the affinities of the branched-chain amines with nH values that were 
shallower than -1, the K50 values were converted to pK50 values, represented in Figure 4.9. 
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Figure 4.9: Summary of the simple tertiary branched-chain ammonium salts with nH 
values shallower than -1, binding to the σ-1R. The pK50 (± SEM) values are, 
triisobutylammonium 5.1 ± 0.6 and triisopentylammonium 4.1 ± 0.4. (n=6). 
 
 
The shallow nH is a potential indication of G-protein coupling with the σ-1R (Connick et 
al., 1992, Itzhak, 1989) and is discussed in detail with relation to σ-1R antagonists in 
chapter 5.   
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4.5 Calcium response to branched-chain ammonium salts 
The branched-chain ammonium salts with the statistically significant shallow nHs were 
tested for σ-1 activity using the calcium response assay with Fura-2 loaded MDA-MB-468 
cells. The calcium influx into the cytoplasm in response to the branched-chain ammonium 
salts at doses ten times the affinity for the σ-1R are represented in Figure 4.10. 
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Figure 4.10: Calcium response to branched-chain ammonium salts. 
A: 1mM Diisobutylammonium was added to a stirred suspension of Fura-2-AM loaded 
MDA-MB-468 cells, no increase in cytosolic free [Ca2+] was observed. B: 1mM bis(2-
ethylhexyl)ammonium was added to the stirred suspension of Fura-2-AM loaded MDA-
MB-468 cells which resulted in a large increase in cytosolic free [Ca2+]. C: 1mM 
Triisobutylammonium was added to the stirred suspension of Fura-2-AM loaded MDA-
MB-468 cells and no increase in cytosolic free [Ca2+] was observed. D: 1mM 
Triisopentylammonium was added to the stirred suspension of Fura-2-AM loaded MDA-
MB-468 cells and a small increase in cytosolic free [Ca2+] was observed. 
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Bis(2-ethylhexyl)ammonium gave the largest calcium response after the addition of  
branched-chain ammonium salt at approximately ten times the affinity for the σ-1R and 
triisopentylammonium gave a small calcium response, whereas triisobutylammonium and 
diisobutylammonium (which did not have the 2 site model as the preferred model) did not 
give a response at all with the doses tested.  
 
Since bis(2-ethylhexyl)ammonium gave the highest calcium influx on addition of 1mM, a 
full dose response was carried out. The dose response curve for calcium influx in response 
to bis(2-ethylhexyl)ammonium is shown in Figure 4.11. 
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Figure 4.11: Cytosolic [Ca2+] increase dose response to bis(2-ethylhexyl)ammonium. 
Bis(2-ethylhexyl)ammonium dose response in a suspension of MDA-MB-468 cells loaded 
with Fura-2-AM at 37°C. The pEC50 for bis(2-ethylhexyl)ammonium was 2.9 ± 0.1, with 
an nH value of 4 ± 3. Error bars represent SEM from 6 independent Fura-2 calcium assays. 
 
 
Bis(2-ethylhexyl)ammonium dose-dependently caused an increase in calcium response, 
with a pEC50 value of 2.9 ± 0.1 which is over a 10 times higher dose than its affinity for 
the σ-1R pKi 4.54 ± 0.26.  
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4.6 Branched-chain ammonium salts effect on cell metabolism  
 
σ-1R antagonists cause cell death in σ-1R expressing cancer and tumour cell lines (Brent et 
al., 1996a, Brent and Pang, 1995, Spruce et al., 2004, Vilner et al., 1995a). The branched-
chain amines that induced a calcium response in the MDA-MB-468  (bis(2-
ethylhexyl)ammonium and triisopentylammonium) were tested for their effects on cell 
metabolism in the MDA-MB-468 cell line using the MTS assay, the dose response curves 
are shown in Figures 4.12 and 4.13. 
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Figure 4.12: MTS assay dose response to bis(2-ethylhexyl)ammonium. The effect of 
bis(2-ethylhexyl)ammonium MDA-MB-468 cell metabolism, measured using the MTS 
assay kit, error bars represent SEM from 4 independent MTS assays. The pIC50 (±SEM) 
for bis(2-ethylhexyl)ammonium was 3.3 ± 0.1. 
 
Bis(2-ethylhexyl)ammonium dose-dependently reduced cell metabolism in MDA-MB-468 
cells, the pIC50 (±SEM) 3.3 ± 0.1 is over ten times higher than the affinity of bis(2-
ethylhexyl)ammonium for the σ-1R (pK50 4.54 ± 0.26). 
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Figure 4.13: Triisopentylammonium dose response MTS assay. The effect on 
triisopentylammonium on MDA-MB-468 cell metabolism, measured using the MTS assay 
kit, error bars represent the SEM from 4 independent MTS assays. The pIC50 ± SEM, for 
triisopentylammonium was 2.96 ± 0.06.  
 
Triisopentylammonium dose dependently reduced cell metabolism in MDA-MB-468 cells, 
with a pIC50 of   2.96 ± 0.06. The affinity of triisopentylammonium for the σ-1R is is pKi 
(±SEM) 3.86 ± 0.41, almost ten times lower than the does needed to cause a 50% drop in 
cell metabolism.  
 
4.7 σ-1 receptor knock-down: Are the branched-chain ammonium salts 
causing their effect through the σ-1 Receptor? 
 
Bis(2-ethylhexyl)ammonium dose dependently increased the response seen in the calcium 
response assay in the Fura-2-AM loaded MDA-MB-468 cells, and dose dependently 
caused a decrease in cell metabolism in the MDA-MB-468. Triisopentylammonium also 
dose-dependently caused a decrease in cell metabolism in the MDA-MB-468 cells, and 
induced a small response in the Fura-2-AM loaded MDA-MB-468 cells. However the EC50 
for the bis(2-ethylhexyl)ammonium calcium response assay and the IC50s for the effects of 
both triisopentylammonium and bis(2-ethylhexyl)ammonium around a ten times higher 
dose than the affinities established from the [3H] (+) pentazocine binding competition 
assays. It is possible that this discrepancy could be accounted for by the presence of 
HEPES in the DMEM in the MTS assay (as HEPES has σ-1R affinity), however in the 
calcium assay there is no HEPES in the buffer.  Therefore in order to see if the branched-
chain ammonium salts were having their effect thought the σ-1R, the σ-1R expression was 
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knocked down using a σ-1R siRNA. The expression of the σ-1R was measured using the 
specific binding of 30nM (+) pentazocine (Figure 4.14). 
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Figure 4.14: σ-1R knock-down with σ-1 siRNA compared to the non-targeting 
control siRNA. σ-1R expression in permeabilised MDA-MB-468 cells measured using 
30nM [3H] (+) pentazocine. The mean (fmol/mg ± SEM) for the binding of [3H] (+) 
pentazocine in the MDA-MB-468 cells treated with the non-targeting control was 1749 ± 
115 and for the MDA-MB-468 cells treated with the σ-1 siRNA 838 ± 200. The mean 
difference in binding from 8 independent experiments was 911 ± 151 fmol/mg *** t-test P 
value < 0.0001.  
 
 
The σ-1 siRNA treatment of the MDA-MB-468 cells routinely resulted in an approximate 
50% knock-down of the σ-1R, and caused no noticeable cell death, in the non targeting 
control or the σ-1 siRNA treated cells.  Once the extent of the knock-down was 
established, the effect of the branched-chain amines on cell metabolism, in the siRNA 
treated MDA-MB-468 cells could be tested using the MTS assay. The dose-response 
curves to the branched-chain ammonium salts in the presence of the σ-1 siRNA or the non-
targeting siRNA are show in Figure 4.15.  
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Figure 4.15: The effect σ-1R knock-down on the reduction in cell metabolism caused 
by σ-1R ligands. A The effect of triisopentylammonium on cellular metabolism in MDA-
MB-468 cells in the presence of the σ-1 siRNA or the non-targeting siRNA. The pIC50 in 
the presence of the non-targeting siRNA for triisopentylammonium is 2.87 ± 0.17 and in 
the presence of the σ-1 siRNA 2.26 ± 0.21. B The effect of bis(2-ethylhexyl)ammonium in 
MDA-MB-468 cells in the presence of the σ-1 siRNA or the non-targeting siRNA. The 
pIC50 of bis(2-ethylhexyl)ammonium in the presence of the non-targeting siRNA is 3.19 
±0.20 and in the presence of the σ-1 siRNA is 2.64 ±0.19. 
 
 
The addition of the σ-1 siRNA resulted in an increase in the concentration of the branched-
chain ammonium salt required to cause a 50% drop in cell metabolism, whilst the non-
targeting control had little effect on the cells. A comparison of the siRNA treated and 
control pIC50 for bis(2-ethylhexyl)ammonium can be seen in Figure 4.16, and 
triisopentylammonium in Figure 4.17. 
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Figure 4.16: Summary of pIC50 values for the effect of bis(2-ethylhexyl)ammonium on 
MDA-MB-468 cell growth. The effect of knocking down the σ-1R on the pIC50 of cell 
metabolism when treated with bis(2-ethylhexyl)ammonium. The σ-1 siRNA treated MDA-
MB-468 cells have a pIC50 (2.64 ± 0.19) significantly lower than that of the MDA-MB-468 
cells treated with the non targeting siRNA (3.19 ±0.20). Error Bars represent SEM from 3 
independent experiments.  * t-test P value 0.038. 
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Figure 4.17: Summary of pIC50 values for the effect of triisopentylammonium on 
MDA-MB-468 cell metabolism. The effect of knocking down the σ-1R on the pIC50 of 
cell metabolism when treated with triisopentylammonium. The σ-1 siRNA treated MDA-
MB-468 cells have a pIC50 (2.26 ± 0.21) significantly lower than that of the MDA-MB468 
cells treated with the non targeting siRNA (2.87 ± 0.17). Error bars represent SEM from 4 
independent experiments. * t-test P value 0.018. 
 
With an approximate 50% knock-down of the σ-1R, the effect of the branched-chain 
ammonium salts on MDA-MB-468 cell metabolism is reduced by approximately 10 times 
the concentration required to cause a 50% reduction in cell metabolism for both 
triisopentylammonium and bis(2-ethylhexyl)ammonium, which suggests there is no 
receptor reserve.  
 
  * 
Simple branched-chain ammonium salts  
Antagonists at the σ-1 receptor 
 112 
4.8 Alternative binding model for bis(2-ethylhexyl)ammonium 
 
The single binding site model is not the only binding model that can be fitted to the data. A 
possible explanation for a shallow nH is that there are multiple sites to which the ligand is 
competing for, which have different affinities.  A model for two affinity sites is fitted to 
the bis(2-ethylhexyl)ammonium data in Figure 4.18 below. 
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Figure 4.18: Multiple affinity sites for the binding of bis-2-(ethyl)ammonium to the σ-
1R. Two-site fit to the bis(2-ethylhexyl)ammonium competition with [3H] (+) pentazocine, 
with high affinity pIC50 ± SEM, 5.59 ± 2.26 (55.4 % of total binding) and low affinity 
pIC50 ± SEM, 2.91 ± 0.33 (44.6% of total binding) binding. (n=5). 
 
Using the extra sum of squares F test the 2-site model was preferred with an F value of 
4.01 and P value 0.049. The two site binding model was applied to the binding data for all 
the branched-chain ammonium salts, the data are shown in table 4.1 for the secondary 
ammonium salts and table 4.2 for the tertiary ammonium salts. 
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4.9 Branched-chain ammonium salt specificity for the σ-1 receptor: 
Muscarinic receptors 
 
As described with the straight-chain ammonium salts in chapter 3 σ-1R ligands (+) 
pentazocine, BD737 and haloperidol have been shown to have µM affinity for the mAChR 
(Hong and Werling, 2002).  In order to assess whether the branched-chain ammonium salts 
had affinity for the mAChR, they were put into the [3H] QNB competition assay, an 
example curve (triisopentylammonium) can be seen below in Figure 4.19, and the full list 
of branched-chain ammonium salts tested, their affinity for the mAChR, and the σ-1R can 
be seen in table 4.3 
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Figure 4.19: Example of branched-chain ammonium salts QNB displacement. The 
affinity of triisopentylammonium for the mAChR is  (pKi ± SEM) 3.60 ± 0.11. Error bars 
represent SEM from between 4 and 7 independent radioligand competition assays. 
 
 
Table 4.3: Affinities of branched-chain ammonium salts for the σ-1R and mAChR, along 
with atropine a mAChR antagonist and rimcazole a σ-1R antagonist. 
 
Compound name Type of compound σ-1R  
affinity pKi 
± SE 
mAChR 
Affinity pKi 
± SE 
mACh 
Ki/σ-1 Ki 
Number 
of assays 
(n) 
Atropine mACh antagonist 4.51 ± 0.42 9.40 ± 0.34 0.000012 4 
 
Rimcazole σ-1R ligand 6.22 ± 0.23 4.49 ± 0.10 53 7 
 
Bis(2-
ethylhexyl)ammonium  
Secondary branched-
chain ammonium salt 
4.54 ± 0.26 3.92 ± 0.23 4.2 6 
Triisopentylammonium Tertiary branched-
chain ammonium salt 
6.03 ± 0.19 3.60 ± 0.11 269 5 
2-adamantylammonium Primary branched-
chain ammonium salt 
3.23 ± 0.09 3.37 ± 0.05 0.72 7 
1-adamantylammonium Primary Branched-
chain ammonium salt 
3.13 ± 0.06 3.22 ± 0.10 0.81 5 
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All of the branched-chain ammonium salts tested in the [3H] QNB competition assay had a 
lower affinity for the mAChR than the σ-1R antagonists rimcazole and haloperidol, and the 
σ-1R agonists (+) pentazocine and BD737. 
4.10 Branched-chain ammonium salt specificity for the σ-1 receptor: 
dopaminergic and adrenergic receptors 
 
As described in chapter 3 many σ-1R ligands have affinities with the dopaminergic 
receptors (Gundlach et al., 1986, Quirion et al., 1987). Therefore the branched-chain 
ammonium slats were tested for dopaminergic activity using the cAMP assay, and since 
MDA-MB-468 cells express both dopaminergic (Lang et al., 2004) and adrenergic 
receptors (Drell et al., 2003), which also couple through Gs G-protein activation of AC, the 
branched-chain ammonium salts (100µM) were tested for adrenergic receptor and 
dopaminergic receptor activity by measuring cAMP production in response to the ligands 
in MDA-MB-468 cells. Mean cAMP concentrations in response to ligands is shown in 
table 4.4. The dose response to dopamine and isoprenaline can be seen in chapter 3, (figure 
3.27). 
 
Drug cAMP fmol/mg Number of assays 
Control (no drug) 8.7 ± 1.4 8 
Dopamine 17.63 ± 2.5 8 
Isoprenaline 22 ± 2.9 8 
IPAG 8.9 ± 1.9 7 
(+) Pentazocine 11.7 ± 2.0 3 
Bis(2-ethylhexyl)ammonium 6.8 ± 2.0 6 
Triisopentylammonium 7.8 ± 1.3 5 
Dopamine + bis(2-ethylhexyl)ammonium 16.5 ± 7.2 4 
Dopamine + triisopentylammonium 16.0 ± 2.0 6 
Isoprenaline + bis(2-ethylhexyl)ammonium 20.1 ± 5.0 6 
Isoprenaline + triisopentylammonium 30.3 ± 5.3 6 
 
Table 4.4: cAMP concentration in response to dopamine, isoprenaline and branched-
chain ammonium salts. 
 
None of the branched-chain ammonium salts alone altered in cAMP levels in MDA-MB-
468 cells, nor did they interfere with dopamine (100µM) cAMP production or isoprenaline 
(100nM) cAMP production, one way ANOVA P value 0.95. 
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4.11 Effects of branched-chain ammonium at the cell membrane  
 
The σ-1R has been found to associate with membrane microdomains containing 
sphingolipids and rich in cholesterol, known as lipid rafts (Hayashi and Su, 2001, Hayashi 
and Su, 2003b, Hayashi and Su, 2003a, Hayashi and Su, 2004, Hayashi and Su, 2005b, 
Palmer et al., 2007, Takebayashi et al., 2004). The ganglioside GM1 is found in membrane 
microdomains enriched with cholesterol and sphingolipids, and it is this that the non toxic 
cholera toxin subunit B binds to, therefore fluorescent labelled cholera toxin B was used to 
highlight lipid raft formation, in response to σ-1R ligands (Figures 4.20-4.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Control MDA-MB-468 cells stained with fluorescent cholera toxin B. Scale 
bar 50µm. Representative figure of 3 independent experiments. 
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Figure 4.21: MDA-MB-468 cells treated with 1mM bis(2-ethylhexyl)ammonium, stained 
with fluorescent cholera toxin B.  Scale bar 50µm Representative figure of 3 independent 
experiments.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: MDA-MB-468 cells treated with 10µM IPAG stained with fluorescent 
cholera toxin B. Scale bar 50µm. Representative figure of 3 independent experiments. 
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A 30 minute incubation of the MDA-MB-468 cells with bis(2-ethylhexyl)ammonium 
resulted in an increase in ganglioside GM1 patch formation (Figure 4.21), visualised with 
the florescent labelled cholera toxin B under a florescent microscope, compared to the 
control (Figure 4.20) which was incubated for 30 mins with PBS. IPAG (a σ-1R 
antagonist) was used as a positive control to show ganglioside GM1, lipid raft patch 
formation (Figure 4.22).  
4.12 In vivo effects of branched-chain ammonium salts  
In order to assay the branched-chain ammonium salts that had σ-1R antagonist properties 
(bis(2-ethylhexyl)ammonium and triisopentylammonium) in vivo for anti-tumour activity, 
the cell line to be used in the assay needed to express the σ-1R. The Mac 13 cells were 
assayed for σ-1 receptor expression using radioligand binding ([3H] (+) pentazocine 
saturation) (Figure 4.23). 
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Figure 4.23 [3H] (+) pentazocine saturation binding in Mac 13 cells. Non specific 
binding was determined in the presence of 1mM rimcazole. This is a representative figure 
of 3 independent experiments.  
 
The mean ± SEM Bmax for [3H] (+) pentazocine saturation in the Mac 13 cell line, was 
1310 ± 141 fmol/mg, and the mean ± SEM pKd was 7.4 ± 0.1. Having established that Mac 
13 cells express the σ-1R, the ammonium salts were again tested to see if they were able to 
affect cell growth using the MTS assay (Figure 4.24). 
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Figure 4.25: Effect of triisopentylammonium and bis(2-ethylhexyl)ammonium on cell 
metabolism of Mac 13 cells. Cultured Mac 13 cells treated with bis(2-
ethylhexyl)ammonium and triisopentylammonium, cell metabolism measured using the 
MTS assay. Error bars represent SEM from 6 independent replicates.  
 
Triisopentylammonium and bis(2-ethylhexyl)ammonium both cause a reduction in Mac 13 
cell metabolism in vitro with mean ± SEM pIC50 (n=6) values of 4.4 ± 0.2 and 5.3 ± 0.2 
respectively, this is higher than the pIC50 values observed for MDA-MB-468 cells (2.96 ± 
0.06 and 3.3 ± 0.1 respectively).  
 
Once the effects of the ammonium salts were established in the Mac 13 cells in vitro the 
ammonium salts were tested in vivo by Dr Steve Russell at Aston University.  Mac 13 
tumours were established in the mice 12 days before treatment with the ammonium salts 
began. Figure 4.26 shows the growth of the tumours for the ammonium salt treated mice 
compared to the control mice. 
 
 
 
 
 
Simple branched-chain ammonium salts  
Antagonists at the σ-1 receptor 
 119 
0 1 2 3 4 5 6 7 8 9 10
0
200
400
600
800
1000
Control
Bis(2-ethylhexyl)ammonium
Triisopentylammonium
a
b
a a
b b
b b b b
Time (days)
 
Figure 4.26: Effect of 10mg/kg bis(2-ethylhexyl)ammonium and 
triisopentylammonium on Mac13 tumour growth in mice. Bis(2-ethylhexyl)ammonium 
and triisopentylammonium treatment of mice carrying implanted Mac 13 tumours result in 
an inhibition of tumour growth compared to the control. Error bars represent SEM from 3 
mice. ANOVA Dunnett’s post test a P<0.001 from Day 0, b P<0.001 from control. 
 
 
Daily treatment with 10mg/kg of bis(2-ethylhexyl)ammonium and triisopentylammonium 
resulted in a statistically significant reduction in tumour growth (ANOVA P<0.001), 
suggesting that the two σ-1R antagonist ammonium salts exhibit anti-tumour properties 
similar to that seen with the σ-1R antagonists IPAG and rimcazole (Spruce et al., 2004). 
 
4.13 Branched-chain ammonium salts discussion  
 
Twelve branched-chain ammonium salts were tested for σ-1R affinity, all of which had 
never been assessed for σ-1R activity previously, and differ from all known σ-1R ligands 
in their simplicity, and differ from the ammonium salts tested in the previous chapter in 
being ever so slightly more complex in that the carbon chains are now branched. 
 
The primary ammonium salts 1-adamantylammonium and 2-adamantylammonium are 
more complex than the other branched-chain ammonium salts tested, and resemble part of 
the well-known σ-1R antagonist IPAG. However, these two primary ammonium salts only 
had low affinity for the σ-1R, over 100,000 times lower affinity than IPAG for the σ-1R. 
Therefore it is clear that just the adamantyl group alone is not enough to make a high 
affinity σ-1R ligand. The adamantyl group may be responsible for the affinity of IPAG for 
the mACh receptor, since other previous studies have shown the adamantyl group to 
increase affinity for the mAChR (Gabrielevitz et al., 1980) as well as 1-
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adamantylammonium and 2-adamantylammonium both were more selective for the 
mAChR than the σ-1R (table 4.3). 
 
The secondary and tertiary ammonium salts tested bear much more resemblance to the 
straight-chain ammonium salts tested in the previous chapter, with long carbon chains, 
only differing in that these chains are branched not straight. By adding these side branches 
to the chains of the simple ammonium salts dramatically altered their affinity for the σ-1R, 
and changed its activity at the σ-1R. The most dramatic example in change of affinity and 
change in activity at the σ-1R is bis(2-ethylhexyl)ammonium, by adding an ethyl group 
(C2H5) to the 2nd carbon along each of the carbon chains of dihexylammonium changed the 
binding properties of the ammonium salt giving a binding curve with a low nH value, and 
resulted in a 100 times loss of affinity, however in doing so it was now able to induce an 
increase in cytoplasmic calcium in the Fura-2-AM loaded MDA-MB-468 cells. The nH 
value for the cytoplasmic calcium influx into the cytoplasm in response to bis(2-
ethylhexyl)ammonium (pseudo Hill slope since we are not looking at a simple 1 step 
event) of 4 ± 3 is very steep, this could be due to the fact that we are looking at 
cytoplasmic calcium influx which is further down stream of the ligand binding, meaning 
that the cytoplasmic calcium increase may not be proportional to receptor occupancy due 
to amplification of the signal. There are other potential explanations for the high nH value 
one of which could be allosteric regulation of the receptor. 
 
A similar pattern was seen with the tertiary branched-chain ammonium salts, with 
triisopentylammonium, in adding a methyl (CH3) group to the 4th carbon of each of the 
carbon chains in tripentylammonium, changed the shape of the binding curve resulting in a 
curve with a shallow nH and a reduction in affinity of almost 100 times. However this 
lower σ-1R affinity ammonium salt is able to induce an increase in cytoplasmic calcium in 
Fura-2-AM loaded MDA-MB-468 cells. The addition of the branches on the longer chain 
ammonium salts appears to have changed the activity at the σ-1R of the ammonium salt 
from agonists to antagonists, capable of inducing a calcium response, and causing a  
decrease in cellular metabolism, measured using the MTS assay. Moreover this reduction 
of cellular metabolism appears to be being mediated through the σ-1R, by knocking the σ-
1R down by approximately 50% there is a 10 times reduction in cellular metabolism in 
response to bis(2-ethylhexyl)ammonium and triisopentylammonium. However, the dose 
required to induce a 50% reduction in cell metabolism, or 50% maximal calcium response 
was around ten times that of the affinity of bis(2-ethylhexyl)ammonium for the σ-1R. In 
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the case of the MTS assay there is 25mM HEPES in the buffer, which could account for 
any small discrepancy, although HEPES has an affinity for the σ-1R of 10mM so it is 
unlikely that HEPES could cause the 10 times discrepancy between IC50 and the affinity of 
bis(2-ethylhexyl)ammonium for the σ-1R. Moreover there is no HEPES in the calcium 
buffer, and the difference is the same. This difference can however be accounted for by 
there being two affinity states of the σ-1R for bis(2-ethylhexyl)ammonium. By fitting a 
different model to the bis(2-ethylhexyl)ammonium binding data, two affinities of bis(2-
ethylhexyl)ammonium can be identified for the σ-1R. Giving a high affinity site of (pIC50 
± SEM) 5.59 ± 2.26 and a low affinity site of (pIC50 ± SEM) 2.91 ± 0.33, it is this low 
affinity site which corresponds to the doses at which bis(2-ethylhexyl)ammonium has its 
effects (Cytoplasmic [Ca2+] increase pEC50 2.9 ± 0.1 and cell metabolism inhibition pIC50 
3.3 ± 0.1).  
 
Further evidence that bis(2-ethylhexyl)ammonium is acting as a σ-1R antagonist is shown 
by its effects at the cell membrane on the formation of lipid rafts. A 1mM dose of bis(2-
ethylhexyl)ammonium (the same as the dose required for 50% maximal calcium influx and 
a 50% reduction in cell metabolism) resulted in an increase in ganglioside GM1 patch 
formation, visualised with florescent cholera toxin B, in the same way as a 10µM dose of 
IPAG (a σ-1R antagonist). The formation of lipid rafts on the plasma membrane in 
response to σ-1R ligands could be the trigger of the calcium influx into the cytoplasm, 
since many types of ion channel (including voltage-gated calcium channels, voltage-gated 
potassium channel and calcium-activated potassium channels) are found localized within 
lipid rafts (Balijepalli et al., 2006, Barfod et al., 2007, Davies et al., 2006, Martens et al., 
2001, Xia et al., 2007) along with many regulators of ion channels which control calcium 
signalling (Isshiki and Anderson, 1999). The σ-1R has been shown to inhibit ion channels 
in the absence of ligands (Aydar et al., 2002) and interact with lipid rafts possibly 
controlling the cholesterol content on the plasma membrane (Hayashi and Su, 2003b, 
Hayashi and Su, 2004, Hayashi and Su, 2005b, Mavlyutov and Ruoho, 2007, Palmer et al., 
2007, Takebayashi et al., 2004).  
 
Other secondary and tertiary branched-chain ammonium had low nH values, and lower 
affinities than the straight-chain ammonium salts, however they failed to induce a increase 
in cytoplasmic calcium when added at the same dose as bis(2-ethylhexyl)ammonium or 
triisopentylammonium (1mM). Triisopentylammonium and bis-2(ethyl)hexylammonium 
were the only two ammonium salts to have a preferred two site binding model, and were 
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also the only ammonium salts that were able to induce cytoplasmic calcium increase. In the 
case of diisobutylammonium which has a low nH value but did not induce a calcium 
response in Fura-2-AM loaded MDA-MB-468 cells, could be due to the fact that it has a 
much lower affinity for the σ-1R compared to bis(2-ethylhexyl)ammonium and 
triisopentylammonium, and therefore possibly requires a much higher dose to induce a 
calcium response. Another explanation for the lack of a calcium response to the other 
branched-chain ammonium salts, could be that they are partial agonists of the σ-1 receptor 
with low efficacy (note in the case of the σ-1R ligand nomenclature these are the σ-1R 
antagonists).  
 
The radioligand binding data, with the low nH values, and preferred two site binding 
model, suggested that the secondary branched-chain ammonium salt bis(2-
ethylhexyl)ammonium and the tertiary branched-chain ammonium salt 
triisopentylammonium are σ-1R antagonists. Further investigation into the effects of theses 
ammonium salts on membrane organisation, cytoplasmic calcium and cell growth revealed 
that both these ammonium salts had the same effects on the cell membrane, cytoplasmic 
calcium and cell growth as the previously characterised σ-1R antagonists IPAG, rimcazole, 
(Spruce et al., 2004), and haloperidol (Brent et al., 1996a). With this strong evidence 
suggesting that these branched-chain ammonium salts are σ-1R antagonists their in vivo 
effects in mice with transplanted σ-1R expressing Mac 13 tumours was assessed.  
 
The Mac 13 cells were first tested for σ-1Rs using the MTS assay, the pIC50 values for 
bis(2-ethylhexyl)ammonium and triisopentylammonium were 4.4 ± 0.2 and 5.3 ± 0.2 
respectively. These pIC50 values are considerably higher than those in the MDA-MB-468 
cells (2.96 ± 0.06 and 3.3 ± 0.1 respectively), this could be explained by the lower 
expression of the σ-1R in these cells resulting in an easier release from the anti-apoptotic 
drive the σ-1R has over the cells, or it is a possibility that these cells express a higher level 
of mACh receptors compared to the MDA-MB-468 cells. Most colon cancer cell lines 
overexpress the m3 subtype of mAChR (Cheng et al., 2008) and antagonising mAChRs 
has been shown to result in apoptosis (Cheng et al., 2008, Song et al., 2003a, Song et al., 
2003b). Both triisopentylammonium and bis(2-ethylhexyl)ammonium had affinity for the 
mAChR (table 4.3) (pKi 3.6 ± 0.11 and 3.92 ± 0.23 respectively) meaning it is possible to 
speculate that the additional apoptotic effect seen in the Mac 13 cells is related to the 
mAChR affinity.  
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Mice with implanted Mac 13 tumours treated with the branched-chain ammonium salts 
(bis(2-ethylhexyl)ammonium and  triisopentylammonium) showed a statistically 
significant inhibition of tumour growth compared to the control. These results suggest that 
bis(2-ethylhexyl)ammonium and  triisopentylammonium are effective in vivo anti-tumour 
agents, most likely to be acting through a σ-1R mechanism, possibly involving calcium 
influx and plasma membrane reorganisation to form lipid rafts, to bring together signals 
that lead to apoptosis. 
 
Summary 
To sum up this chapter, I have shown that branched-chain ammonium salts have lower 
affinity for the σ-1R than the straight-chain ammonium salts from chapter 3. However, the 
binding studies revealed low nH values which suggested that they may be σ-1R 
antagonists. Two branched-chain ammonium salts in particular stood out, with statistically 
preferred 2 site binding models. These ammonium salts were bis(2-ethylhexyl)ammonium 
and triisopentylammonium, they were both capable of increasing cytoplasmic calcium in 
the same fashion as other well known σ-1R antagonists such as IPAG. Furthermore, bis(2-
ethylhexyl)ammonium had the same effects on plasma membrane organisation into lipid 
rafts as the σ-1R antagonist IPAG. Both of these ammonium salts showed in vitro anti-cell 
growth in both human and mouse cell lines (MDA-MB-468 and Mac 13), and when tested 
in vivo they were both effective at inhibiting tumour growth in mice. Further investigation 
is required to ascertain whether these branched-chain ammonium salts can be developed as 
anti-tumour agents targeting the σ-1R.  
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Chapter 5 
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5 σ-1 receptor antagonists and G-protein coupling 
 
5.1 Background 
 
IPAG is a ‘potent’ σ-1R antagonist with a published affinity of 2.8nM (Whittemore et al., 
1997, Wilson et al., 1991). When IPAG is added to the highly σ-1 expressing MDA-MB-
468 cells it induces calcium influx into the cytoplasm. In order to assess the biological 
activity of the simple ammonium salts, the intention was to identify the EC50 for IPAG 
giving a suitable dose of IPAG to see if the simple ammonium salts affected the calcium 
influx into the cytoplasm. IPAG was chosen instead of the commonly used σ-1 antagonist 
rimcazole as preliminary experiments showed that rimcazole fluoresced at 510nm when 
excited between 280 and 360 nm (Figure 5.1). 
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Figure 5.1: Rimcazole fluorescence. A: Rimcazole (100µM) wavelength scan showing an 
increase in emissions at 510nm when excited between 290 and 360nm, compared to water 
alone. B: Rimcazole dissolved in two different solvents (methanol (MeOH) or DMSO) 
added to a calcium free buffer not containing cells, with or with out Fura-2 shows an 
increase in 340/380 ratio, whereas IPAG does not. C: Rimcazole dose-response in the 
absence of Fura-2-AM loaded cells.  
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The intrinsic fluorescence of rimcazole leads to an apparent EC50 of 10µM in the absence 
of Fura-2-AM loaded cells, this brings into question the validity of previously published 
data studying the effects of rimcazole on intracellular calcium levels using a ratiometric 
Fura-2 system, therefore data such as that found in Aydar et al. (2006), Brent et al., 
(1996b), Church and Fletcher, (1995), Spruce et al., (2004) should be reviewed and re-
interpreted.  
 
Rimcazole therefore could not be used in the Fura-2 calcium assay and IPAG was selected 
instead, a dose-response curve was generated using increasing doses of IPAG added to 
stirred Fura-2-AM loaded MDA-MB-468 cells (Figure 5.2). The EC50 and 95% CI for 
IPAG in the calcium influx assay was 124 (96 – 160) µM. 
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Figure 5.2: Cytosolic [Ca2+] increase in response to IPAG, dose response. Data 
represented % maximum cytosolic calcium increase in response to IPAG in Fura-2-AM 
loaded MDA-MB-468 cells. The EC50 (95% CI) for IPAG was 124 (96 – 160) µM. Error 
bars represent SEM from 6 independent Fura-2 calcium assays. 
 
IPAG also dose dependently leads to a reduction in cell metabolism in the σ-1R expressing 
MDA-MB-468 cells, this was measured using the MTS assay. A dose response was carried 
out in order to identify the IC50 for IPAG in the cell proliferation assay (Figure 5.3). The 
IC50 and 95% CI for IPAG’s effect on cell proliferation was 30 (11.7 - 48.2) µM  
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Figure 5.3: IPAG MTS assay dose response. Data represented as % cellular metabolic 
activity of MDA-MB-468 cells in response to IPAG, the IC50 (95% CI) for this assay was 
30 (11.7 - 48.2)  µM. Error bars represent SEM from 3 independent MTS assays. 
 
The EC50 for IPAG in the Fura-2 calcium assay and the IC50 in the MTS assay are over 
10,000 times higher than the published affinity for IPAG (Whittemore et al., 1997, Wilson 
et al., 1991). In order to assess whether IPAG was indeed causing its effects though the σ-
1R, as there was a large discrepancy between the observed EC50  and IC50 values and the 
published affinity for the σ-1R, the σ-1 siRNA was used to knock-down the σ-1R in the 
MDA-MB-468 cell line and the calcium response to IPAG measured (Figure 5.4). 
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Figure 5.4: Effect of knocking down the σ-1R on cytoplasmic [Ca2+]. Data represented 
% maximum cytosolic calcium increase in response to IPAG in Fura-2-AM loaded MDA-
MB-468 cells treated with either the σ-1R siRNA or the non-targeting control. Error bars 
represent SEM from 3 independent Fura-2 calcium assays. 
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Knocking down the σ-1R by approximately 50% resulted in a decrease in maximal 
response by 50%, but did not affect the EC50. This suggested that the σ-1R is involved in 
the effects of IPAG and therefore IPAG’s affinity for the σ-1R was reassessed in the 
MDA-MB-468 cells. It also suggests that there is no receptor reserve for calcium 
signalling since reducing the receptor number by approximately 50% the maximal 
response is reduced by 50%.  
 
5.2 IPAG affinity for the σ-1 receptor 
 
To investigate the discrepancy between the published affinity of 2.8nM for IPAG (in 
guinea pig brain membranes) and the EC50 value observed in the calcium influx assay of 
125µM and the IC50 of 30 µM in the MTS cell proliferation assay (using MDA-MB-468 
cells), IPAG’s affinity for the σ-1R in MDA-MB-468 cells was checked using [3H] (+) 
pentazocine competition binding (Figure 5.5).   
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Figure 5.5: Single site fit for IPAG binding to the σ-1R. IPAG competition assay with 
30nM [3H] (+) pentazocine. A single site binding model gives a pK50 7.82 ± 0.49 with an 
nH of -0.206. Error bars represent SEM from 9 independent radioligand competition 
assays. 
 
The radioligand binding assay did indeed give an affinity for IPAG for the σ-1R in the low 
nanomolar range (15.1 nM compared to the published affinity of 2.8nM). However the 
single site binding model had a very low nH of -0.206, and the data did not appear to fit 
this model well. The 2 site binding model fits the data better (Figure 5.6).  
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Figure 5.6: Multiple site fit for IPAG binding to the σ-1R. IPAG competition assay 
with 30nM [3H] (+) pentazocine. The 2 site binding model fits the binding data better 
giving pKi high (±SEM) 12.8 ± 0.6 (37% of total binding) and pKi low 6.3 ± 0.2 (63% total 
binding). Error bars represent SEM from 9 independent radioligand competition assays. 
 
 
Using the extra sum of squares F test the 2-site model was preferred with an F value of 
31.1 and P value less than 0.0001.  
5.3 Effects of GTP on IPAG binding to the σ -1 receptor 
 
 
The low nH value and two site binding fit can be an indication of G-protein coupling 
(Connick et al., 1992, Itzhak, 1989). There are, however, other explanations for a multiple 
site curve, including pentazocine binding other receptors, such as the σ-2R. This can 
however be ruled out as pentazocine is 200 times more selective for the σ-1R than the σ-
2R (Akunne et al., 1997). In order to test for σ-1 interaction with a G-protein the [3H] (+) 
pentazocine / IPAG competition binding assay was carried out in the presence and absence 
of 1mM GTP (10 times the normal physiological concentration of GTP (Reinhardt et al., 
2002)). A saturating dose of GTP will encourage the spontaneous GDP/GTP exchange in 
the alpha sub unit of a heterotrimeric G-protein and therefore force the G-protein to remain 
active effectively uncoupling the G-protein from the receptor. If a G-protein is coupled 
with the σ-1R its activation and uncoupling will result in the loss of the 2 site binding 
curve. 
Firstly, to see if GTP had any effect on the affinity of [3H] (+) pentazocine for the σ-1R 
saturation binding in the presence and absence of GTP was carried out (Figure 5.7).  
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Figure 5.7: Saturation binding of  [3H] (+) pentazocine in permeabilised MDA-MB-
468 cells in the presence and absence of GTP. Representative figure of 3 independent 
radioligand saturation experiments. + GTP Kd 25.8 nM –GTP 26.4 nM. 
 
1mM GTP has no noticeable effect on the binding of [3H] (+) pentazocine to the σ-1R in 
the permeabilised MDA-MB-468 cells, therefore the competition assay with IPAG was 
repeated in the presence of 1mM GTP  (Figure 5.8). 
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Figure 5.8: IPAG binding to the σ-1R in MDA-MB-468 cells. IPAG competitive 
binding assay using permeabilised MDA-MB-468 cells that had been washed with TBS to 
remove any endogenous GTP. With 30nM [3H] (+) pentazocine in the presence and 
absence of 1mM GTP. Error bars represent SEM from 9 independent radioligand 
competition assays. 
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The addition of 1mM GTP dramatically changes the shape of the binding curve; there is a 
dramatic increase in the nH (compared to the single site fit is used in the absence of GTP) 
(Figure 5.9). The affinity of IPAG for the σ-1R also shifts to the low affinity site (pKi ± 
SEM 6.3 ± 0.2) in the presence of 1mM GTP, which has no significant difference from the 
low affinity site seen in the 2 site fit in the absence of GTP (pKi ± SEM 6.8 ± 0.3) (t-test P 
value 0.183). 
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Figure 5.9: Hill coefficients for IPAG ± GTP: Hill coefficients for IPAG competition 
with 3H (+) pentazocine binding in MDA-MB-468 cells. The mean nH for + GTP was -
0.81 ± 0.05, and –GTP was -0.29 ± 0.07. Error bars represent SEM from 9 independent 
assays. ** P value 0.0015. 
 
5.4 Effects of GTP on rimcazole binding to the σ-1 receptor 
 
Rimcazole is a σ-1R antagonist, which has an affinity for the σ-1R of 1µM (Gilmore et al., 
2004, Husbands et al., 1999) and has been previously shown to cause apoptosis in cancer 
cells through a σ-1R dependent pathway (Spruce et al., 2004). Rimcazole could not be 
used in the calcium assay as it interfered with the wavelengths at which Fura-2 is read. 
However rimcazole did not interfere with the reading of the MTS assay, Figure 5.9 below 
shows the effect of the metabolic activity of MDA-MB-468 cells treated with rimcazole. 
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Figure 5.10: Rimcazole MTS assay dose response. % Cellular metabolism of MDA-MB-
468 cells in response to rimcazole, with a pIC50 of 4.35 ± 0.20. Error bars represent SEM 
from 3 independent MTS assays. 
 
Rimcazole dose dependently caused a reduction in MDA-MB-468 cell metabolic activity, 
with and IC50 of 45µM (95% CI 15-130µM) which is over 10 times higher than the 
published affinity for the σ-1R (0.9µM) (Gilmore et al., 2004). The affinity of rimcazole 
was therefore assessed, and the effect of GTP on rimcazole binding measured in Figure 
5.11. 
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Figure 5.11: Effect of GTP on rimcazole binding. Rimcazole competitive binding assay 
using permeabilised MDA-MB-468 cells that had been washed with TBS to remove any 
endogenous GTP. Assays were performed using 30nM [3H] (+) pentazocine in the 
presence and absence of 1mM GTP. Error bars represent SEM from 5 independent 
radioligand competition assays.  
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The binding of rimcazole to MDA-MB-468 cells that have had the GTP washed out shows, 
in the single site binding model, a low nH value (-0.4 ± 0.1, mean ± SEM n=5) with a pK50 
6.9 ± 0.5 (mean ± SEM), with the addition of GTP there is a statistically significant 
increase in the Hill slope (-1.0 ± 0.4, mean ± SEM) with a P value of 0.025. Furthermore, 
the preferred model for binding of rimcazole in the absence of GTP is the 2-site binding 
model, using the extra sum of squares F test gave an F value of 3.54 and a p value of 
0.028. The affinities for the σ-1R are pKhigh 8.3 ± 0.4 (mean ± SEM) pKlow 5.23 ± 2.8 
(mean ± SEM) with the pKhigh occupying 47% of the curve.  
 
5.5 GTP metabolism in response to σ-1 receptor ligands  
 
As shown above in Figures 5.8 to 5.11, GTP has a dramatic effect on the binding of IPAG 
and rimcazole to the σ-1R in permeabilised MDA-MB-468 cells. In order to assess the 
effect of σ-1R ligands on GTP metabolism to GDP and therefore the activity of G-proteins 
in response to the σ-1R ligands in the MDA-MB-468 cells, the GTP and GDP 
concentrations in the MDA-MB-468 cells was measured after a 30 minute treatment with 
the σ-1R ligands using HPLC. Some example dose response curves are shown below in 
Figure 5.12. 
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Figure 5.12: GTP metabolism to GDP in response to σ-1R ligands. σ-1R ligand 
inhibition of GTP metabolism to GDP measured using HPLC (GDP represented as a % of 
total GTP added at the start), after 30min treatment with the σ-1R ligand. Error bars 
represent SEM from between 4 and 5 GTP/GDP assays.  
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The two σ-1R ligands, IPAG and rimcazole, and the branched-chain ammonium salts 
resulted in a dose dependent reduction of GTP metabolism to GDP, whereas the straight-
chain ammonium salts did not have a positive or negative effect on GTP metabolism to 
GDP. The full list of σ-1R ligands effects on GTP metabolism can be seen in table 5.1 
 
Drug pIC50 ± SEM σ-1 Affinity pKi or pKlow N 
IPAG 3.6 ± 0.1 6.3 ± 0.2 4 
Rimcazole 3.8 ± 0.2 5.2 ± 2.8 4 
Triisopentylammonium 2.1 ± 0.1 3.5 ± 0.5 3 
Diisopentylammonium 1.3 ± 0.13 2.5 ± 0.3 3 
Bis-(2ethyl 
hexyl)ammonium 
2.6 ± 0.14 2.9 ± 0.3 3 
Tripentylammonium No curve 7.8 ± 0.2 3 
Dipentylammonium No curve 7.4 ± 0.5  3 
 
Table 5.1: Inhibition of metabolism of GTP to GDP. Represented as pIC50 ± SEM; 
measured using HPLC. 
 
The σ-1R antagonists IPAG and rimcazole and the branched-chain ammonium salts 
triisopentylammonium, diisopentylammonium, and bis(2-ethylhexyl)ammonium all dose 
dependently inhibited the metabolism of GTP to GDP, whereas the high σ-1R affinity 
straight-chain ammonium salts tripentylammonium and dipentylammonium did not 
increase or decrease GTP metabolism to GDP. 
5.6 The effect of cholera toxin on IPAG-induced calcium influx 
 
In order to assess which G-protein may be coupled to the σ-1R the MDA-MB-468 cells 
were treated with various G-protein inhibitors, one of which being cholera toxin (Figure 
5.13). The α subunit of the cholera toxin is responsible for permanently ribosylating the Gs 
α subunit of the heterotrimeric G-protein, leading to permanent activation and uncoupling 
from receptors.  
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Figure 5.13: Effect of cholera toxin on IPAG-induced increase in cytosolic [Ca2+]. A: 
Peak intracellular calcium above basal, in Fura-2 loaded MDA-MB-468 cells in response 
to 100µM IPAG. B: Peak intracellular calcium above basal, in Fura-2 loaded MDA-MB-
468 cells in response to 100µM IPAG in cells treated overnight with 100µg/ml cholera 
toxin compared to untreated cells measured ratio of emissions at 510nm when excited at 
340/380nm, ratio then converted to [Ca2+]. C: Mean ± SEM calcium increase in response 
to IPAG from 3 independent Fura-2 calcium assays. ** P-value 0.0067.  
 
The mean calcium response of the untreated MDA-MB-468 cells in response to 100µM 
IPAG was 600 ± 100 nM, whereas in cells treated with 100µg/ml cholera toxin had almost 
a three times greater response to 100µM IPAG with a mean calcium influx of 1600 ± 200 
nM.  
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5.7 The effect of suramin on σ-1 ligand binding 
 
Suramin is a synthetic polysulphonated naphthylamine benzamide-derivative that has been 
used for many years to treat African sleeping disease and river blindness. It however is 
also a G-protein inhibitor (Chung and Kermode, 2005); in the micromolar range it 
suppresses the release of GDP from the α subunit (Freissmuth et al., 1996), which is the 
rate limiting step in G-protein activation. At low micromolar concentrations suramin 
inhibits the Gs α subunit (Hohenegger et al., 1998), and at over 30 times higher 
concentrations will inhibit Gi and Gq (Beindl et al., 1996). Suramin had no effect on 
pentazocine binding, therefore suramin was added to the radioligand competition assay 
with IPAG, in order to see if it had any effect on IPAG binding to the σ-1R in the 
permeabilised MDA-MB-468 cells (Figure 5.14). 
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Figure 5.14: IPAG binding to the σ-1R ± suramin. IPAG competitive binding assay 
using permeabilised MDA-MB-468 cells that had been washed with TBS to remove any 
endogenous GTP. Assays were performed using 30nM [3H] (+) pentazocine in the 
presence and absence of 100µM suramin. Error bars represent SEM from 5 independent 
radioligand competition assays. 
 
 
The addition of 100µM suramin to the radioligand competition assay with IPAG resulted 
in a dramatic change in the nH (of the one site fit) shown in Figure 5.15 below. 
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Figure 5.15: Hill coefficient (nH) for IPAG competition ± suramin. nH for IPAG 
competition with [3H] (+) pentazocine binding in MDA-MB-468 cells. The mean nH value 
for untreated was -0.2 ± 0.1 and in the presence of 100µM Suramin -0.8 ± 0.2. * t-test P 
value 0.0342. 
 
5.8 σ-1 receptor ligand efficacy  
 
The activity of a drug at a receptor is not an all or nothing event where the drugs activity is 
simply a measure of its affinity for the receptors and the response is linearly proportional 
to the number of receptors occupied. Rather a drug may occupy just a small fraction of the 
available receptors and produce the maximal response whereas another drug may need to 
occupy a larger proportion of available receptors in order to produce the same response 
(Stephenson, 1956). The ability of a drug to cause a response is referred to as the drugs 
efficacy, and is different from a drugs affinity, which is a measure of the ability of a drug 
to bind to its target, and EC50, which is a measure of potency (and is proportional to both 
affinity and efficacy). The 2-state receptor model (Figure 5.16) can be used to explain drug 
efficacy (although a very simple model). 
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Figure 5.16: The 2-state model. The receptor has 2 conformational states R (resting) and 
R* (active), and exist in equilibrium. In the absence of ligand the equilibrium usually 
resides to the left (resting state). The addition of an agonist which has higher affinity for 
R* causes the shift of the equilibrium to the right, whereas the addition of an inverse 
agonist, which has higher affinity for R results in a shift of the equilibrium to the left. An 
antagonist has no preference for R or R* and does not affect the conformational 
equilibrium rather reduces the available sites for other ligands by competition. 
 
The activated receptor R* and resting receptor R exist in an equilibrium which can be 
shifted on the addition of a drug, if this drug prefers R* over R (i.e. has higher affinity for 
R* than R) more of the receptor to which the drug is bound will adopt the R* formation 
and cause a response (these drugs are known as agonists) if there is a very large difference 
in the drugs affinity for R over R* nearly all the receptors will adopt the R* formation (a 
full agonist) if the difference in affinity is not so large less of the occupied receptors will 
adopt the R* formation (a partial agonist) therefore a greater proportion of receptors will 
need to be occupied in order to achieve the same amount of R*.  
 
Should the drug prefer the R formation to R* then the equilibrium will be shifted to the 
inactive state (these types of drugs are known as inverse agonists). Antagonists are drugs 
that have no preference for R or R* and do not shift the equilibrium in either direction and 
do not invoke a response. It is thought there are relatively few full agonists, more likely 
they are partial agonists with very high efficacy, and the same for antagonists, which are 
more likely to be agonists or inverse agonists with very low efficacy.   
 
R R
* Response 
Agonist Inverse Agonist 
Antagonists 
Resting  Activated 
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Therefore the ratio of affinity of a drug for R to R* can be used to describe a drugs 
efficacy. The σ-1R ligands that showed a preference for the 2 site binding model in the 
radioligand binding assays are shown below in table 5.2, along with their affinities for the 
high affinity site (usually associated with the activated receptor state), low affinity site 
(usually associated with the resting receptor state) and the ratio of the low affinity to the 
high affinity giving an estimate measure of efficacy for the σ-1R ligand. 
 
σ-1R ligand Klow µM Khigh µM Klow/Khigh 
IPAG 0.16 0.00000017 941176.5 
Rimcazole 2.33 0.0021 1109.5 
Triisopentylammonium 3800 5.7 666.6 
Bis(2-ethylhexyl)ammonium 621.7 1.3 489.5 
 
 
Table 5.2: σ-1R ligand affinities for the 2 site fit to σ-1Rs. 
 
IPAG has the highest difference between the low affinity state and the high affinity state 
and there for should be the most efficacious, followed by rimcazole, bis(2-
ethylhexyl)ammonium and triisopentylammonium. 
 
5.9 σ-1 receptors and ion channels  
 
The σ-1R has been previously shown to interact with a number of ion channels including 
N-, L, P/Q- and R-type calcium channels (Zhang and Cuevas, 2002), and voltage-gated 
potassium channels (Aydar et al., 2002, Soriani et al., 1999, Soriani et al., 1998). Aydar et 
al. (2002) showed using co-expression of the σ-1R and Kv ion channels in Xenopus  
oocytes,  that the σ-1R could inhibit voltage-gated potassium channels  in the presence or 
absence of σ-1R drugs, which suggests that the σ-1R is involved in a multi protein 
complex. Soriani et al. (1998) showed that σ-1R agonists could down-regulate potassium 
currents, and that this down-regulation is sensitive to cholera toxin, suggesting that this 
involves Gs dependent mechanism.  
 
In order to ascertain whether the σ-1R antagonist IPAG causes its effects through 
modulation of voltage-gated potassium channels (in the MDA-MB-468 cell line) the cells 
were pre-treated with 1mM 4-aminopyridine (4-AP) which blocks voltage-gated potassium 
channels (Yuan et al., 1995) before a 10µM dose of IPAG (Figure 5.16).  The L-type 
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calcium channel blocker diltiazem (Tokuyama and Ho, 1996) was also used to assess the 
involvement of L-type calcium channels in IPAG-induced cytoplasmic calcium increase 
(Figure 5.17). 
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Figure 5.17: Peak cytosolic [Ca2+] in response to 10µM IPAG. Fura-2 loaded MDA-
MB-468 cells were pre-treated with TBS for the control, 10µM diltiazem or 1mM 4-AP, 
and the peak response above basal to IPAG measured taking the ratio of emission at 
510nm when excited at 340/380nm, ratio then converted to [Ca2+]. n=3. * P value 0.045 
 
Diltiazem had no statistically significant effect on the increase cytoplasmic [Ca2+] in 
response to 10µM IPAG (t-test P value 0.28). However 4-AP did cause a small but 
statistically significant increase in cytosolic calcium (t-test P value 0.045). 
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5.10 σ-1 receptor mutagenesis  
 
Using site directed mutagenesis a series of σ-1R mutants, at sites within the extra-cellular 
loop or in the potential cholesterol binding site, were created and cloned into an expression 
vector containing a GFP tag, which allowed the expression of the σ-1R and mutants in 
HEK 293 cells to be visualised under a fluorescence microscope (Figure 5.18).  
 
A           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C           D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18: HEK 293 cells expressing σ-1R mutants viewed using a florescence 
microscope A: σ-1 GFP expressing HEK 293 cells, B: σ-1 E172G GFP expressing HEK 
293 cells, C: σ-1 DHE53/55GHG GFP expressing HEK 293 cells, D: σ-1 EE41-42GG 
GFP expressing HEK 293 cells. Scale bar 50µm. 
 
The affinity of the σ-1R mutants for (+) pentazocine was assessed using saturation binding 
assays, the saturation binding curves for σ-1 GFP and the untransfected cells can be seen 
in Figures 5.19 and 5.20 respectively. The other mutants’ affinities are shown in table 5.3.  
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Figure 5.19: [3H] (+) pentazocine saturation binding in σ-1R transfected HEK-293 
cells. Representative Figure of 6 independent [3H] (+) pentazocine saturation assays, 
Scatchard shown for visualization purposes as Kd and Bmax were calculated using non-
linear regression. 
 
The Bmax for pentazocine binding to the σ-1 GFP expressed in the HEK 293 cells is 1057 ± 
47 fmol/mg that is approximately half of the expression seen in MDA-MB-468 cells (2300 
± 200 fmol/mg). 
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Figure 5.20: [3H] (+) pentazocine saturation binding in untransfected HEK-293 cells. 
Representative figure of 3; Scatchard shown for visualization purposes as Kd and Bmax were 
calculated using non-linear regression. 
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σ-1R Mutant pKd ± SEM Bmax fmol/mg Number of assays 
σ-1 GFP 7.8 ± 0.1  1057±47 6 
σ-1 E172G GFP 6.8 ± 0.1 1651±120 3 
σ-1 DHE 53/55 GHG GFP 7.38 ± 0.05 1129±173 3 
σ-1 EE 41-42 GG GFP 6.4 ± 0.1 745±165 2 
Control (untransfected HEK293 cells) 6.2 ± 0.2 352±200 3 
 
Table 5.3: Affinity (pKd ± SEM) of pentazocine for σ-1R mutants 
 
Mutants D126G, E102G and E64G appeared not to express, as after several attempts at 
transfecting the HEK-293 cells with different clones of the mutant there was no visible 
GFP signal when viewed under the fluorescence microscope.  
 
Mutants E172G and EE41-42GG showed a statistically significant reduction in affinity for 
[3H] (+) pentazocine, compared to the σ-1 GFP (ANOVA P Value <0.001 and < 0.001 
respectively) whilst expression remained at a similar level. The mutation in σ-1 E172G 
GFP is located in the putative cholesterol binding site described by Palmer et al., 2007 and 
the mutation in EE41-42GG GFP is located in the putative extracellular loop proposed by 
Aydar et al. 2006. 
 
σ-1R knock-down results in restriction of growth and cell death in human lens cells (Wang 
and Duncan, 2006), therefore the σ-1 GFP construct and its mutants were expressed in 
HEK 293 cells which show little to no σ-1 expression to see if would increase cell growth 
(Figure 5.21). 
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Figure 5.21: Increase in cell metabolism of HEK 293 cells transfected with σ-1 GFP 
and its mutants. Measured with the MTS assay, the control consisted of HEK 293 cells 
treated with transfection agent without DNA. Error bars represent SEM from 2 
independent MTS assays. *ANOVA Tukey’s post test vs control P<0.01, # ANOVA 
Tukey’s post test vs σ-1 GFP P< 0.05. 
 
Expressing the σ-1 GFP receptor more than doubled the growth of the HEK 293 cells 
compared to the control (*ANOVA Tukey’s post test P<0.01) as did the σ-1 DHE 53-55 
GHG GFP mutant (with the mutation in the extracellular loop)  (*ANOVA Tukey’s post 
test p<0.01), whereas the σ-1 E172G GFP, with the mutation in the putative cholesterol 
binding site (Palmer et al., 2007) receptor did not showed a significant increase in cell 
growth (#ANOVA Tukey’s post test p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
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5.11 σ-1 receptor antagonists and G-proteins discussion  
 
σ-1R ligands such as IPAG and rimcazole are thought of as antagonists, yet they are 
responsible for the cytoplasmic calcium increase in the cell that leads to PLC activation 
and PKB inhibition, whereas σ-1R ligands such a (+) SKF-10,047 and (+) pentazocine are 
thought of as agonists (due to the original effects seen in animals), yet they block the 
effects of the antagonists (Spruce et al., 2004). All the studies that have looked at σ-1R 
coupling through G-proteins have focused of the σ-1R agonists, whereas the antagonists 
have been ignored. Considering the effects the σ-1R antagonists have on the cell, if there is 
G-protein coupling with σ-1R, the antagonists are possible the more likely tools to 
highlight it. In this chapter I focused on the σ-1R antagonists IPAG and rimcazole. 
 
There is a large discrepancy between the IC50/EC50 (30µM/124µM) values observed for the 
response to IPAG in the MTS and calcium assay compared to its published affinity 
(2.8nM) (Wilson et al., 1991). This 10,000 times difference between the published affinity 
and the effective dose prompted a suspicion that either the published affinity was wrong or 
IPAG was having its effects through another receptor. Knocking down the σ-1R with the 
σ-1R specific siRNA resulted in a reduction in the maximal response to IPAG in the 
calcium assay. This taken with data from Spruce et al. (2004) which shows σ-1R agonists 
blocking the effects of IPAG (although a 30 minute pre-incubation is required), indicates 
that IPAG does indeed act through the σ-1 R. The attention turned therefore to the affinity 
of IPAG for the σ-1R. Wilson et el., (1991) identified IPAG as a high affinity σ-1R ligand, 
although they do not present the competitive binding isotherm in the paper. The affinity of 
IPAG for the σ-1R was therefore reassessed using [3H] (+) pentazocine and permeabilised 
MDA-MB-468 cells. The competitive binding data revealed that when fitted with a single 
site model the affinity was 15nM, not far from the affinity given in Wilson et al. (1991), 
however the nH value for the single site model was very low (-0.21). Another study in 
which a similar compound to IPAG, 1-(4-iodophenyl)-3-(1-adamantyl)guanidine (PIPAG) 
was shown to have an nH value of 1 (Kimes et al., 1992), however, the highest dose they 
use is 10nM, so it is likely that they have not gone high enough to see the low affinity 
binding site. 
 
If the unlabelled drug (in this case IPAG) is competing for a single class of receptor the 
curve should descend from 90% specific binding to 10% specific binding over an 81 fold 
increase in concentration, resulting in an nH of -1. There are a number of explanations for 
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the low nH value, including negative cooperativity where the binding at one site lowers the 
affinity of other sites for the ligand, heterogeneous receptor population, where the 
receptors do not all bind the ligand with the same affinity and G-protein coupling where 
the interaction with a G-protein changes the affinity of the ligand for the receptor.  
 
The heterogeneous population of σ receptors is not a satisfactory explanation, since for this 
to result in a shallow binding curve the radiolabelled drug has to have the same affinity at 
both sites, (+) pentazocine is reportedly highly selective for the σ-1R, 500 times more 
selective for the σ-1R over the σ-2R, 1000 times more selective for the σ-1R than the PCP 
site (Whittemore et al., 1997), and 150 times more selective for the σ-1R over the mAChR 
(Hong and Werling, 2002). The negative cooperativity explanation is also unlikely as the 
σ-1R is only a small protein with a single binding site for (+) pentazocine potentially with 
in the a membrane spanning section of the receptor (Yamamoto et al., 1999).  
 
The binding data for IPAG and rimcazole in this chapter, and the binding data for bis(2-
ethylhexyl)ammonium in the previous chapter, all have low nH values with the single site 
model and when compared to the two site model, using the difference in sum of squares F 
test, they all have high F values and significant P values, therefore the preferred binding 
model for these σ-1R ‘antagonists’ is the 2 site model. Figure 5.22 shows a simple model 
of how G-protein coupling results in two affinity states for a receptor.  
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Figure 5.22: G-protein coupling affecting the affinity of the σ-1R for IPAG. A: The G-
protein is bound to GDP and is inactive, coupled to the receptor causing the receptor to 
have high affinity for IPAG. B: The G-protein is bound to GTP and is activated and 
dissociated from the receptor causing the receptor to have low affinity for IPAG. 
 
Addition of GTP (promoting G-protein activation) to the binding assay resulted in the nH 
value approaching -1 and the affinity of IPAG and rimcazole for the σ-1R shifting to the 
low affinity state (which coincides with EC50 and IC50 doses for the calcium and MTS 
assay), suggesting G-protein coupling. Furthermore, when suramin (which inhibits Gs 
(Hohenegger et al., 1998), Gi and Gq (Beindl et al., 1996)) is added to the IPAG binding 
assay, the binding curve is again shifted to the low affinity state with a nH value of -1, 
providing yet more evidence that the σ-1R is coupled in some way to a G-protein.  
 
Further evidence that the σ-1R is coupled to a G-protein comes from the HPLC 
measurement of GTP metabolism to GDP in response to the σ-1R antagonists. The σ-1R 
antagonists rimcazole and IPAG, along with the ammonium salts triisopentylammonium 
diisopentylammonium and bis(2-ethylhexyl)ammonium, all dose-dependently reduced the 
formation of GDP suggesting that the σ-1R antagonists are preventing G-protein 
activation, or coupling with the receptor. This may go somewhat to explain the fact that the 
σ-1R antagonists are unusual in that they are causing their effects through the low affinity 
state of the σ-1R (G-protein uncoupled), although it should be noted that the model fitted 
to the binding data and described in Figure 5.19 above is a very simple view of G-protein 
coupling since it allows for the two affinity states (R and RG) but does not allow for the 
conversion between R and RG, and therefore the Ki values obtained should be treated with 
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care, Figure 5.23 shows more complex models that can be applied to G-protein receptor 
coupling. 
 
L+R + G  LR+G  
      Simple model  
L+RG   LRG 
 
L+R + G  LR+G 
      Ternary Complex model 
L+RG    LRG 
 
L+R+G   LR+G 
 
L+R*+G  LR*+G  Extended Ternary complex model 
 
L+R*G  LR*G 
 
 
Figure 5.23 Ligand, Receptor and G-protein interactions 
L- Ligand, R- Receptor, G- G-protein 
 
These observations showing that the σ-1R is interacting with a G-protein, and that the σ-
1R antagonists are reducing G-protein activity and causing their effects at doses that 
coincide with the low affinity state could possibly help explain the function of the σ-1R 
within the cell.  
 
The σ-1R is not directly causing its effects via G-protein activation; rather the G-proteins 
are changing the σ-1Rs interactions with ion channels. With the G-protein uncoupled σ-
1Rs are able to cause the influx of calcium in to the cytoplasm (or unable to prevent the 
influx of calcium into the cytoplasm). This is shown in the cholera toxin treated MDA-
MB-468 cells, where there was a 3 times higher calcium response in the cells that had been 
G-protein uncoupled with cholera toxin compared to the control cells. Below are possible 
explanations for how this could be happening. 
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Figure 5.24: Possible multi-protein interaction A: Inactive G-protein coupled to the σ-
1R and the ion channel preventing influx of ions into the cytoplasm. B: σ-1R, G-protein 
and ion channel complex dissociates allowing ions into the cytoplasm. 
 
 
The σ-1R has been shown to interact with a wide range of ion channels (Aydar et al., 
2004, Soriani et al., 1999, Soriani et al., 1998, Tchedre et al., 2008, Zhang and Cuevas, 
2002), and it is possible that it may interact with whichever ion channel is available 
depending on the cell type (Campbell et al., 1989). Soriani et al. (1999) showed that the σ-
1R could inhibit potassium currents and that this interaction was cholera toxin sensitive, 
this is similar to the data I have presented in Figure 5.13, showing an larger increase in 
cytoplasmic calcium in the cholera toxin cells in response to IPAG. Both Lupardus et al. 
(2000) and Aydar et al. (2002) show the σ-1R inhibiting potassium currents, although they 
suggest no interaction with a G-protein. However both studies only look at agonist 
interactions with the σ-1R and both studies use ectopically overexpressed ion channels and 
receptors in oocytes, whereas the work by Soriani et al (1998), and the data I have 
presented in Figure 5.13 makes use of endogenous ion channels and receptors. Figure 5.24 
shows how the σ-1R and G-proteins may interact with various ion channels.  
 
Another possible explanation for the greater calcium response to IPAG seen in the cholera 
toxin treated MDA-MB-468 cells, could be that Kv channel activation is able to block (at 
least in part) calcium signalling (Chakraborti et al., 2009). The Kv channel can be activated 
by Gs (Michaelevski et al., 2002), such that activation of the σ-1R causes calcium channel 
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opening and the activation of Gs which causes Kv channel opening and inhibition of the 
calcium channel (Figure 5.25). Therefore when the Gs is uncoupled using cholera toxin 
there is no Kv channel opening resulting in no inhibition of the calcium channel resulting in 
a larger calcium response, as seen in Figure 5.13.  
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Inside the cell      βγ 
 
    Outside the cell 
 
 
 
 
 
                    βγ 
 
    Inside the cell 
 
Figure 5.25: Possible G-protein activation of Kv channels resulting in decreased 
calcium influx. A: σ-1R G-protein and calcium channel form a complex preventing 
calcium entry, the G-protein inactive, and the Kv channel is closed. B: σ-1R activation 
causes the dissociation of the receptor from the calcium channel causing calcium influx 
and from the G-protein which activates the Kv channel allowing potassium into the extra-
cellular space causing the inhibition of the calcium channel. 
 
This model is supported at least in part by the data in Figures 5.13 and 5.16 however there 
are some problems. Firstly there is no evidence of cAMP production in response to σ-1R 
antagonists (table 3.2), which you would expect if you were activating Gs. Furthermore, 
the σ-1R antagonists result in a dose dependent reduction of GTP metabolism to GDP, 
which is the reverse of what you would expect if there were G-protein activation. There is 
also the problem that the increase in cytosolic calcium is smaller with the Kv channel 
blocker than when the G-protein is uncoupled using cholera toxin, although it may be 
possible that the G-protein has a larger role in reducing the calcium influx then just 
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activating the Kv channel, possibly by helping form the complex between the σ-1R and the 
calcium channel which prevents calcium influx.  
 
The main problem with the explanations above for the effects of Gs on σ-1R-induced 
cytoplasmic calcium increases (which is itself the explanation put forward to explain the 
effects of GTP on antagonist binding to the σ-1R) is that there is a dose dependent 
reduction in GTPase activity in response to σ-1R antagonists, and that there is no evidence 
of cAMP production in response to σ-1R antagonists. These observations could be 
explained by the G-protein not being activated by the σ-1R but rather acting as part of the 
complex causing the inhibition of ion channels and dissociation of the G-protein from the 
σ-1R and ion channel is not caused by the G-protein being activated but rather some other 
factor. This other factor could be lipid raft formation, causing the separation of the σ-1R, 
G-protein and ion channel complex (Figure 5.26).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26: Lipid rafts and σ-1Rs. A: The σ-1R forms a complex with the G-protein and 
ion channel preventing channel opening. B: σ-1R interaction with σ-1R antagonists leads 
to lipid raft formation and the G-protein is partitioned away from the ion channel causing 
the σ-1R to dissociate from the ion channel allowing channel opening. 
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There are many examples of the σ-1R interacting with lipid rafts (Hayashi and Su, 2003b, 
Hayashi and Su, 2003a, Hayashi and Su, 2004, Hayashi and Su, 2005b, Palmer et al., 
2007, Takebayashi et al., 2004), and in Chapter 4 I have shown that the σ-1R antagonists 
cause lipid raft formation (Figures 4.20 to 4.22). There are several lines of evidence that 
lipid rafts are able interact with G-proteins and modulate their activity (Miura et al., 2001, 
Morris et al., 2008, Pontier et al., 2008, Quinton et al., 2005, Stuven et al., 2003). Work by 
Mirura et al. (2001) and by Pontier et al. (2008) showed, by measuring cAMP production, 
that Gs signalling is increased after disruption of lipid rafts by depleting cholesterol, 
suggesting that lipid rafts are capable of partitioning Gs preventing it from interacting with 
other proteins. The cholera toxin calcium data in Figure 5.13, the σ-1R antagonist induce 
lipid rafts in Figures 4.21 and 4.22, and the GTPase activity shown in Figure 5.12 all 
support this hypothesis that lipid rafts being created in response to σ-1R antagonists, and 
that this results in the G-protein being partitioned away from the ion channel (and 
preventing the G-protein being activated reducing GTPase activity) which allows the ion 
channel to open. The cAMP data however do not appear to support this hypothesis, as σ-
1R antagonists did not cause a statistically significant reduction in cAMP production in 
response to isoprenaline (adrenergic β1 and β2 agonist) and dopamine which couple 
through Gs, although the decrease may only be a small one depending on the abundance of 
Gs in the MDA-MB-468 cells, and in order to see the effect a pre-incubation with σ-1R 
antagonist may be required for lipid rafts to form before the addition of isoprenaline or 
dopamine. 
 
In this chapter I set out to determine whether the σ-1R couples though a G-protein, using 
σ-1R antagonists rather than agonists as previously used in most other studies of this 
aspect of the σ-1R. The binding studies using the σ-1R antagonists IPAG and rimcazole 
revealed low nH values (characteristic of multiple binding sites) and 2 site binding model 
was statistically preferred over the single site model. Addition of GTP to the assay 
completely abolished the high affinity site and returned the nH value to 1, which strongly 
indicates that there is some form of G-protein interaction with the σ-1R. However, this 
interaction is far from conventional since when GTP metabolism to GDP is measured in 
response to well known σ-1R antagonists and the branched-chain ammonium salts from 
chapter 4, the GTP metabolism goes down dose dependently. It is tempting at this point to 
try to redefine the σ-1R antagonists IPAG, rimcazole and bis(2-ethylhexyl)ammonium as 
inverse agonists, as they dose dependently reduce G-protein activity and dose dependently 
cause apoptosis. However, the GTP shift is in the wrong direction as an inverse agonist 
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(according to the 2 site model Figure 5.16) should have a higher affinity for the free (not 
interacting with G-protein) receptor. If the σ-1R was being activated by the antagonists, 
which in turn activated a G-protein, the GTP metabolism to GDP should have gone up. 
Further evidence suggests an interaction the σ-1R with G-proteins, since suramin, which 
uncouples Gs alone or with Gi depending on the concentrations used also abolished the 
high affinity binding site.  Furthermore,  cholera toxin treatment of MDA-MB-468 cells 
resulted in an enhanced calcium response to IPAG. Despite the interaction being 
unconventional it seems clear that there is an interaction between the σ-1R and a G-protein 
or G-proteins. I have suggested a number of possible mechanisms for the σ-1Rs interaction 
with a G-protein, using the evidence gathered within this chapter, however, further 
investigation of the σ-1R is required to either build on or improve the explanations I have 
put forward. 
 
In this chapter I also investigated the molecular biology of the σ-1R and looked into the 
effects of σ-1R mutants on ligand binding and on cell growth of cells containing the 
mutant receptors. The σ-1R mutant (σ-1 E172G GFP) with the mutation in the putative 
cholesterol binding site (Palmer et al., 2007) had a significantly reduced affinity for the σ-
1R, furthermore when transfected into (σ-1R negative) HEK 293 cells it was unable to 
increase cell growth (measured with the MTS assay) compared to the control HEK cells, 
whereas the wild type σ-1R transfected into the HEK 293 cells resulted in approximately 3 
times more cell growth (measured using the MTS assay). As previously discussed the σ-
1R is potentially important in the transport of cholesterol from the endoplasmic reticulum 
to the plasma membrane, and this evidence suggests that preventing the σ-1R from 
interacting with cholesterol reduces its ability to protect the cell from apoptosis, and 
possibly drive cell growth and division. 
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6 General discussion and conclusions 
 
6.1 Summary: What is the σ-1R really doing, and how is it doing it? 
 
The σ-1R’s ability to bind to a wide range of compounds, and interact with an equally 
wide range of intracellular effectors such as G-proteins, ion channels and other receptors as 
well as appearing to modulate the plasma membrane, has led to confusion about what the 
σ-1R does, and how it does it. A major example of this is the σ-1R ligand nomenclature, 
with the σ-1R antagonists causing an increase in cytoplasmic calcium, and the σ-1R 
agonists blocking these effects. This is the reverse of a normal receptor agonist: antagonist 
relationship; it came about as discussed in the introduction, through the observations seen 
in animal experiments with σ-1R agonists, and agents that blocked these effects were 
designated antagonists. It was only later identified that the σ-1R antagonists have a 
biochemical effect, causing an increase in cytoplasmic calcium and activating apoptotic 
mechanisms. Although it should be noted that not all σ-1R antagonists have a biochemical 
effect and as such may be true σ-1R antagonists in the pharmacological sense of the word. 
For example progesterone is designated as a σ-1R antagonist, yet does not induce the 
aforementioned effects, it could also be a partial agonist (partial antagonist as far as σ-1R 
terminology is concerned) with low efficacy. A full review of σ-1R ligands is required to 
sort out what biological effects each ligand has and whether it should be designated as an 
agonist, antagonist or inverse agonist. However, without properly defining what the σ-1R 
does and how it does it this would be a pointless exercise, as without knowing what the 
activated σ-1R does it is impossible to assign the label agonist to a ligand.  
 
As it stands it has been shown that the σ-1R expression is involved in cell survival (Aydar 
et al., 2004, Bem et al., 1991, Wang and Duncan, 2006, Zhu et al., 2003), and controlling 
its actions with σ-1R agonists led to increased cell survival, whereas σ-1R antagonists 
have the opposite effect, activating apoptotic pathways leading to cell death (Spruce et al., 
2004, Wang et al., 2005). The evidence from previous reports suggests that treatment with 
σ-1R agonists led to the translocation of the σ-1R to the plasma membrane (Hayashi and 
Su, 2003a, Morin-Surun et al., 1999) where it can interact with ion channels, preventing 
apoptotic signals (Cantarella et al., 2007), overexpressing the σ-1R has the same effect and 
this is seen in tumour cell lines expressing the σ-1R this suggests that the current 
nomenclature regarding agonists may in fact be the correct one. It is possible that the σ-1R 
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agonist treatment results in an increased receptor reserve by sending more σ-1Rs to the 
plasma membrane, which would explain why a pre-incubation period was required to 
reduce the effects of the σ-1R antagonists seen in work by Spruce et al. (2004).   
 
The ability to control cell survival is at the root of the σ-1Rs activities, ‘activating’ the 
receptor with σ-1R agonists potentially leads to greater expression of the σ-1R at the 
plasma membrane, and causes increased cell growth (or prevents cell death). This process 
has potentially evolved to protect cells during ischemic conditions and a number of studies 
have looked into the potential for σ-1R agonists as protective agents during ischemic 
conditions (Goyagi et al., 2003, Goyagi et al., 2001, Katnik et al., 2006, Maurice and 
Lockhart, 1997). The anti-apoptotic effect of the σ-1R is possibly responsible for the 
chronic effects of antidepressants; studies have shown increased neurogenesis with chronic 
treatment with fluoxetine (Marcussen et al., 2008), since fluoxetine and many other 
clinically used antidepressants have σ-1R activity (Itzhak and Kassim, 1990, Narita et al., 
1996). Within this thesis, in chapter 3, I have identified a novel selective, high affinity σ-
1R ligand, dipentylammonium, which has shown significant antidepressant activity in 
animal models of depression, and these antidepressant effects were reversed with a σ-1R 
antagonist, strongly suggesting that dipentylammonium exerts its antidepressant effect 
through a σ-1R mediated mechanism. Whether this mechanism involves the endoplasmic 
reticulum stress response (Itzhak and Kassim, 1990, Narita et al., 1996), controlling 
cytoplasmic calcium, preventing apoptosis and driving cell division or by inducing 
increased neurotransmitter release (Bermack and Debonnel, 2001), has yet to be identified. 
There is the possibility of both of these mechanisms taking place, accounting for the acute 
and chronic effects seen with other antidepressants in animal models. 
 
The flip side of the σ-1R coin are the σ-1R antagonists (as discussed previously these are 
possibly inverse agonists if we were going to stick to correct pharmacological terminology 
although as discussed in chapter 5 the GTP shift is in the wrong direction), which induce 
apoptosis in a dose dependent manner as seen in chapter 5 with IPAG and in chapter 4 with 
the branched-chain ammonium salts. Knocking down the σ-1R showed that the branched-
chain ammonium salts were having their effect through the σ-1R as their effects were 
reduced (chapter 4). Furthermore, the calcium response to IPAG was reduced (chapter 5). 
Previous studies have shown that σ-1R antagonists (Brent and Pang, 1995, Palmer et al., 
2007, Spruce et al., 2004, Wang et al., 2005) and σ-1R silencing (Wang and Duncan, 
2006) leads to cell death, and have suggested mechanisms through which this may occur. 
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Spruce et al. (2004) suggest the activation of caspases in response to calcium influx into 
the cytoplasm, whilst other studies also suggest lipid raft formation and cholesterol 
transport to the plasma membrane disruption as a trigger for apoptosis (Hayashi and Su, 
2003b, Hayashi and Su, 2003a, Hayashi and Su, 2004, Hayashi and Su, 2005b, Palmer et 
al., 2007, Takebayashi et al., 2004). In chapter 4 I show that IPAG and the branched-chain 
ammonium salt, bis(2-ethylhexyl)ammonium, induce an increase in cytoplasmic calcium 
and lipid raft formation, as I discussed in chapter 5 these two processes could be linked and 
possibly explain the unconventional G-protein coupling. In chapter 4 I also show that the 
branched-chain ammonium salts bis(2-ethylhexyl)ammonium and triisopentylammonium 
are effective against tumour growth both in vitro and in vivo. The hypothesis that the σ-1R 
is a ligand operated endoplasmic reticulum chaperone protein, when activated helps 
mediate the endoplasmic reticulum stress response, appears to explain the two sides of the 
σ-1Rs actions, although the exact details still need to be identified. Activating the σ-1R 
protects the cell from apoptosis most likely by controlling plasma membrane ion channels 
and cholesterol content/transport from the endoplasmic reticulum. Disruption of the σ-1R 
leads to dysregulation of ion channels, and cholesterol content/transport from the ER and 
ultimately leading to apoptosis. 
 
Within this thesis I have identified a structure activity relationship between the simple 
ammonium salts and the σ-1R. The straight-chain ammonium salts increase in affinity for 
the σ-1R between two and six carbon long chains, with the highest affinity ammonium 
salts being the five carbon long chain secondary and tertiary ammonium salts. 
Dipentylammonium was shown to have effective antidepressant like effects, which were 
σ-1R antagonist sensitive, when tested in the animal model.  
 
Slightly changing the ammonium salts structure, resulting in branched-chain ammonium 
salts, dramatically changed their effect at the σ-1R, there was a marked reduction in 
affinity for the σ-1R and the nH values were low. When the branched-chain ammonium 
salts were tested in the calcium assay and in the MTS assay two showed responses, bis(2-
ethylhexyl)ammonium and triisopentylammonium, these were also the two ammonium 
salts which had a preferred two site binding model. These two ammonium salts were tested 
in vivo where they were shown to inhibit tumour growth compared to the control. 
 
Also in this thesis I have investigated the coupling of the σ-1R with G-proteins. σ-1R 
antagonists show low nH values in the binding experiments, which suggests multiple 
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affinity binding sites. In addition to the low nH values in the binding experiments for 
IPAG, rimcazole, and the two branched-chain ammonium salts with σ-1R activity, I show 
that the presence of GTP is capable of returning the nH value to 1 and abolishing the high 
affinity binding site for IPAG and rimcazole. Furthermore, suramin treatment of the cells 
has the same effect as adding GTP to the binding assay (uncoupling G-proteins) resulting 
in the loss of the high affinity binding site. All this evidence suggests G-protein coupling, 
however, when the metabolism of GTP to GDP was measured using HPLC, the 
metabolism of GTP to GDP was reduced dose dependently in response to the σ-1R 
antagonists and branched-chain ammonium salts (not, however, the straight-chain 
ammonium salts), this suggested a reduction in G-protein activity in response to the σ-1R 
antagonists.  
 
In summary with in this thesis I have shown the identification of a series of novel σ-1R 
ligands, three of which I have shown to have in vivo activity, two antagonists which were 
effective against tumour growth and one agonist which produced antidepressant like 
effects in the animal models. 
6.2 Future directions and perspectives  
 
The σ-1R agonists that I have identified had high affinity of the σ-1R. Modifying these to 
try to create σ-1R antagonists (two of which appeared to be effective), the affinity for the 
σ-1R was dramatically reduced. One way to try to increase the affinity whilst retaining the 
σ-1R antagonist activity would be to create a series of mixed ammonium salts (with both 
branched and straight carbon chains) as well as varying the length and position of the 
branches (table 6.1).  
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Ammonium salt Structure 
Pentyl bis(2-
ethylhexyl)ammonium 
N
 
Pentyl bis-3-
(ethyl)hexylammonium 
N
 
Pentyl bis-3-
(propyl)hexylammonium 
N
 
Diisopentylpentylammonium 
N
 
dipentylisopentylammonium 
N
 
 
Table 6.1 A selection of possible ammonium salt structures that could increase σ-1R 
affinity whilst keeping the σ-1R antagonist activity. 
 
 
Branched-chain ammonium salts with higher affinity for the σ-1R could yield more 
effective anti-proliferative drugs, and effective labels for tumour imaging. Anavex is 
investigating a compound (Anavex 1007) which is currently in preclinical trials as part of 
its Sigmaceptor-C program, its reported action is to modulate σ-1Rs controlling ion 
channels as well as antagonising the subgroup of muscarinic receptors, mAChR3, which 
also has an anticancer effect (Song et al., 2007). Increasing mAChR3 affinity along with σ-
1R affinity of the branched-chain ammonium salts could yield an effective anticancer 
agent. Acetylcholine is synthesised and released from tumours as an autocrine growth 
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factor. Antagonising the mAChR leads to apoptosis (Cheng et al., 2008, Song et al., 
2003b, Song et al., 2003a). As discussed in chapter 4 this could be an explanation for the 
increased activity of bis(2-ethylhexyl)ammonium and triisopentylammonium in the mouse 
colon cancer cells compared to the human breast cancer cell line. The increase in affinity 
that the adamantyl group gives (Gabrielevitz et al., 1980) could be used to try to create a 
higher affinity mixed σ-1R antagonist mAChR agonist by adding the adamantyl group to 
bis(2-ethylhexyl)ammonium, or to triisopentylammonium along with the other 
combinations suggested in table 6.1 
 
In order to further assess the G-protein coupling of the σ-1R and the effects of agonists and 
antagonists, GTPγ[35S] binding studies could be used to assess the effects of the σ-1R with 
σ-1R agonists and antagonists alone and on other G-protein coupled receptors. A similar 
study has already looked at the effects of σ-1R antagonists on µ opioid receptors (Kim et 
al., 2010) The results of which appear to contradict the GTP metabolism data which I 
present in chapter 5.  Their data suggest the σ-1R antagonist BD1047 has no effect on G-
protein activity alone but increases G-protein activity when administered along with µ 
opioid agonists. The doses of σ-1R antagonist used in this study were quite low, since I 
have shown that σ-R antagonists show a multiple affinity binding states, with the lower 
affinity state appearing to be the state through which the antagonists have their effects. It is 
possible that they did not use a high enough dose to see the effect of the σ-1R antagonist 
alone. Further GTPγ[35S] binding studies utilizing a wider range of σ-1R antagonists, and 
doses within the range used in chapter 5 could add to the evidence that the σ-1R interacts 
with G-proteins. Attempting co-immunoprecipitation of the σ-1R and its potentially 
coupled G-protein is another way of possibly identifying the G-protein that is coupling to 
the σ-1R. Looking for multiple bands in a polyacrylamide gel electrophoresis (PAGE) of 
the immunoprecipitated material before using mass spectrometry to identify the material 
isolated along with the σ-1R. This may prove difficult since the σ-1R has been shown to 
interact with a number of other receptors depending on the cells investigated and 
maintaining the G-protein coupling during the immunoprecipitation may not be possible, 
also the G-protein interaction may not be direct as discussed in chapter 5 with respect to 
lipid rafts.  
 
It has been shown that σ-1R expression alone is not enough to show susceptibility to 
apoptosis in response to σ-1R antagonists (Spruce et al., 2004) which is in part why the σ-
1R antagonists make potentially attractive anticancer agents as they appear to only target 
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σ-1R-expressing tumours rather than other non cancer tissues. The selection of cancer 
tissue over normal tissues by the σ-1R antagonists is likely to be caused by different 
coupling of the receptor within different cell types. Repeating the experiments from 
chapter 5 with the antagonists in other systems such as brain tissue could yield different 
binding patterns with respect to the two site binding and GTP shift, different calcium 
responses and potentially reveal different coupling of the σ-1R.  
 
The σ-2R, which I have largely ignored due to the fact little is known about it in 
comparison to the σ-1R, needs to be identified. As yet it has not been cloned although 
photolabelling suggests it has a lower molecular weight that the σ-1R (Hellewell and 
Bowen, 1990) and it is not clear whether it is a real protein or just a pharmacological 
artefact, possibly through alternative splicing of the σ-1R (Aydar et al., 2004) although in 
the σ-1R knock-out mouse DTG (which is not specific to the σ-1R) binding appeared to be 
unaffected (Langa et al., 2003). The σ-2R has been suggested as the major anti-apoptotic 
receptor of the sigma receptor “family” although it is not confirmed whether the σ-1R and 
σ-2R form a receptor family. They could be entirely distinct proteins that happen to have 
very similar binding properties. This made its identification through bioinformatics 
difficult as it may share little resemblance to the σ-1R at the DNA or protein level. 
Knowing the molecular weight of the protein should make it possible to isolate, using 
fractionation and/or two dimensional PAGE and then using mass spectrometry to try to 
identify the protease treated proteins within the fraction. With the identification of the σ-
2R its coupling with and mechanism by which it can cause apoptosis may become clearer 
and the relation to the σ-1R may be identified. 
 
Further investigation into the straight-chain ammonium salts, and σ-1R agonists in general 
could be carried out, to investigate the mechanism by which they cause their anti-
depressant effect. σ-1R agonists may increase neurotransmitter release or the response to 
the neurotransmitter by interaction with the neurotransmitter receptor. Alternatively, σ-1R 
agonists may cause increased neurogenesis, which could lead to the antidepressant effects. 
The monoamine theory of depression fails to explain why chronic treatment with 
antidepressant drugs is required to see a clinical effect in patients. Since a large number of 
clinically effective antidepressant drugs have σ-1R affinity the σ-1R could be the 
explanation for many antidepressant effects. Anavex is currently investing a number of 
compounds in relation to neuroprotective agents, which act as σ-1R agonists. Further 
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investigation into dipentylammonium as a neuroprotective agent could lead to an effective 
agent combating not only depression but with potential against Alzheimer’s disease, 
epilepsy, Parkinson’s and other neurodegenerative diseases. 
 
The extent of the σ-1Rs involvement in depression could be investigated further making 
use of the σ-1R knock-out mouse. By simply comparing the effects of antidepressants, 
which have known σ-1R affinity, in wild type and knock-out mice would indicate the σ-
1Rs involvement in the antidepressant effects. If the σ-1R is not involved in the effects of 
drugs such as fluoxetine, the knock-out mice will respond equally well to the 
antidepressant as the wild type. This could also be carried out to assess the effects of the σ-
1R agonists, which appear to have antidepressant activity, this could confirm beyond doubt 
that the σ-1R agonists cause their antidepressant effects through the σ-1R. 
 
I have identified simple ligands can have high affinity for the σ-1R and they can be 
agonists and antagonists. Preliminary studies show these ligands show good selectivity and 
go against the dogma put forward by leading chemists (Ley and Baxendale, 2002). I have 
also shown that σ-1Rs are G-protein coupled; further work required in understanding this 
interaction as it does not fit the model derived from traditional (seven transmembrane) G-
protein coupled receptors. It is unclear at this stage whether σ-R ligands have a role to play 
in modern medicine. 
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7 Appendices 
 
7.1 Abbreviations used 
 
Abbreviation  Full name 
(+) Pentazocine (1S,9S,13S)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-
azatricyclotrideca-2,4,6-trien-4-ol 
[3H] Tritium 
[Ca2+] Calcium ion concentration 
[K+] Potassium ion concentration 
3PPP (3-(3-hydroxyphenyl)-N-n- propylpiperidine) 
4-AP 4-Aminopyridine  
5-HT 5-hydroxytryptamine  
AC Adenylyl cyclase  
ATCC American Type Culture Collection 
BD1047 N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-
(dimethylamino)ethylamine 
BD737 1S,2R-(−)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-
pyrrolidinyl)cyclohexylamine  
Bmax Maximum binding of a ligand to a receptor 
BSA Bovine serum albumin  
cAMP Cyclic adenosine monophosphate 
CI Confidence intervals  
CNS Central nervous system 
CO2 Carbon Dioxide 
cpm  Counts per minute  
DHEAS Dehydroepiandrosterone 
DISC Death inducing signalling complex 
DMEM Dulbecco Modified Eagle’s minimum essential media 
DMSO Dimethyl sulfoxide 
DPM Disintegrations per minute 
DTG 1,3-di-o-tolylguanidine  
E. coli Escherichia coli  
Appendices  
EC50 Effective concentration of a drug to cause 50% maximal  response 
ECACC European Collection of Cell Cultures  
EDTA Ethylenediaminetetraacetic acid 
EPB Emopamil binding protein  
FCS Foetal Calf serum  
GDPβS Guanosine-5'-O-(2-thiodiphosphate) 
GPI Glycosylphosphatidylinositol 
GppNHp 5'-Guanylyl imidodiphosphate 
G-Protein GTP-binding protein 
GTP guanosine triphosphate 
GTPγS guanosine 5'-O-(gamma-thio)triphosphate 
H1R Histamine 1 Receptor 
H2R Histamine 2 Receptor 
H3R Histamine 3 Receptor 
H4R Histamine 4 Receptor 
HCl Hydrochloric acid 
HCl• Hydrochloride salt 
HEK 293 Human Embryonic Kidney cell line  
HPLC High Performance Liquid Chromatography 
IC50 Concentration required to cause a 50% drop in maximal response. 
IP3 Inositol 1,4,5-trisphosphate  
IP5 Inositol 1,3,4,5,6 pentakisphosphate 
IPAG 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine 
K50 Equilibrium dissociation constant for binding that does not follow 
the laws of mass action 
Kd Equilibrium Dissociation Constant derived from saturation binding 
Ki Equilibrium Dissociation Constant derived from competitive 
radioligand binding 
MAC 13 Mouse Colon Cancer Cell line 
MAC 16 Mouse Colon Cancer Cell line 
mAChR Muscarinic acetylcholine Receptor 
MDA-MB-468 Human Breast adenocarcinoma cell line 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
nH The Hill coefficient (slope factor) of competitive binding curves 
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NMDA N-methyl-D-aspartic acid  
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate Buffered saline 
PCP 1-(1-phenylcyclohexyl)piperidine  
pEC50 Negative logarithm of the dose required to generate 50% of the 
maximal response. 
pH The negative logarithm of the concentration of Hydrogen ions in a 
solution in moles per litre 
pIC50 Negative logarithm of the dose required to reduce a response by 
half. 
PIPAG 1-(4-Iodophenyl)-3-(1-adamantyl)guanidine 
pK50 Negative logarithm of the concentration of ligand required to 
occupy 50% of receptors when the binding does not follow the laws 
of mass action  
PKB Protein Kinase B 
pKd Negative logarithm of the equilibrium dissociation constant that is 
derived from saturation binding assays 
pKi Negative logarithm of the equilibrium dissociation constant that is 
derived from competitive binding assays 
PLC Phospholipase C 
PMS 
QNB 
Phenazine methosulphate 
L-quinuclidinyl [phenyl-4-3H] benzilate 
R Resting state receptor 
R* Activated state receptor 
Rimcazole 9-(3-((3R,5S)-3,5-dimethylpiperazin-1-yl)propyl)-9H-carbazole  
RPMI Roswell Park Memorial Institute 
SD Standard deviation 
SEM Standard Error of the mean (SD/√n) 
siRNA Short Interfering Ribonucleic Acid 
SKF-10,047 N-allylnormetazocine 
SSRI Selective Serotonin Reuptake Inhibitor 
TBS Tris(hydroxymethyl)aminomethane buffered saline 
Tris Tris(hydroxymethyl)aminomethane 
σ-1R Sigma-1 receptor 
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7.2 σ-1 receptor coding gene sequence 
 
atgcagtggg ccgtgggccg gcggtgggcg tgggccgcgc tgctcctggc 
tgtcgcagcg gtgctgaccc aggtcgtctg gctctggctg ggtacgcaga 
gcttcgtctt ccagcgcgaa gagatagcgc agttggcgcg gcagtacgct 
gggctggacc acgagctggc cttctctcgt ctgatcgtgg agctgcggcg 
gctgcaccca ggccacgtgc tgcccgacga ggagctgcag tgggtgttcg 
tgaatgcggg tggctggatg ggcgccatgt gccttctgca cgcctcgctg 
tccgagtatg tgctgctctt cggcaccgcc ttgggctccc gcggccactc 
ggggcgctac tgggctgaga tctcggatac catcatctct ggcaccttcc 
accagtggag agagggcacc accaaaagtg aggtcttcta cccaggggag 
acggtagtac acgggcctgg tgaggcaaca gctgtggagt gggggccaaa 
cacatggatg gtggagtacg gccggggcgt catcccatcc accctggcct 
tcgcgctggc cgacactgtc ttcagcaccc aggacttcct caccctcttc 
tatactcttc gctcctatgc tcggggcctc cggcttgagc tcaccaccta 
cctctttggc caggaccctt ga 
7.3 σ-1 Receptor protein sequence 
 
mqwavgrrwa waalllavaa vltqvvwlwl gtqsfvfqre eiaqlarqya 
gldhelafsr livelrrlhp ghvlpdeelq wvfvnaggwm gamcllhasl 
seyvllfgta lgsrghsgry waeisdtiis gtfhqwregt tksevfypge 
tvvhgpgeat avewgpntwm veygrgvips tlafaladtv fstqdfltlf 
ytlrsyargl rlelttylfg qdp 
 
rr – Endoplasmic localisation signal 
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